Impact of diet on vascular and biomarkers of injury: role of non invasive vascular assessment in quantifying risk and the effect of Metformin in addressing risk by Varma, Madhusudham Chittari
 warwick.ac.uk/lib-publications  
 
 
 
 
 
 
A Thesis Submitted for the Degree of PhD at the University of Warwick 
 
Permanent WRAP URL: 
http://wrap.warwick.ac.uk/85053 
 
Copyright and reuse:                     
This thesis is made available online and is protected by original copyright.  
Please scroll down to view the document itself.  
Please refer to the repository record for this item for information to help you to cite it. 
Our policy information is available from the repository home page.  
 
For more information, please contact the WRAP Team at: wrap@warwick.ac.uk  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Impact of diet on vascular and biomarkers of injury,
role of non invasive vascular assessment in
quantifying risk and the effect of Metformin in
addressing risk
By
Dr Madhusudhan Chittari Varma
MBBS, MRCP (UK)
A thesis by publications submitted to
The Faculty ofMedicine
At the University of W arwick
For the degree of
Doctor of Philosophy
WarwickMedicalSchool,
University ofWarwick,UK
December 2015
ACONTENTS
List ofFigures and Tables K
Acknowledgments P
Dedication Q
Declaration R
Synopsis S
Abbreviations U
Chapter 1
Introduction 1
1.1 Cardiovascular disease (CVD) 2
1.1.1 Prevalence of Cardiovascular disease 2
1.1.2 Risks for Cardiovascular disease 3
1.2 Highriskgroups 4
1.2.1 Definition of high risk groups 4
1.2.2 Coronary Artery Disease (CAD) risk 4
1.2.3 Obesity 5
1.2.3.1 Definition of Obesity 8
1.2.3.2 Ethnic and Gender Variation 9
1.2.3.3 Consequences of Obesity 11
1.2.3.4 Obesity and Insulin Resistance (IR) 12
1.2.4 Impaired Glucose Tolerance (IGT) 15
B1.2.5 Type 2 Diabetes Mellitus (T2DM) 15
1.3 Post prandialstress 17
1.3.1 Post prandial glucose 18
1.3.2 Post prandial lipids 19
1.3.3 Mechanism of postprandial stress 20
1.4 Assessment ofrisk 20
1.4.1 Vascular endothelium 20
1.4.2 Anatomy of endothelial cell 21
1.4.3 Function of endothelium 21
1.4.4 Mechanism of Nitric oxide release 22
1.4.5 Mechanism of Oxidative stress 25
1.4.6 Endothelial dysfunction (ED) 26
1.4.7 Inflammation and ED 26
1.4.8 Triggers for ED 27
1.4.9 Assessment of ED ( Macrovascular function ) 29
1.4.10 Measurement of ED 31
1.5 Microvascular function 32
1.5.1 Definition 32
1.5.2 Anatomy and physiology of Retinal vessels 32
1.5.3 The vascular system of the retina 33
1.5.3.1 The Retinal blood vessels 33
1.5.3.2 The choroid vessels 34
C1.5.4 Diabetic retinopathy 35
1.5.5 Retinal vessel analysis on Retinal vessel analyser (RVA) 37
1.5.6 Functional measurement of Micro circulation and utility 38
1.6 Comparison withMacrovascular function 38
1.6.1 Brachial artery Flow mediated dilatation (FMD) 39
1.6.2 Vascular function predicting cardiovascular disease 39
1.7 Aims ofthesis 41
Chapter 2
GeneralMaterials and Methods 43
2.1 GeneralMaterials and Methods 44
2.1.1 Patient selection and recruitment 44
2.1.2 Research clinic 44
2.1.3 Selection criteria 45
2.1.3.1 Inclusion criteria 45
2.1.3.2 Exclusion criteria 45
2.2 ClinicVisit 46
2.2.1 Patient recruitment 48
2.2.2 Serum and plasma isolation 48
2.3 PhysiologicalTests 49
D2.3.1 Study Outline 49
2.3.2 Study Protocol 49
2.3.3 Endothelial function at Macro vascular level 51
2.3.4 Flow mediated dilatation (FMD) measurements 53
2.3.5 Retinal vessels reactivity (RVR) measurements 64
2.3.6 Mechanism of wall motion detection- Retinal vessel Analyser 65
2.3.7 Retinal vessel analyser (RVA) protocol 66
2.3.8 Arterio-venous ratio (A/V Ratio) on RVA 67
2.4 Molecular Analysis 68
2.4.1 Immediate bed side plasma and serum isolation 68
2.4.2 MultiplexImmunoassay 69
2.4.3 Protein Glycation and oxidation damage to LDLproducts 69
2.4.3.1 Isolation of LDL 69
2.4.3.2 In vitro modification of LDL 70
2.4.3.3 Delipidation of LDL 71
2.4.3.4 Enzymatic digestion of apoB100 71
2.4.3.5 Protein biomarker determination by LC-MS/MS 72
2.5 StatisticalAnalysis 72
2.6 Validation ofVascular tests 72
2.7 Summary 73
EChapter 3
Impact ofAcute Lipid ingestion on Circulating endotoxin Levels with
assessment ofvascular function 74
3.1 Introduction 75
3.2 Patients and methods 80
3.2.1 Study subjects 80
3.2.2 In vivo Assessment of the Biochemical profile 83
3.2.3 Analysis of circulating endotoxin levels 86
3.2.4 FMD Methodology 86
3.2.5 RVA Methodology 87
3.2.6 Statistical Analysis 88
3.3 Results 89
3.3.1 Baseline characteristics across Groups 89
3.3.2 Post-prandial change in Endotoxin levels over time in individual groups 90
3.3.3 Post-prandial Change in endotoxin levels between groups 92
3.3.4 Post-prandial Changes in lipids over time in individual groups 94
3.3.5 Post-prandial Changes in lipid levels between groups 94
3.3.6 Post-prandial Changes in FMD levels between groups 96
3.3.7 Post-prandial Changes in RVA levels between groups 100
F3.3.8 Correlation between endotoxin levels and vascular function 103
3.3.9 The effect of cholesterol levels on vascular reactivity 104
3.4 Discussion 105
Chapter 4
Impact ofendotoxaemia on sub-clinicalinflammation and endothelial
dysfunction in obese children 114
4.1 Introduction 115
4.2 Methods and Materials 118
4.2.1 Study subjects 118
4.2.2 Biochemical Measurements 119
4.2.3 Statistical Analysis 120
4.3 Results 121
4.3.1 Effect of gender on Biomarkers of Inflammation 121
4.3.2 Correlation of Endotoxin with Biomarkers of Inflammation and
CVD in Childhood & Adolescent Obesity 123
4.4 Discussion 128
GChapter 5
Assessment ofEDusingNon invasive vascular function in
Healthy subjects 132
5.1 Introduction 133
5.1.1 Endothelium 133
5.1.2 Endothelial dysfunction (ED) 133
5.2 Materials and Methods 135
5.2.1 Demographics 135
5.2.2 Patient recruitment and selection 137
5.2.3 Clinic visit 137
5.2.4 Study protocol 138
5.2.5 Serum and plasma isolation 138
5.3 Vascular function tests 139
5.3.1 Endothelial function at macro vascular level 139
5.3.2 Flow mediated dilatation measurements 139
5.3.3 Retinal vessel reactivity measurements 140
5.3.4 Mechanism of wall motion detection- RVA 141
5.3.5 Retinal vessel analyser (RVA) protocol 141
5.4 Results 143
5.4.1 Physiologic stress response 143
5.4.2 Macrovascular response to OGTT 144
H5.4.3 Micro vascular response to OGTT 146
5.4.4 Summary 147
5.5 Discussion 148
Chapter 6
Assessment ofED using Non invasive vascular function in high risk
subjects (T2DM)compared withHealthy subjects 153
6.1 Introduction 154
6.2 Subjects and methods 156
6.2.1 Study protocol 158
6.2.2 Flow mediated dilatation 158
6.2.3 Retinal vessel reactivity measurements 158
6.2.4 Biochemical and physical parameters 159
6.2.5 Power calculations 159
6.2.6 Validity measurements of vascular tests 159
6.2.7 Statistical Analysis 160
6.3 Results 161
6.3.1 Serum Triglycerides 161
6.3.2 Serum Glucose 162
6.3.3 Mean Flow mediated dilatation (FMD) 163
I6.3.4 Mean Retinal vessel reactivity (RVR) 165
6.4 Discussion 166
Chapter 7
Effect ofMetformin in reducingthe Cardiovascular riskin subjects with
T2DM 169
7.1 Introduction 170
7.2 Subjects and methods 173
7.2.1 Study population 173
7.2.2 Isolation of LDL 175
7.2.3 In vitro modification of LDL 175
7.2.4 Delipidation of LDL 176
7.2.5 Enzymatic digestion of apoB100 176
7.2.6 Protein biomarker determination by LC-MS/MS 177
7.2.7 Statistical Analysis 177
7.3 Results 178
7.3.1 Isolation of LDLand glycation by methylglyoxal and glucose in vitro 178
7.3.2 Protein damage markers in apolipoprotein B100 of LDLin healthy
human subjects and patients with T2DM 179
7.3.3 Correlation analysis for markers of glycemic control and protein
Damage in plasma apoB100 of T2DM patients 182
J7.3.4 Protein damage markers in apolipoprotein B100 of LDL
In patients with T2DM receiving metformin 183
7.4 Discussion 186
Chapter 8
FinalDiscussion 193
8.1 Discussion 194
8.2 Future Directions 200
8.3 Conclusion 201
APPENDICES
AppendixI Methods and checklists 203
1 a Patient’s information sheet 204
1 b Patient’s Informed consent form 209
1 c Patient’s proforma and check list 211
1 d Validated Dietary questionnaire 214
1 e Study protocol 223
AppendixII Protocols and examples 241
AppendixIIIStatisticalcalculations 250
KLISTOFFIGURES
CHAPTER1
Figure 1.2.3
Assessing cardiometabolic risk in children 6
Figure 1.4.2
Endothelial cell 21
Figure 1.4.4
Vascular effects mediated by Nitric Oxide 22
Figure 1.5.4
Different stages of Diabetic Retinopathy 36
CHAPTER2
Figure 2.3.4.1
VIA software detecting anterior and posterior walls in the ROI 58
Figure 2.3.4.2
VIA software displaying real time diameter changes over cardiac cycle 59
Figure 2.3.4.3
Protocol for Brachial artery scan using VIA software 61
Figure 2.3.4.4
VIA software displaying real time diameter changes over time 62
Figure 2.3.4.5
VIA software final reports on an FMD scan 63
CHAPTER3
Figure 3.3.2.1
Endotoxin levels in ND, IGT, obese and T2DM subjects 91
Figure 3.3.2.2
TG levels in ND, IGT, obese and T2DM subjects 91
Figure 3.3.3.1
Endotoxin levels between the non-obese and obese subjects on fat stress 92
LFigure 3.3.3.2
Endotoxin levels between the non-obese subjects and IGT on fat stress 93
Figure 3.3.3.3
Endotoxin levels between the non-obese subjects and T2DM on fat stress 93
Figure 3.3.5.1
TG levels between the non-obese and obese subjects on fat stress 95
Figure 3.3.5.2
TG levels between the non-obese subjects and IGT on fat stress 95
Figure 3.3.5.3
TG levels between the non-obese subjects and T2DM on fat stress 96
Figure 3.3.6.5
Intergroup analysis comparing FMD differences across groups 99
Figure 3.3.7.5
RVR changes between cohorts pre and post meal 102
CHAPTER4
Figure 1A and 1B
Correlation between log endotoxin (EU/ml) levels and the inflammatory markers 123
Figure 2A-F
Correlation between log endotoxin (EU/ml) levels and the markers of CVD 125
Figure 3A and 3B
Correlation between log endotoxin (EU/ml) levels and blood pressure (mm Hg)
in BMI and age-matched children 126
Figure 4
Comparison of mean relative endotoxin and BMI and age matched children 127
CHAPTER5
NIL
MCHAPTER6
Figure 6.3.2.1
Serum Glucose levels on OGTT comparing T2DM with ND subjects 162
Figure 6.3.3.1
FMD % dynamic change to OGTT between T2DM and ND subjects 163
Figure 6.3.3.2
Vascular reactivity on OGTT in T2DM subjects 164
Figure 6.3.4.1
RVA % dynamic change to OGTT between T2DM and ND subjects 165
CHAPTER 7
Figure 7.3.4
AGEand methionine sulfoxide residue contents in T2DM patients 185
NLISTOFTABLES
CHAPTER1
Table 1.2.3.1
The International Classification of obesity according to BMI 9
CHAPTER2
Table 2.3.2
ASDA fresh double cream: Nutritional content 51
CHAPTER3
Table 3.2.1.1
The International Classification of obesity according to BMI 80
Table 3.2.1.2
Anthropometric data for different cohorts
(ND, IGT, obese and T2DM) 82
Table 3.2.2
Variable data for the different cohorts over time,
(ND, IGT, obese and T2DM) 85
Table 3.3.6.1
FMD of brachial artery in response to fat stress in ND subjects 97
Table 3.3.6.2
FMD of brachial artery in response to fat stress in T2DM subjects 97
Table 3.3.6.3
FMD of brachial artery in response to fat stress in IGT subjects 98
Table 3.3.6.4
FMD of brachial artery in response to fat stress in Obese subjects 98
Table 3.3.7.1
ORVA of Retinal vessels in response to fat stress in ND subjects 100
Table 3.3.7.2
RVA of Retinal vessels in response to fat stress in T2DM subjects 101
Table 3.3.7.3
RVR of Retinal artery in response to fat stress in IGT subjects 101
Table 3.3.7.4
RVR of Retinal artery in response to fat stress in obese subjects 102
Table 3.3.8.1
Correlation between endotoxin and vascular studies 103
Table 3.3.9.1
Correlation between log cholesterol levels and vascular function 104
CHAPTER4
Table 4.3.1
Demographic profile and baseline characteristics of Obese, BMI and age matched
subjects 122
CHAPTER5
Table 5.2.1
ND subjects’demographic profile and baseline characteristics 136
Table 5.4.1.1
Serum glucose levels following OGTT on ND subjects 143
Table 5.4.1.2
Serum TG levels following OGTT in ND subjects 144
Table 5.4.2
FMD of brachial artery response to OGTT in ND subjects 145
Table 5.4.3
RVA of retinal artery in response to OGTT in ND subjects 146
PCHAPTER6
Table 6.2
Baseline characteristics of patients with T2DM 157
Table 6.3.1
Serum triglyceride (TG) levels on OGTT on subjects with T2DM 161
CHAPTER7
Table 7.2.1
Characteristics of T2DM patients and healthy control subjects 174
Table 7.3.1
Changes in protein glycation adduct residues in human LDLminimally
modified by methylglyoxal and glucose in vitro 179
Table 7.3.2
Markers of protein damage in apolipoprotein B100 of LDL 181
Table 7.3.3
Correlation triangle of glycaemic control and protein damage-related variables
of T2DM patients 183
Table 7.4
Comparison of the predicted reactivity of apolipoprotein B100 of LDLand total
plasma protein towards early glycation, advanced glycation, oxidation and nitration 188
PUBLICATIONS 266
PRESENTATIONSANDPOSTERS 316
BIBLIOGRAPHY 319
QACKNOWLEDGEMENTS
I would like to thank my academic supervisors, without whom this thesis would not have
been possible. Specifically, to Dr Philip McTernan who has been exceptionally helpful in
supporting my work. He has given long hours of his own time towards fruition of this project
and in so doing, became not only a teacher, but also a mentor and friend. He has been
inspirational as an academic. I also want to extend my sincere gratitude to my Cardiology
team and department lead by Dr Martin Been and Dr Peter Glennon. They have provided
valuable support in terms of logistics apart from creating a pleasant atmosphere to conduct
research. My thanks to the Nuclear Physics and Radiology departments at UHCW
(University Hospital), Coventry as well as Cardiology and Physics departments at St
George’s Hospital, London, for their contribution towards the studies. I am grateful for the
support of Dr Alijah and Foleshill Medical Centre, at Coventry, who facilitated the research
in the community. I would also like to thank our diabetic nurse specialists, Kay, Kam and
Suki, for their invaluable support in the conduct of this research project.
My additional regards to all team members including Dr Gyanendra Tripathi and Prof Kumar
based at CSRI (Clinical services research institute), Coventry for their assistance in technical
training and advice. Finally, I acknowledge and thank the assistance given to me by Ms
Nahla Bawazeer and Dr Kostas Constantinides during the physiological testing period of the
research project. Their dedication and perseverance in attending with me, during the long
phase of physiologic testing which included working almost all weekends for a period of upto
12 months did not go unnoticed. Kostas was trained to perform RVA and he was assisting me
by performing almost all RVA cases whilst I was involved in performing FMD
simultaneously.
RDEDICATION
I dedicate this work to my parents- Dr C.M Krishnamurthy and Dr /Mrs
C.M Rajeswari, on whose support and hard work this project was built. Their
unwavered support, steadfast resolve and great aspiration for this work to be
completed, along with their prayers, unconditional love and constant affection
delivered this project. I am deeply and eternally indebted to them.
My family including younger brother, sister, wife and two young daughters
stayed committed with me with their constant supportive nature and positive
encouragement. Their sweat and hardship are equal to mine in delivering this
work. I extend my sincere gratitude to my family for their continuous and
unparalleled love, help and support. This work has come to fruition because of
them.
I am also extremely grateful to my supervisors who stayed committed with me
during this long journey.
SDECLARATION
I declare that the work presented in this thesis is my own and has not previously
been submitted at this or any other institution. All work described in this thesis
was carried during the period of study for this examination and no work carried
out previous to that period is included. All publications relating to the work
presented in this thesis are attached at the back of the thesis.
All sources have been specifically acknowledged by means of reference.
TSYNOPSIS
Cardiovascular disease (CVD) continues to be a significant cause of mortality in W estern
society despite improvement in medicine and clinical management. Both CVD and coronary
artery disease (CAD) are caused by a pathological process known as atherosclerosis which
occurs due to deposition of lipid rich cholesterol material into the arterial inner lining, the
endothelium. The endothelium is a thin mononuclear layer that covers the inner surface of all
the blood vessels. It acts an athero-protective organ which mediates its actions through
vasoactive mediators, such as nitric oxide (NO). Endothelium derived nitric oxide is
synthesised from the amino acid L-arginine by the endothelial nitric oxide synthase (eNOS).
The synthesis of nitric oxide by vascular endothelium is responsible for the vasodilator tone
which is essential for the regulation of blood pressure and flow. The eNOS enzyme is
constitutive, calcium- and calmodulin-dependent, and releases pico-moles of nitric oxide in
response to receptor stimulation. A physiologic vaso-dilator tone mediated by nitric oxide is
in part maintained through the physical activation of endothelial cells by stimuli such as
pulsatile flow and shear stress. This current thesis, as a first stage, investigated vascular
function of the endothelium, following a physiological stress, at the macrovascular level
(flow mediated dilatation of brachial artery-FMD) in healthy subjects and other CVD risk
groups - type 2 diabetes (T2DM), obesity and impaired glucose tolerance (IGT). Oral glucose
and high fat meal were used for inducing physiological stress.
On the application of a physiological glucose stress, the mean FMD significantly and
profoundly reduced in all CVD groups revealing the acute effects of post-prandial stress on
the endothelium (p<0.05).
This thesis, further evaluated the microvascular function at the level of retina (using a retinal
vessel analyser, RVA) in all risk groups concurrent with macrovascular function assessment.
Such analysis identified that microvascular function, in contrast to FMD, at 1 and 2 hour post
Uglucose stress, appeared not to reveal significant reduction in healthy population compared
with T2DM;
This thesis also explored the impact of high fat diet on markers of endothelial dysfunction,
inflammatory markers including TNF-α and endotoxin; which are known to be increased in 
conditions of CVD and CAD. Studies determined that endotoxin levels increased over time
post a high fat meal. Specifically circulating endotoxin levels remained significantly and
exponentially high in T2DM even 4 hours after ingesting high fat diet (p<0.05);whilst
endotoxin levels in healthy subjects revealed only mild raise over time. This thesis explored
the role of high endotoxin levels not only in T2DM subjects but also in obese children to
demonstrate its association with subclinical inflammation and CVD risk.
As a lipid meal appeared to affect vascular function which was most pronounced in T2DM
subjects, this thesis further assessed the potential influence of medication to protect or reduce
vascular damage. As such this thesis investigated whether metformin treatment had protective
effect on lipoprotein damage and in turn on endothelial function on the high risk group of
T2DM compared with control subjects. Glycation, oxidation and nitration reactions lead to
significant damage of the apoB100 of LDL increasing atherogenicity and plasma residence
times (p<0.01). Metformin appeared to reduce this damage (P<0.05 for all AGE (advanced
glycation end) products and methionine sulphoxide) and thereby protect against endothelial
dysfunction.
This thesis determined the relevance of post-prandial stressors on vascular function at
different levels. It investigated the impact such stress could exert on different CVD risk
groups and how medication such as metformin may have protective effects. Microvascular
reactivity measurements using Retinal vascular analyser appears to demonstrate potential to
reliably study acute changes in endothelial function with potential long-term benefits for
providing individualized medicine to “at risk”patients.
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1Chapter 1
Introduction
21.1 Cardiovascular disease (CVD)
1.1.1 Prevalence of Cardiovascular Disease
Cardiovascular disease (CVD) and coronary artery disease (CAD) are caused by a
pathological process known as atherosclerosis which occurs due to deposition of lipid rich
cholesterol material into the arterial inner lining, the endothelium. Subsequent smooth muscle
proliferation and arterial wall thickening result in luminal narrowing, which impacts on blood
flow and oxygen delivery to the dependant tissues. At the level of coronary arteries, this
process results in symptoms of angina. Further progress of this condition leads to thrombosis
when platelets aggregate over the disrupted endothelium. The thrombosis causes further
reduction of arterial luminal diameter and acute reduction or complete cessation of blood flow
leads to acute myocardial infarction (AMI) at the level of coronary arteries. AMI is a
dangerous and life threatening complication of the atherosclerotic process. CAD (Coronary
artery disease) accounts for approximately one half of all CVD related deaths (Thom, Haase
et al. 2006). CVD continues to be one of the biggest killers in western countries. CAD is the
most common type of heart disease, killing over 370,000 people annually in the United States
of America. .Every year about 735,000 Americans have a heart attack. Of these, 525,000 are a
first heart attack and 210,000 happen in people who have already had a heart attack. Data are
from the Multiple Cause of Death Files, 1999-2013, as compiled from data provided by the
57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. Underlying
Cause of Death 1999-2013 on CDC W ONDER Online Database, released 2015Accessed Feb.
3, 2015. According to the last available Office of National Statistics document “Statistical
bulletin: Deaths Registered in England and W ales (Series DR), 2014”, the most common
cause of death in males for England and W ales (Rank 1) is Ischemic Heart disease (IHD)
(ICD10 code 120-125). It accounts for 14.8% of all male deaths which is more than twice the
3frequency of the Second most common cause of death (dementia and Alzheimer’s disease).
Similarly for females, IHD continues to be the second most common cause of death in 2014.
Age standardized mortality rate per million population for males is 1647 and for females it is
1020 in 2014. Therefore, CVD continues to be a serious medical condition and results in
significant burden on the National Health Service (NHS). Similarly, CVD impacts on other
serious health conditions like type 2 diabetes mellitus (T2DM) leading to a significant
increase in morbidity and mortality. According to the British Heart Foundation (BHF), total
CVD burden on the UK is estimated to cost around £30 billion every year. According to the
W orld Health Organization (W HO), the prevalence of CVD in T2DM individuals ranges
from 26% to 36%. CVD accounts for as much as 75% of hospital admissions for diabetic
complications and 75% of deaths in T2DM subjects (Charbonnel and Del Prato 2003). In
view of such a significant impact, urgent measures will be needed, not only to reduce the
burden of CVD, but also to prevent it at an earlier stage.
1.1.2 Risks for Cardiovascular Disease (CVD)
T2DM subjects have a two to four fold increased risk of CVD compared with non diabetic,
healthy (ND) subjects (Kannel and McGee ;Kannel and McGee 1979;Kannel and McGee
1979;Stamler, Vaccaro et al. 1993). The risk appears to be progressive with raised serum
glucose levels. A systematic review found that the relationship between glucose levels and
occurrence of cardiovascular events is graded, a relationship that is apparent even for glucose
levels below diabetic threshold (Kuusisto, Mykkänen et al. 1994) (Coutinho, Gerstein et al.
1999). Similarly, obese subjects also have a higher risk of developing CVD (Kannel, Gordon
et al. 1979). In obesity, prediction of a cardiovascular event risk is not as straight forward as
impaired glucose tolerance (IGT) or T2DM because the pathology involved in obesity is
4varied. Some of the factors involved include insulin resistance (IR), pro-thrombotic state, pro-
inflammatory state and the type of obesity, i.e., android or gynoid, abdominal or otherwise
(Rimm, Stampfer et al. 1995;Eckel and Krauss 1998;Grundy 2002). The underlying risk in
all of the above groups linking obesity, IGT, T2DM and IR with cardiovascular risk is
endothelial dysfunction (Steinberg, Chaker et al. 1996;Caballero 2003;Hsueh, Lyon et al.
2004).
1.2 HighRiskGroups
1.2.1 Definition of High Risk Groups
High risk groups are subjects with factors or features which predispose them to high
propensity for future CVD. These groups were initially identified by the Framingham heart
study in the early 60’s (Kannel, Gordon et al. 1979).
1.2.2 Coronary Artery Disease (CAD) Risk
Subsequent to the Framingham heart study, 10 year cardiovascular risk of a healthy
individual could be calculated as a percentile risk, referred to as the Framingham risk score.
This risk predictive tool was able to identify high risk groups like diabetics, hypertensive’s,
obese, smokers and subjects with high cholesterol levels (Kannel, Gordon et al. 1979;Kannel
and McGee 1979;Kannel and McGee 1979;Kannel and McGee 1979) who each had
independent risk of premature CVD compared with healthy controls. However during the
subsequent decades post Framingham, it was evident that the risk predictor could be over
estimating risk in certain populations who, themselves, had lower baseline risk. Therefore, in
5order to develop a risk predictor for Europe, “Systematic coronary risk evaluation”(SCORE)
project was developed. This tool can now predict the 10 year risk of fatal cardiovascular
events (coronary risk) with different combinations of risk factors (Conroy, Pyorala et al.
2003).
1.2.3 Obesity
Obesity is a worldwide health problem which has spread in epidemic proportions throughout
most countries. Excess weight gain within populations predicts an increased burden of
diseases such as cardiovascular diseases, T2DM and cancers. In a recently published report,
using a simulation model, health and economic consequences of a continued rise in obesity
over the next two decades in the UK were calculated (W ang, McPherson et al. 2011). These
trends projected 11 million more obese adults in the UK by 2030, leading to an additional
544 000–668 000 cases of diabetes, 331 000–461 000 of coronary heart disease and strokes, 
and 87 000–130 000 of cancer with 2·2–6·3 million quality-adjusted life years lost for UK 
(W ang, McPherson et al. 2011). The combined medical costs associated with treatment of
these preventable diseases were estimated to increase by £1·9–2 billion/year in the UK by
2030 (W ang, McPherson et al. 2011). “Health survey of England (HSE) 2009”, a document
published by  The NHS National Statistics, identified, obesity or overweight as a signiﬁcant 
public health problem in view of its association with significant risk factors for disease and
mortality. Body mass index (BMI) and waist circumference are the tools used to identify
general obesity and abdominal obesity respectively.
As childhood obesity is increasing in prevalence in the western countries, conditions such as
the metabolic syndrome, type 2 diabetes and CHD all tend to have peak prevalence in middle-
aged and older individuals but assessments of cardio metabolic risk in childhood and
6adolescence become important to define early causal factors and characterise preventive
measures. Typically, researchers investigating prospective cohort studies have relied on the
thesis that cardiovascular risk factors, such as dyslipidaemia, hypertension and obesity, track
from childhood into adult life. A recent review summarises some of the evidence that these
factors, when measured in childhood, may be of value in assessing the risk of adult cardio
metabolic disease, and as such proceeds to describe some of the methods for assessing cardio
metabolic risk in children (Huang, Prescott et al. 2015) (Figure 1.2.3).
Figure 1.2.3 - Methods for assessing cardio metabolic risk in children (Huang, Prescott et al.
2015).
Obese children are at higher risk of being obese as adults, and adult obesity is associated with
an increased risk of morbidity. A systematic review and meta-analysis investigated the ability
of childhood body mass index(BMI) to predict obesity-related morbidities in adulthood. It
found that high childhood BMI was associated with an increased incidence of adult diabetes
7(OR 1.70;95% CI 1.30-2.22) and coronary artery disease (OR 1.20;95% CI 1.10-1.31)
(Llewellyn, Simmonds et al. 2015).
In 2008, almost a quarter of adults (24% of men and 25% of women aged 16or over) in
England were classified as obese (BMI 30kg/m2 or over). A greater proportion of men than
women (42% compared with 32%) in England were classified as overweight in 2008(BMI 25
to less than 30kg/m2). Thirty-nine per cent of adults had a raised waist circumference in 2008
compared to 23% in 1993. W omen were more likely than men (44% and 34% respectively) to
have a raised waist circumference (over 88cm for women and 102 cm for men). Using both
BMI and waist circumference to assess risk of health problems, for men: 20% were estimated
to be at increased risk;14% at high risk and 21% at very high risk in 2008. Equivalent figures
for women were 15% at increased risk;17% at high risk and 24% at extremely high risk.
Mean BMI increased with age in both sexes up to the age of 74, but dropped back slightly
beyond age 75. Almost a quarter of adults (22% of men and 24% of women) were obese. 66%
of men and 57% of women were overweight or obese. Among both men and women,
prevalence of overweight and obesity was lowest in the 16-24age groups, and increased in
the older groups up to the age of 74. Levels of obesity have increased over the period
measured by the Health survey of England (HSE) document 2009. In men, the prevalence of
obesity increased from 13% in 1993 to 22% in 2009. In women, 16% were obese in 1993 and
24% were obese in 2009. Recently focus in Europe, and particularly in the UK, has shifted
towards the alarming rise in childhood obesity and its subsequent consequences. The annual
rate of increase in the prevalence of childhood obesity is currently 10 times higher than it was
in the 1970s (W HO Europe 2007 report). Furthermore, as overweight and obesity are
responsible for about 80% of cases of T2DM, 35% of ischaemic heart disease and 55% of
hypertensive disease among adults in the UK,this new epidemic of childhood obesity (Chinn
8and Rona 2001) is extremely concerning all European governments. Obesity and its
consequences are already responsible for more than 1 million deaths and 12 million life-years
of ill health each year, and taking up to 6% of national health care costs in the W HO
European Region (W HO Europe 2007 report). As the burden of illness is predicted to rise
exponentially, it is critical that effective preventive strategies are adopted to focus on early
identification and risk stratification ultimately to reduce its burden.
1.2.3.1 Definition of Obesity
Obesity is a medical condition where excess body fat accumulation may have an adverse
impact on health leading to reduced life expectancy. In adults, excess body weight is defined
as having a body mass index (BMI) ≥25 kg/m2. Obesity is defined as a BMI ≥30 kg/m2
(W orld health organization, W HO Europe report 2007). The following table 1.2.3.1 defines
the body mass index(BMI) cut off for the definition of overweight and obesity. Even though
an attempt was made by the W HO to adopt an alternative BMI chart with more suitable
criteria for people of Asian origin, the consensus document currently still holds the following
universal BMI cut offs for all definitions of weight parameters (Table 1.2.3.1).
9Classification BMI(kg/m)
Underweight <18.50
Normal range 18.50 - 24.99
Overweight ≥25.00 
Pre-obese 25.00 - 29.99
Obese ≥30.00 
Obese class I 30.00 - 34-99
Obese class II 35.00 - 39.99
Obese class III ≥40.00 
Table 1.2.3.1 The International Classification of adult underweight, overweight and obesity
according to BMI. The W orld health Organization (W HO) –2009.
The definition of obesity based solely on BMI measurements meant other vital information
might be ignored. Vital information about important factors like age, sex, race, abdominal
circumference and waist hip ratio could be missed. These factors have significant influence
on risk stratification (Flegal and Ogden 2011). In view of this, the true picture of obesity
might not be reflected in the official data collections.
1.2.3.2 Ethnic and Gender Variation
The percentage body fat and BMI vary widely between different ethnic groups, including
Caucasians of European and American origin (Deurenberg, Yap et al. 1998;Gurrici,
Hartriyanti et al. 1998). This implies that current method of diagnosing obesity solely based
BMI/body weight may not be accurate. These studies also reveal that some ethnic groups,
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such as Asians, tend to have more body fat for the same BMI compared to Europeans. This
means that the true definition of obesity could be different in different ethnic groups (Gurrici,
Hartriyanti et al. 1998;Nishida 2004). However, in the absence of any robust alternative, the
W HO has continued to use BMI to diagnose obesity across various age, sex and ethnic
groups.
Similarly, distribution of body fat is not comparable between the sexes. Men tend to
accumulate excess fat around the abdominal region of the body whereas young women appear
to predominantly accumulate fat around the hips and thighs. This was originally described in
a sentinel paper by Vague in the 1950s (Vague 1956), which distinctly illustrates the Android
(male) and Gynoid (female) types of fat distribution in obesity. It also clearly mentions the
fact that in every area of the body, except for the first three cervical vertebral region, the fat
percentage is higher in women than men (Vague 1956), a finding that translates into differing
risk between men and women. Men, with their android distribution, appear to be at a higher
risk for diabetes and heart disease compared with women, due to the latter’s gynoid
distribution of fat. This lead to the next stage of obesity measurement, where the differing
patterns of fat distribution were taken into account to measure obesity and the concept of
waist to hip ratio was formulated (Grundy 2002). Subsequently, various studies have started
to look at the best parameters for obesity identification between BMI, waist to hip ratio, waist
circumference and weight itself. Studies investigated differences in metabolic effects of
obesity (Brook, Bard et al. 2001), (Snijder, Dekker et al. 2003), ultimately trying to identify
better predictive tools for measuring risk of diabetes and heart disease (Molarius, Seidell et al.
1999;Molarius, Seidell et al. 1999). A review paper in 1990 demonstrated the significant
impact of body fat distribution on the risk of CVD (Després, Moorjani et al. 1990).
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1.2.3.3 Consequences of Obesity
Obesity is a result of an imbalance between energy expenditure and energy obtained from
ingesting food. The resultant excess energy is stored in the fat cells of the body. The
consequences of obesity are related to the effects of the increased mass of cells and their
metabolic output. The excess fat mass production and distribution in the body is not uniform
between subjects, sexes or races, hence creating a differing risk. Apart from physical issues
due to the mass of cells and their metabolic reactions, social, behavioural and psychological
consequences of obesity are not uncommon (Bray 2004). According to a W HO report, the
risk of ill health and other detrimental effects get progressively worse with increasing BMI.
The health consequences of obesity can be categorised into CVD, T2DM, insulin resistance,
musculo-skeletal disorders –especially osteoarthritis and some types of cancers (e.g. Breast,
endometrial and colon). The W HO projects that deaths due to diabetes will increase by more
than 50% worldwide in the next 10 years. The heart diseases and stroke are already the
world’s number one cause of death leading to 17 million deaths every year. Childhood
obesity is associated with a higher chance of premature death and disability in adulthood
(W HO report 2009). Obesity is considered a global epidemic with important public health
issues (Pires, Castela et al. 2015). It is an independent risk factor in the development of
cardiovascular disorders. W hen it is evident in obese children, it potentially contributes
towards cardiovascular disease in the adult (Pires, Castela et al. 2015). The
anatomic/pathological changes begin early in childhood and studies in children with excess
weight or obesity have shown endothelial changes that represent the precursors of the
atherosclerotic lesions (Pires, Castela et al. 2015).
The most important of these consequences, T2DM, will be explored further in this chapter.
Even though the development of T2DM occurs due to concurrent multi-factorial metabolic
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factors, obesity represents the single most important factor for the pathogenesis of T2DM.
The epidemiological link between obesity and diabetes is so closely inter- linked that the
common syndrome has been termed ‘diabesity’since early 2000. This epidemiological
relationship between obesity and T2DM has been highlighted by numerous studies (Chan,
Rimm et al. 1994;Colditz, W illett et al. 1995;W annamethee and Shaper 1999;Mokdad, Ford
et al. 2003), demonstrating the increasing incidence of T2DM with increasing BMI. Obesity
results in IR, increasing insulin secretion and ultimately metabolic syndrome (Bray 2004). A
recent review provides good mechanistic insights into obesity and its consequences including
cardio metabolic syndrome (Lovren, Teoh et al. 2015).
1.2.3.4 Obesity and Insulin Resistance (IR)
IR appears to be the primary mechanism by which obesity leads to development of metabolic
and vascular complications. These complications include T2DM, dyslipidaemia, hypertension
and CVD. IR is a condition where normal amounts of insulin are inadequate to produce an
expected insulin response from fat (adipose), muscle and liver cells. The exact mechanisms
leading to the development of IR in obese individuals are unclear. Various theories and
mechanisms have been put forward over the past few decades to explain the link between
obesity and IR. As the interplay between insulin and glucose is most significant in skeletal
muscle, adipose tissue (fat) and liver, most of the research has concentrated on these tissues,
and continues to do so, in order to understand the underlying causes of IR.
IR can also be seen in normal physiologic conditions during puberty, pregnancy and old age
(Kahn, Hull et al. 2006). Similarly, increased physical activity reduces IR (Chen, Bergman et
al. 1988;Kahn, Hull et al. 2006). Adipose tissue, being a metabolically active endocrine
tissue, normally releases various hormones such as adiponectin, some pro-inflammatory
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cytokines, glycerol and free fatty acids (FFA). Most of these products are produced in excess
in obesity, which is important in the progression of IR, particularly as FFA have the potential
to induce IR and impair beta cell function (Roden, Price et al. 1996;Kahn, Hull et al. 2006).
Routinely, insulin would inhibit the release of FFA from adipose tissue (Rabinowitzand
Zierler 1962). However, if plasma insulin levels are not able to rise with increasing FFA
production and release, then circulating FFA levels will increase. This will eventually lead to
elevated blood glucose levels by increasing hepatic glucose production and hyperglycaemia
(Reaven 1988). FFA induces insulin resistance by inhibition of glucose phosphorylation and
oxidation, ultimately resulting in reduced muscle glycogen synthesis and hyperglycaemia
(Roden, Price et al. 1996). In obese subjects, FFA ultimately fails to stimulate insulin
secretion (Boden 1997). Another critical product which induces IR in obese subjects is retinol
binding protein 4(RBP4) (Yang, Graham et al. 2005;Kahn, Hull et al. 2006). RBP4is the
only specific transport protein for delivering retinol to tissues. Liver and adipose cells are the
main source of circulating RBP4. As the adipose cell mass increases, RBP4production from
these cells also increases. At the same time, RBP4clearance from plasma is also altered in
obese subjects, explaining the observed increase in RBP4levels (Yang, Graham et al. 2005).
RBP4leads to insulin resistance by increasing hepatic glucose output and impairing insulin
signalling in muscle (Yang, Graham et al. 2005). Furthermore, it can reduce phosphatidyl
inositol-3-OH kinase (PI3K) signalling in muscle and enhance gluconeogenesis in the liver.
(Kahn, Hull et al. 2006).
In obese subjects, alteration in glucose transportation systems also leads to insulin resistance.
This system consists of a group of 5 homologous transmembrane proteins which are involved
in facilitated transport of glucose down the concentration gradient. Glucose uptake is the rate-
limiting step in glucose utilization in mammals and is tightly regulated by a family of
specialized proteins, called the facilitated glucose transporters (GLUTs). There are two types
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of glucose transporters. One of them is the sodium dependent glucose transporters (SGLTs)
which transport glucose against its concentration gradient and the other- sodium independent
glucose transporters (GLUTs), which transport glucose by facilitative diffusion in its
concentration gradient (Jurcovicova 2014). The GLUT1 is produced in brain
microvasculature and ensures glucose transport across the blood brain barrier (BBB). GLUT2
is present in hypothalamic neurons and serves as a glucose sensor in regulation of food
intake. GLUT3 is the most abundant glucose transporter in the brain having five times higher
transport capacity than GLUT1. It is present in neurones, mostly in axons and dendrites. Its
density and distribution correlate well with the local cerebral glucose demands (Jurcovicova
2014). GLUT5 is predominantly fructose transporter. GLUT4 and GLUT8 are insulin-
regulated glucose transporters (Jurcovicova 2014). GLUT4, the major isoform in insulin-
responsive tissue, translocates from an intracellular pool to the cell surface and determines
insulin-stimulated glucose uptake (Lacombe 2014). In muscle and adipose cells, the
predominant glucose transporter isoform is GLUT4. Studies have observed that insulin
resistant adipocytes from obese subjects show depletion of GLUT4transporters (Shepherd
and Kahn 1999), with as much as 40 to 80 % depletion of GLUT4in adipocytes from these
subjects (Garvey, Maianu et al. 1991). Similarly in skeletal muscle, the principal site of
glucose disposal, insulin resistant cells show decreased glucose transport activity (Lockwood
and Amatruda 1983;Friedman, Dohm et al. 1992). However, these effects are not necessarily
irreversible, as weight loss has been shown to improve glucose transport activity (Friedman,
Dohm et al. 1992). The adverse effects on glucose transport in the adipocyte and skeletal
muscle cell may be further compounded by the negative effects of obesity on the beta (β) cell 
of the pancreas. The β cell is crucial in ensuring that plasma glucose concentrations are 
maintained within a narrow physiological range but, in obesity, β cell function and its insulin 
sensitivity are reduced leading to IR (Kahn, Hull et al. 2006). In the early stages of IR, the
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effects can be counteracted by an increase in fasting insulin levels, balancing hepatic glucose
production in response to glycaemic load. At a later stage, increases in insulin secretion will
be unable to overcome the effect of whole body insulin resistance, at which point the
condition progresses to a state of impaired glucose tolerance (IGT).
1.2.4 Impaired Glucose Tolerance (IGT)
IGT is a condition in which fasting plasma glucose levels are higher than normal but lower
than those diagnostic of diabetes mellitus. In some subjects, this can progress towards
diabetes but, in others, this condition could stabilise or even regress. The diagnosis of IGT is
currently based on the 2006 W HO criteria, with fasting glucose levels of ≤ 7.0 mmol/l and 2 
hour post plasma glucose load of ≥ 7.8 mmol/l and < 11.1 mmol/l. IGT usually progresses 
towards T2DM. Insulin resistance is a common finding in the majority of IGT subjects
(Reaven 1988), obese children and adolescents (Invitti, Guzzaloni et al. 2003). The onset of
IGT in all these subjects is associated with development of hyperinsulinaemia (Polonsky,
Sturis et al. 1996). Hyperinsulinaemia is a state of increasing insulin levels over time. This
leads to decreasing insulin sensitivity and impaired pancreatic β cell function, which will 
ultimately lead to T2DM (Lillioja and Bogardus 1988).
1.2.5 Type 2 Diabetes Mellitus (T2DM)
Several follow up studies have looked at predictive markers of increased T2DM risk in obese
and IGT subjects. Further progression to T2DM depends, not only on IR, but sometimes on
the gradual failure of the pancreas to maintain high levels of insulin production (Bogardus,
Lillioja et al. 1984;Saad, Knowler et al. 1989;Polonsky, Sturis et al. 1996). As insulin
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production drops, the subjects progress from IGT to overt diabetes. One of the most powerful
indicators for predicting the onset of diabetes is initial blood glucose levels (O'Sullivan and
Mahan 1965;Jarrett, Keen et al. 1979;Keen, Jarrett et al. 1982;Sasaki, Suzuki et al. 1982;
Kadowaki, Miyake et al. 1984). Multivariate analysis revealed diminished insulin response
and high level of fasting and 2-hr glucose values at the initial 100-g oral glucose tolerance
test as significant predictive independent risk factors for the development of diabetes in
Japanese subjects (Kadowaki, Miyake et al. 1984). In other studies, it has been estimated that
up to 70 % of IGT subjects eventually develop diabetes (Jarrett, Keen et al. 1979;Sasaki,
Suzuki et al. 1982;Shaw, Zimmet et al. 1999;Gabir, Hanson et al. 2000;de Vegt, Dekker et
al. 2001;Nathan, Davidson et al. 2007). However, the natural history of IGT subjects is
variable. It appears that around 25% of IGT subjects, over a period of 3 to 5 years, progress to
T2DM, whilst another 25% might regress back to ND, but the majority may remain in the
same altered glucose state (Nathan, Davidson et al. 2007). Finally, as this state is considered
pre-diabetic, it is still possible to reverse this condition both by physical activity and by
medication (Tuomilehto, Lindström et al. 2001;Knowler, Barrett-Connor et al. 2002). Even
though the 2 hour oral glucose tolerance test (OGTT) is regarded as the gold standard for
identification of these groups, it is not used as widely as required. Recent studies have shown
that prediction models can also estimate the risk of developing T2DM at the pre-diabetes
stage with similar confidence (Stern, W illiams et al. 2002). Although there are practical
benefits in using a predictive model, it is not, at present, a widely used method, even though
obese and IGT subjects are important to evaluate, in view of their high risk of developing
CVD.
Once T2DM sets in, life expectancy is predicted to be 5 to 10 years lower than in the ND
general population (Charbonnel and Del Prato 2003). The relationship between diabetes and
cardiovascular events is so stringent that the American Diabetes Association has identified
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diabetes as a type of CHD itself. The National Cholesterol Education Program Expert Panel
(NCEP) on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult
Treatment Panel III) agree with the conclusion that diabetes should be considered as a CHD
risk equivalent (Charbonnel and Del Prato 2003). In the same vein, it is now highlighted that
hyperglycaemia, in addition to hypertension and dyslipidaemia, should also be considered an
independent risk factor for CVD in diabetic subjects (Ceriello 2005;Ceriello 2009).
Hyperglycemia continues to be an important threat to the health of patients, independent of
diabetes status. A recent retrospective cohort study comparing 1- and 5-year risk of death and
cardiovascular (CV) complications in patients with a diagnosis of diabetes versus those
without diabetes but found to have hyperglycemia at hospital admission for risk of all-cause
death and CV complications (acute myocardial infarction [AMI], revealed the following.
Compared to patients with diagnosed diabetes, patients with peak serum glucose level >200
mg/dLhad significantly higher 1-year risk (hazard ratio [HR]: 1.31, 95% confidence interval
[CI]: 1.20-1.43) and 5-year risk (HR: 1.13, 95% CI: 1.06-1.22) of death. In-hospital
hyperglycemia is an important clinical indicator, carrying a higher 1- and 5-year mortality
risk than those with diagnosed diabetes (Tuna, Manuel et al. 2014).
1.3 Post-prandialStress
The post prandial state is characterised by increasing levels of both glucose and triglycerides,
with the time to peak measurement for both glucose and triglyceride levels varying in
different subjects. Similarly the value of peak measurements differs between healthy
individuals and diabetic subjects. The post prandial phase, characterised by both
hyperglycaemia and hypertriglyceridaemia, may lead to endothelial dysfunction by producing
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oxidative stress (Ceriello, Taboga et al. 2002), a phenomenon that is often represented as
post- prandial stress.
1.3.1 Post-prandial Glucose
Obesity, IGT and T2DM reveal endothelial dysfunction at an early stage (Lam and LeRoith
2000). Post-prandial glucose (PPG) can be used as a common denominator and stressor for all
the above conditions to differentiate and evaluate the endothelial function between the above
groups. Hyperglycaemia induces endothelial dysfunction by producing oxidative stress
(Kawano, Motoyama et al. 1999;Marfella, Quagliaro et al. 2001;Ceriello, Taboga et al.
2002). As such, PPG has already been used in previous studies as a physiological stress
inducer to evaluate endothelial function (Ceriello, Taboga et al. 2002;Ceriello, Quagliaro et
al. 2004). PPG can lead to the production of Advanced Glycation End products (AGE)
(W olff and Dean 1987) which can lead to production of oxidative stress. AGEs are created by
a non-enzymatic reaction between reducing sugars and biological proteins. These compounds
accumulate slowly throughout the life span and contribute to structural and physiological
changes that can lead to endothelial dysfunction and subsequent CVD (Zieman and Kass
2004). PPG has thus been suggested as an independent risk factor for CVD (Ceriello 1998) in
T2DM subjects. Similarly, PPG may also be considered an independent risk factor for the
development of retinopathy in diabetes and in IGT (Shiraiwa, Kaneto et al. 2005). Recent
evidence suggests that post-challenge hyperglycaemia is a better predictor of cardiovascular
risk than fasting glucose. Acute glucose elevations have been associated with a reduced
endothelial-dependent flow mediated dilation indicating a decrease in nitric oxide production
(Siervo, Corander et al. 2011). Post-prandial hyperglycaemic peaks have been directly
associated with increased intima media thickness in type 2 diabetic patients indicative of an
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increased atherosclerotic risk (Siervo, Corander et al. 2011). The increase in intra-cellular
glucose concentrations in the endothelial cells induces a hyper-generation of reactive oxygen
species via the activation of different pathways (polyol-sorbitol, hexosamine, advanced
glycated end products, activation of PKC, asymmetric dimethylarginine (ADMA)). These
mechanisms influence the expression of genes and release of signalling and structural
molecules involved in several functions (inflammation, angiogenesis, coagulation, vascular
tone and permeability, cellular migration, nutrient metabolism). ADMA is considered as a
biomarker of endothelial dysfunction and it has been associated with an increased risk of
atherosclerosis and cardiovascular diseases. The increased generation of ADMA and reactive
oxygen species in subjects with persistent hyperglycaemia could lead to an impairment of
nitric oxide synthesis (Siervo, Corander et al. 2011).
1.3.2 Post-prandial Lipids
Post-prandial hypertriglyceridaemia seems to exert a negative influence on endothelial
function, an effect that has been reported in both normal and T2DM subjects (Anderson,
Evans et al. 2001;Bae, Bassenge et al. 2001;Ceriello, Taboga et al. 2002). This negative
effect seems to be mediated through the production of oxidative stress, resulting in nitric
oxide (NO) inactivation (Ceriello, Taboga et al. 2002). The change in postprandial
triglycerides is also relevant to CVD (Nordestgaard, Benn et al. 2007), as postprandial hyper-
triglyceridaemia and dyslipidaemia are well-recognised risk factors for CVD in T2DM
(Taskinen, Lahdenpera et al. 1996;Taskinen 2003;Pastromas, Terzi et al. 2008) (Karpe,
Steiner et al. 1994;Ceriello 2006;Ceriello, Davidson et al. 2006). In non-obese, T2DM
patients with moderate fasting hypertriglyceridaemia, the atherogenic lipoprotein profile are
amplified in the postprandial state (Cavallero, Dachet et al. 1994). This raises the possibility
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that, in patients with postprandial hyperglycaemia and a concomitant increase in postprandial
hyperlipidaemia, the latter might be the true risk factor (Heine and Dekker 2002).
1.3.3 Mechanism of Post-prandial Stress
The post-prandial state, as evidenced by acute hyperglycaemia, leads to an increase in
nitrotyrosine and peroxynitrite levels. The rise in peroxynitrite levels instigates cytotoxic
reactions in the cells, including lipid peroxidation and protein oxidation. This process also
involves excess generation of superoxide, which inactivates NO leading to endothelial
dysfunction (Ceriello, Taboga et al. 2002). This mechanism of post-prandial hyperglycaemia
and the subsequent endothelial dysfunction appears to occur both in healthy subjects
(Marfella, Quagliaro et al. 2001) as well as subjects with IGT or T2DM (Marfella, Nappo et
al. 2000). Similarly, hypertriglyceridaemia, as part of the post-prandial state, produces a
similar response to post-prandial hyperglycaemia, promoting endothelial dysfunction in both
healthy and T2DM subjects through peroxynitrite formation (Anderson, Evans et al. 2001).
1.4 Assessment ofRisk
1.4.1 Vascular Endothelium
The endothelium is a thin mononuclear layer that covers the inner surface of all the blood
vessels. It separates the circulating blood from the vascular smooth muscle and tissues. The
healthy vascular endothelium functions as an athero-protective organ which mediates its
actions through vasoactive mediators, such as NO, prostacyclin, and endothelium derived
hyperpolarising factor (EDHF).
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1.4.2 Anatomy of Endothelial Cell
Figure 1.4.2 Endothelial cell: It is a three layered cell structure with an inner lining,
intima, smooth muscle laden media and an outer adventitious coat.
1.4.3 Function of Endothelium
The endothelium influences vasomotion, platelet and leukocyte adhesion and plaque
stabilisation. It senses mechanical stimuli, such as pressure and sheer stress, and hormonal
stimuli, such as vasoactive substances. In response to such stimuli, it releases agents that
regulate vasomotor function, trigger inflammatory processes and affect haemostasis. It also
contributes to the control of vascular tone and local blood flow (Marsden, Goligorsky et al.
1991). The healthy endothelium mediates coagulation, immune function, mitogenesis,
angiogenesis, vascular permeability and fluid balance and plays a central role in
cardiovascular control (Poredos 2001;Poredos 2002;Landmesser, Hornig et al. 2004).
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1.4.4 Mechanism of Nitric oxide release
Figure 1.4.4 Vascular effects mediated by Nitric Oxide (Moncada and Higgs 1993).
In panel A, shear stress or receptor activation of vascular endothelium by bradykinin or
acetylcholine results in an influxof calcium. The consequent increase in intracellular calcium
stimulates the constitutive nitric oxide synthase (NOS). The nitric oxide (NO) formed from L-
arginine (L-arg) by this enzyme diffuses to nearby smooth-muscle cells, in which it stimulates
the soluble guanylate cyclase (sGC), resulting in enhanced synthesis of cyclic GMP from
guanosine triphosphate (GTP). This increase in cyclic guanosine monophosphate (cGMP) in
the smooth-muscle cells leads to their relaxation. In Panel B, vasodilators such as sodium
nitroprusside and nitroglycerin release nitric oxide, spontaneously or through an enzymatic
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reaction. The liberated nitric oxide stimulates the soluble guanylate cyclase in the vascular
smooth-muscle cell, resulting in relaxation. In Panel C, the interaction of cytokines with their
receptors on endothelial and smooth-muscle cells results in the induction of calcium-
independent nitric oxide synthase. This induction is inhibited by glucocorticoids. Once
induced, the nitric oxide synthase produces nitric oxide continuously, resulting in sustained
activation of soluble guanylate cyclase.
Nitric oxide from the vascular endothelium is released in different ways. There is a
continuous basal synthesis of nitric oxide which is released to maintain resting vascular tone
(Vallance and Chan 2001). Secondly, both chemical mediators and acetylcholine apart from
physical stimuli like shear stress can activate endothelial nitric oxide synthase (eNOS) and
lead to increased nitric oxide production and release (Vallance and Chan 2001). All the
mechanisms involved in activation and release of nitric oxide are depicted pictographically
above (Vallance and Chan 2001) in Figure 1.4.4.
Endothelium derived nitric oxide is synthesised from the amino acid L-arginine by the
endothelial nitric oxide synthase (eNOS). The synthesis of nitric oxide by vascular
endothelium is responsible for the vasodilator tone that is essential for the regulation of blood
pressure. The eNOS enzyme is constitutive, calcium- and calmodulin-dependent, and releases
pico-moles of nitric oxide in response to receptor stimulation (Moncada 1992;Moncada and
Higgs 1993). A physiologic vaso-dilator tone mediated by nitric oxide is essential for the
regulation of blood flow and pressure. This nitric oxide-dependent vasodilator tone seems to
be maintained through the physical activation of endothelial cells by stimuli such as pulsatile
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flow and shear stress (Moncada 1992;Moncada and Higgs 1993). Nitric oxide is a labile gas
with a very short half life of <4seconds in biological solutions (Vallance and Chan 2001).
It is rapidly oxidised to nitrite before being excreted into the urine (Moncada and Higgs 1993;
Vallance and Chan 2001). Once synthesised, the nitric oxide rapidly diffuses across the
endothelial cell membrane and enters the vascular smooth muscle cells where it activates
guanylate cyclase, leading to an increase in intracellular cyclic guanosine-3’,5-
monophosphate (cGMP). cGMP, acting as a second messenger, mediates many of the
biological effects of nitric oxide including the control of vascular tone and platelet function
(Vallance and Chan 2001). Ca2+-activated calmodulin is important for the regulation of
eNOS activity. Endothelial NOS synthesizes NO in a pulsatile manner with eNOS activity
markedly increasing when intracellular Ca2+rises. Ca2+induces the binding of calmodulin
to the enzyme (Hemmens and Mayer 1998;Forstermann and Sessa 2012). eNOS can also be
activated by stimuli that do not produce sustained increases in intracellular Ca2+, but still
induce a long-lasting release of NO. The best established such stimulus is fluid shear stress.
This activation is mediated by phosphorylation of the enzyme (Fulton, Gratton et al. 1999;
Fleming and Busse 2003; Forstermann and Sessa 2012).The eNOS protein can be
phosphorylated on several serine (Ser), threonine (Thr), and tyrosine (Tyr) residues.
Phosphorylation of Ser1177 stimulates the flux of electrons within the reductase domain,
increases the Ca2+ sensitivity of the enzyme, and represents an additional and independent
mechanism of eNOS activation (Fleming and Busse 2003;Forstermann and Sessa 2012).
Even though all the kinases above can regulate eNOS Ser1177 in vitro, Akt1(Ser/Thr kinase)
is the only kinase proven to regulate eNOS function in vivo (Forstermann and Sessa 2012).
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1.4.5 Mechanism of oxidative stress
Oxidative stress in chemical terms is a large increase in the cellular reduction potential. It is
caused by an imbalance between the production of reactive oxygen and the biological
system’s ability to quickly detoxify. The reducing environment in all mammalian cells is
preserved by constant input of energy by the enzymes. Any imbalance in the normal redox
state including hyperglycemia (Selvaraju, Joshi et al. 2012) could lead to toxic effects on the
cell by production of free radicals and peroxides. Most destructive aspect of oxidative stress
is the production of reactive oxygen species which include peroxides and free radicals.
Reactive oxygen species (ROS) are a family of molecules including molecular oxygen and its
derivatives produced in all aerobic cells. Excessive production of ROS, outstripping
endogenous antioxidant defence mechanisms, has been implicated in processes in which they
oxidize biological macromolecules, such as DNA, protein, carbohydrates, and lipids. This
condition has commonly been referred to as oxidant stress (Cai and Harrison 2000). Of all the
proteins, LDL oxidation is central to the development of atherosclerosis and associated
endothelial dysfunction (Anderson 2003). Similarly oxygen free radicals also lead to
endothelial dysfunction (Chen, W en et al. 2015) and risk of CVD (Selvaraju, Joshi et al.
2012) by directly inactivating NO (Rubanyi and Vanhoutte 1986;Anderson 2003). Oxidant
stress is now shown to be involved in the pathogenesis of many cardiovascular diseases,
including hypercholesterolemia, atherosclerosis, hypertension, diabetes, and heart failure (Cai
and Harrison 2000). Superoxide anion interacts with nitric oxide forming the potent toxin
peroxynitrite via diffusion limited reaction, which in concert with other oxidants triggers
activation of stress kinases, endoplasmic reticulum stress, mitochondrial and poly (ADP-
ribose) polymerase 1-dependent cell death, dysregulates autophagy/mitophagy, inactivates
key proteins involved in myocardial calcium handling/contractility and antioxidant defense,
activates matrix metalloproteinases and redox-dependent pro-inflammatory transcription
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factors (e.g. nuclear factor kappaB) promoting inflammation, AGEs formation, eventually
culminating in myocardial dysfunction, remodelling and heart failure (Varga, Giriczet al.
2015).
1.4.6 Endothelial Dysfunction (ED)
Endothelial dysfunction is a physiological dysfunction of normal biochemical processes
carried out by the endothelium. It is thought to be a key event in the development of
atherosclerosis (Landmesser, Hornig et al. 2004) and predates clinically obvious vascular
pathology by many years (Poredos 2002). Endothelial dysfunction has also been shown to be
of prognostic significance in predicting vascular events (Vita and Keaney 2002;Quyyumi
2003). A systematic review by Garcia in 2012 clearly demonstrated that brachial artery flow
mediated dilatation measuring endothelial dysfunction predicts cardiovascular risk (Garcia,
Lima et al. 2012). A key feature of endothelial dysfunction is the inability of arteries and
arterioles to dilate fully in response to an appropriate stimulus. Dysfunctional endothelial
cells are unable to produce NO to the same extent (or there is increased and rapid destruction
of NO) as healthy endothelial cells, and therefore vasodilatation, is reduced (Candido and
Zanetti 2005). This creates a detectable difference in subjects with endothelial dysfunction
compared to a normal, healthy endothelium.
1.4.7 Inflammation and Endothelial Dysfunction
Obesity and T2DM are associated with sub-clinical inflammation, which is related to adipose
tissue nutrient metabolism (Schoeller and Buchholz2005;Bakker, Eringa et al. 2009). Pro-
inflammatory state in adipocytes is created in obese subjects because of nutrient storage
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rather than steady-state nutrient and glucose concentrations (Bakker, Eringa et al. 2009). This
pro-inflammatory state and subsequent release of inflammatory markers lead to Insulin
resistance, thrombogenic risk and immune response (Roden, Price et al. 1996;Boden 1997;
Kahn and Flier 2000;Grundy 2002;Kahn, Hull et al. 2006;Bakker, Eringa et al. 2009). The
common factors expressed include TNF-, IL-6, PAI-1, resistin and leptin. Endothelial injury
results in the release of various factors that can be detected in the circulation, and these can
then be used as markers of endothelial dysfunction. Circulatory markers of endothelial
dysfunction most often used are: endothelin-1, von W illebrand factor, tissue Plasminogen
Activator (tPA) and Plasminogen Activator Inhibitor-1 (PAI-1) and the adhesion molecules,
vascular cell adhesion molecule (VCAM), intercellular adhesion molecule (ICAM), P-
selectin, as well as amyloid A, fibrinogen, Oxidised LDL-C, homocysteine, C-Reactive
protein (CRP), visfatin, adiponectin and AGE products (Gimbrone 1999; Jager, van
Hinsbergh et al. 2000;Bakker, Eringa et al. 2009).
1.4.8 Triggers for Endothelial Dysfunction
Endothelial dysfunction is, in part, a consequence of the harmful effects of the risk factors of
atherosclerosis on the vessel wall. Atherosclerosis is a chronic pathological process of
hardening and loss of elasticity of arteries. This process starts as early as childhood and can
accelerate with the addition of traditional identifiable risk factors for CAD. It is asymptomatic
in the early stages but, over a period of decades, can promote plaque formation which may
ultimately result in plaque rupture and vascular events, including myocardial infarction (MI).
One tool which is widely used to predict CHD risk is the 10 year Framingham risk score with
its limitations. It is mainly based on traditional and conventional cardiac risk factors. But, it is
also recognised that a sizable chunk of the population, classed as low risk on the Framingham
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risk model, in fact have sub-clinical atherosclerosis, which this tool cannot detect or predict.
Other models include NEW -CHD model (Hu, Root et al. 2014) and multilocus genetic risk
score (MGRS) models (Ganna, Magnusson et al. 2013). Risk factors for atherosclerosis
include raised blood pressure (hypertension), increased cholesterol concentration
(hypercholesterolaemia), raised glucose levels / hyperglycaemia (diabetes), elevated
homocysteine levels, increased pro-inflammatory markers, and constituents of cigarette
smoke –all of which are known to diminish endothelial function (Vallance and Chan 2001;
Poredos 2002). Endothelial dysfunction is associated with impaired tissue perfusion,
particularly during stress, which might contribute to ischemia including myocardial ischemia
(Drexler and Hornig 1999). Subjects with hypertension, T2DM, hypercholesterolaemia and
people who smoke have all been shown to have endothelial dysfunction, thus predicting
future CVD (Chowienczyk, W atts et al. 1992;Sorensen, Celermajer et al. 1994;Heitzer, Yla-
Herttuala et al. 1996; Poredos 2002). Several mechanisms may be involved in the
development of endothelial dysfunction, such as reduced synthesis and release of EDRF
(Drexler and Hornig 1999), reduced niric oxide synthase (NOS) production (Sukhovershin,
Yepuri et al. 2015), over production of endogenous inhibitors of NOS, oxidative stress,
reduced sensitivity of vascular smooth muscle and production of AGE (Vallance and Chan
2001). Increased plasma levels of oxidized LDLhave been noted in chronic smokers and are
related to the extent of endothelial dysfunction, raising the possibility that chronic smoking
potentiates endothelial dysfunction by increasing circulating and tissue levels of oxidized
LDL(Drexler and Hornig 1999). Currently various modalities are used to limit and reduce the
cardiovascular events.
Endothelial dysfunction is an early CV risk marker in obese men and women with
prediabetes. Overweight and obese status denotes an increasing adipose tissue burden which
spills over into ectopic locations, including the visceral compartment, muscle and liver.
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Associated co-morbidities enhance cardiovascular (CV) risk. (Gupta, Ravussin et al. 2012).
Endothelial dysfunction (ED) is the initial perturbation, which precedes fatty streak known to
initiate atherosclerosis: insidious process which often culminates as sudden catastrophic CV
adverse event. Endothelial dysfunction reflective of cardio metabolic changes in obese adults
can be an early risk marker for catastrophic CV events (Gupta, Ravussin et al. 2012).
Invasive modalities like coronary angiograms are relied upon to rule out existing CAD but
there are limitations in interpreting their findings. The most important one, apart from being a
two dimensional technique, is that it can only observe changes seen in the lumen of the
vessel. The atherosclerotic process starts within the wall of the artery. Early changes of
atherosclerosis are unlikely to be appreciated by a diagnostic angiographic procedure. Non-
invasive vascular tests can detect some of the vascular wall changes, mainly functional
changes, thus enabling detection of early stages of the atherosclerosis.
1.4.9 Assessment of Endothelial Dysfunction
Endothelial dysfunction can be assessed both at the level of coronary arteries as well as other
accessible medium size vessels which correlate with coronary endothelial dysfunction and
coronary events. W hilst assessing endothelial dysfunction in coronary arteries involves
invasive equipment and studies, (Bossaller, Hehlert-Friedrich et al. 1989;Chu, Chambers et
al. 1991;Fujino, Mikuniya et al. 1993;van Haare, Kooi et al. 2015), similar assessment in
other accessible medium vessels can be carried out non-invasively. Since, endothelial
dysfunction has been proven as an early event of patho-physiological importance in the
atherosclerotic process, (Celermajer, Sorensen et al. 1992) there is continued interest in the
methods used to assess such risk, at an early stage.
30
Endothelial dysfunction has also been shown to provide an important link between diseases
such as obesity (Steinberg, Chaker et al. 1996), hypertension, chronic renal failure, angina or
diabetes (Hsueh, Lyon et al. 2004) and the high risk for cardiovascular events (Suwaidi,
Hamasaki et al. 2000). This means that a large section of the high risk population could
potentially be identified if a reliable and less invasive system could be developed. As such,
this led to the development of non-invasive scanning methods, which studied endothelial
function at accessible vessels such as carotid artery and brachial artery. Determination of
endothelial dysfunction also has important clinical implications. It was demonstrated that
endothelial dysfunction, at the coronary artery level, is significantly and independently
correlated with the occurrence of cardiac events including cardiovascular death, unstable
angina, myocardial infarction, percutaneous transluminal coronary angioplasty, coronary
bypass grafting, ischemic stroke, or peripheral artery revascularization (Schächinger, Britten
et al. 2000).
Similarly, that endothelial dysfunction, at the level of peripheral vasculature, also found
evidence of prognostic value. Therefore, non-invasive endothelial function testing of forearm
vessels predicted cardiovascular events in patients with CAD (Heitzer, Schlinzig et al. 2001),
peripheral artery disease (Gokce, Keaney et al. 2003) and hypertension (Perticone, Ceravolo
et al. 2001). In addition, non-invasive testing using ankle –arm index(Newman, Shemanski et
al. 1999), common carotid artery (Bots, Hoes et al. 1997) and femoral artery (Belcaro,
Nicolaides et al. 2001) scanning have also shown evidence towards predicting future cardiac
events. Brachial artery FMD predicts cardiovascular risk (Garcia, Lima et al. 2012) and
events (Guazzi, Reina et al. 2009). The chapters 3, 5, 6 and 7 utilized non-invasive flow
mediated dilatation on the brachial artery for predicting risk and measuring function.
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1.4.10 Measurement of Endothelial Dysfunction
There are different techniques to evaluate the endothelium functional capacity, that depend on
the amount of nitric oxide NO produced and the vasodilatation effect. Most of the functional
methods for in vivo endothelial testing examine the ability of the endothelium to cause
vasodilation in response to pharmacological and physiological stimuli that increase the
endothelial release of NO. The percentage of vasodilatation with respect to the basal value
represents the endothelial functional capacity. Taking into account that shear stress is one of
the most important stimulants for the synthesis and release of NO, the non-invasive technique
most often used is the transient flow-modulated "endothelium-dependent" post-ischaemic
vasodilatation (FMD), performed on conductance arteries such as the brachial, radial or
femoral arteries. This vasodilatation is compared with the vasodilatation produced by drugs
that are NO donors, such as nitroglycerine, which is called "endothelium independent". The
vasodilatation is then quantified by measuring the arterial diameter with high resolution
ultrasonography (Celermajer, Sorensen et al. 1992). The technique most commonly used, at
present, involves creating shear stress in the forearm vessel (the brachial artery) by applying a
transient compression in the forearm, up to 200 mmHg, using a pressure cuff. This creates an
artificial transient ischaemia in the down-stream brachial artery. Once the pressure from the
cuff is released, typically after 4to 5 minutes, the blood flow in that section of the artery
rapidly increases, likely as a response to the post-ischaemic environment. This increased flow
creates sheer stress and, in turn, stimulates NO release that causes vaso-dilatation. This is the
underlying mechanism of non-invasive flow mediated endothelial dependant (FMD)
vasodilatation of the brachial artery (Celermajer, Sorensen et al. 1992;Corretti, Anderson et
al. 2002;Esper, Nordaby et al. 2006).
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1.5 Microvascular Function
1.5.1 Definition
Micro vascular function is the orderly functioning of smaller conductance and resistance
vessels, of the size 100 to 200 microns, which play a role in the regulation of blood flow and
micro-circulation.
1.5.2 Anatomy and Physiology of Retinal Vessels
The micro-circulation of the retina is composed of arterioles, capillaries and venules.
Arterioles are small resistance vessels (20-150 μm) composed of an endothelium surrounded 
by one or more layers of smooth muscle cells. The function of the arterioles is to regulate
how much blood is delivered to the downstream capillary bed. The diameter of the arterioles
depends on the contractile state, primarily of the smooth muscle, which is regulated by
multiple factors, such as endothelium derived constricting factors, endothelium derived
relaxing factors (EDRF) and circulating vasoactive hormones. Capillaries (6-10 μm in 
diameter) are single celled endothelial cells surrounded by a basement membrane, presenting
without a smooth muscle layer. Continuous capillaries are present in the retina and are the
most impermeable type, resulting in the formation of the blood retinal barrier, similar to that
of the brain-blood barrier. Physically, the first barrier between blood and tissue in the retinal
circulation are endothelial cells, which prevent plasma from leaking out of the vessel and are
important in the autoregulation of the blood flow. The endothelium consists of a monolayer of
cells covering the inner wall of the vasculature and is strategically located between the
circulating blood and the vascular smooth muscle cells (Haefliger, Flammer et al. 2001). The
second vascular layer is the smooth muscle which can constrict and dilate;these cells are
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enclosed by an internal and an external elastic lamina. The internal elastic lamina is located
between the smooth muscle cells and the endothelium and transmits signals between the two
layers. The outer layer protects the vessel and attaches the vessel loosely to the surrounding
tissues (Levick 2000). In summary, retinal arterioles are composed of endothelial cells and
smooth muscle whereas retinal capillaries are made up of tight, non-fenestrated endothelial
cells surrounded by a basement membrane containing pericytes and mural cells. The
endothelial cells are joined together by zonula occludens, thereby preventing leakage from the
arterioles, capillaries and venules and preserving optimal retinal function (Remington 1998).
1.5.3 The Vascular System of the Retina
The eye obtains its blood mainly from the ophthalmic artery, which is the first branch of the
internal carotid artery and the only branch of the internal carotid outside the cranium (Harris
2nd Edition, Elsevier, 2010. ). The adult neural retina is supported by two distinct vascular
systems, the inner retinal vessels and the choroidal vessels. The two beds vary in both their
embryonic differentiation pattern and functionality in the adult organism. The retinal
vasculature has barrier properties similar to those observed in the brain, whereas the choroidal
vessels demonstrate a greatly fenestrated phenotype (Saint-Geniezand D'Amore 2004).
1.5.3.1 The Retinal Blood Vessels
The retinal blood vessels nourish the inner layers of the retina. The inner retina maintains its
blood via the aortic artery, common carotid arteries, internal artery, ophthalmic artery and,
finally, the central retinal artery (CRA). The CRA enters the optic nerve 10-15 mm behind the
globe and runs forward in the central section of the nerve along the central retinal vein. CRA
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supplies the inner two third of the retina, the most anterior portion of the superficial nerve
fibre layer of the optic nerve head and, to some extent, the retro-laminar optic nerve.
1.5.3.2 The Choroidal Vessels
The outer retinal layers, including the photoreceptors, are nourished by the choroid. The uveal
system, specifically the chorio-capillaries, supplies the deeper layers, including
photoreceptors and bipolar cells. The short posterior ciliary arteries directly supply the
choroid and the long posterior ciliary arteries travel in the supra-choroidal space anteriorly to
supply the choroid anteriorly via recurrent branches.
In summary, retinal tissue is nourished by two vascular systems of blood vessels that differ
anatomically and physiologically. The inner retina is nourished by the distribution of the
central retinal artery. The outer retina is nourished by the underlying chorio-capillaries via the
short and long posterior ciliary arteries. Blood is drained by the retinal venules into the
central retinal vein and finally the ophthalmic vein.
The retina is able to regulate blood flow in response to different metabolic demands. There
are several animal and human studies demonstrating a change in retinal vessel diameters
(Polak, Schmetterer et al. 2002;Dorner, Garhöfer et al. 2003;Dorner, Garhofer et al. 2003) as
well as in retinal (Michelson, Patzelt et al. 2002) and optic nerve head blood flow (Buerk,
Riva et al. 1996;Riva, Falsini et al. 2001;Falsini, Riva et al. 2002) as a result of provocation
with diffuse luminance flicker, O2, CO2, etc. Like in the brain, blood flow in retinal vessels is
strongly coupled to neural activity, which has been recently established using laser Doppler
flow metry (Buerk, Riva et al. 1996) and retinal vessel diameter measurements (Formaz,
Riva et al. 1997;Dorner, Garhöfer et al. 2003;Dorner, Garhofer et al. 2003). Hemodynamics
35
is the study of the properties and mechanisms that control the flow of blood. Blood flow
within an organ or vascular network is driven by the difference between the arterial and
venous pressures across the organ which is termed perfusion pressure (i.e. pressure gradient).
The vascular smooth muscle cells have an intrinsic ability to either constrict or dilate in
response to increase or decrease of the perfusion pressure, respectively. The smooth muscles
respond by contracting when the lumen of a blood vessel is suddenly expanded, as occurs
when intravascular pressure is suddenly increased. Conversely, a reduction in intravascular
pressure results in vasodilation. Therefore the arterioles respond to intravascular pressure as a
stimulus (Johnson 1986).
1.5.4 Diabetic retinopathy
Diabetic retinopathy is a highly specific micro-vascular complication of diabetes and the
leading cause of blindness in people under the age of 60 in industrialised countries (Sibal and
Home 2009). It is also a major cause of blindness in older people. At 20 years from the initial
onset of diabetes, over 90% of people with Type 1 diabetes and more than 60% of people
with Type 2 diabetes will have diabetic retinopathy (Sibal and Home 2009). Due to the sight
threatening potential of this disease, and the availability of methods to slow down the rate of
progression of the disease pathogenesis, the UK National Screening Committee has
recommended screening for diabetic retinopathy as a national priority (Sibal and Home 2009)
which is the current practice now. W hilst the mechanisms underlying diabetic retinopathy are
unclear, the progression of the disease is well known and may take several forms.
The initial stage is background retinopathy which is characterised by capillary micro-
aneurysm formation, dot and blot intra-retinal haemorrhages and lipid exudates. This stage of
the disease does not usually impair any visual function. The next stage of the disease process,
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labelled, pre-proliferative retinopathy, is characterised by capillary and arteriolar closure. The
late stage in this process leads into proliferative retinopathy which is characterised by the
growth of new blood vessels (Figure 1.5.4). This stage commonly leads to progressive visual
impairment caused by scarring and bleeding (Acharya, Chua et al. 2008).
Figure 1.5.4 Different stages of Diabetic Retinopathy.
Pooled data from many of the available screening studies up to 1996, in their modelling
project on the effectiveness of diabetic retinopathy screening programmes, have determined
that retinal photography was the screening test of choice (Sibal and Home 2009). Background
retinopathy in women predicted CVD and CHD death. These associations have been shown to
be independent of current smoking, hypertension, total cholesterol, glycaemic control of
diabetes, duration of diabetes, and proteinuria (Juutilainen, Lehto et al. 2007). A prospective
study involving Type 1 DM patients with retinopathy clearly revealed an increased risk for all
cause mortality and incident CVD (van Hecke, Dekker et al. 2005). A more recent study in
2015 investigating the association of diabetic retinopathy with the risk of cardiovascular
disease in type 2 diabetic patients revealed revealed a clear association (Shoeibi and
Bonakdaran 2015). One-hundred and eighty patients with type 2 diabetes without CVD at
baseline were enrolled in that study. Patients were classified into three categories: no diabetic
retinopathy (NDR), nonproliferative diabetic retinopathy (NPDR) and proliferative diabetic
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retinopathy (PDR) based on fundoscopic findings. Ten-year CVD risk was estimated using
the United Kingdom Prospective Diabetes Study risk engine. Patients were classified as high
risk (>20%), moderate risk (10-20%) and low risk (<10%). The total prevalence of DR was
30.5%. After adjustment for traditional risk factors for CVD, the risk of CVD remained
markedly increased in the presence of diabetic retinopathy (Shoeibi and Bonakdaran 2015).
1.5.5 Retinal vessel Analysis on Retinal Vessel Analyser (RVA)
The RVA comprises a optic fundus camera (model FF 450;Zeiss, Jena, Germany), a video
camera, a real-time monitor, and a computer with image-analysis software for the accurate
determination of retinal arterial and venous diameter. Retinal vessel diameter was analyzed in
real time with a maximum frequency of 40 Hz. Retinal vessel reactivity (RVR) was measured
using the retinal vessel analyser (RVA, Imedos, GmbH). The RVA system was most suited to
undertake quantitative investigation of retinal vasosclerosis, especially in association with
arteriosclerotic disease. Using RVA system, diameter changes in retinal arterioles was first
reported in a clinical methodological study by Nagel (Nagel and Vilser 2004). The RVA
measured the diameter of the column of the red blood cells. After the fundus camera was
adjusted to the dilated pupil, a vessel section of the eye, measuring approximately 1.5 mm in
length, was evaluated. Retinal vessel diameter was analysed in real time with a maximum
frequency of 40 Hz, so that every second a maximum of 25 readings of vessel diameter could
be obtained. For this purpose the fundus was imaged onto the charge-coupled device (CCD)
(camera with an apparatus which was designed to convert optical brightness into electrical
amplitude signals using a plurality of CCDs. It then reproduced the image using the electric
signals without time restriction) chip of the video camera (Appendix I, Figure 1 h ). The
consecutive fundus images were digitized with a frame grabber. The vessel diameters were
measured with the software, Vesselmap 2 (IMEDOS) (Mandecka, Dawczynski et al. 2007;
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Nagel, Vilser et al. 2007). Evaluation of the retinal venous and arterial diameter was
performed using above software in a “Live”format ( real time) instantly. These pictures could
also be reviewed and re- analyzed retrospectively, from the recorded videotapes (Seifertl and
Vilser 2002). The position of the vessel edges was determined and the angle and diameter of
the vessel was calculated automatically, online. After baseline recording of 50 seconds, three
flicker periods of 20 seconds each was applied, interrupted with 80 seconds of still
illumination. The point of maximum dilation was determined for each period of flicker
stimulation as the highest 1-second mean vessel diameter during the period of 50 seconds. A
graph was generated which described the capability of the vessel to dilate. This function is
highly standardized and thus applicable in clinical routine (Nagel and Vilser 2004).
1.5.6 Functional Measurement of Micro-circulation and Utility
The RVA system has the ability to reliably measure the vascular reactivity of the micro-
circulation, the retinal vessels. Dynamic Vessel Analysis (DVA) is the key technology for the
early detection of functional vessel changes. Dynamic microvascular changes in response to
stress can be reliably and consistently compared between groups. Therefore this method of
RVA analysis might be sensitive enough and may prove to be a valuable research tool and
source of data analysis for assessing the impact of the post-prandial state on the risk of CVD
and retinopathy in T2DM (Nagel and Vilser 2004;Gugleta, Zawinka et al. 2006).
1.6 Comparison withMacrovascular Function
Microvascular disease, by definition, is disease of the small and finer blood vessels in the
body, including the capillaries. By contrast, macrovascular disease describes disease of the
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large blood vessels including the aorta, as well as the coronary arteries and major arteries of
the limbs and the brain. Until recently, the effects of hyperglycaemia, physiological stress and
its effects on macrovascular function, resulting in cardiovascular risk, have been clearly
understood and published. However, similar physiological explanations, with regard to
stressors and cardiovascular risk, have not been proven in microvascular endothelium. Our
previous publication (Chittari, McTernan et al. 2011) defines the functioning of endothelium
at both macrovascular and microvascular levels, simultaneously. For the first time, we can
reveal that physiological alterations inside the lumen of blood vessels could be detected
immediately at both vascular beds. This detection leads to a simultaneous but a varied and
divergent response from both macro- and microvascular endothelium.
1.6.1 Brachial Artery Flow Mediated Dilatation (FMD)
Endothelial dysfunction can be detected in the forearm as an impairment of endothelium
dependent flow mediated vasodilation, even before the development of clinical
atherosclerosis. Atherosclerosis is common in the human brachial artery and is significantly
correlated with both coronary and carotid disease. These results suggest that the brachial
circulation may serve as a reasonable "surrogate" for studying atherosclerosis, particularly in
younger adults (Sorensen, Kristensen et al. 1997).
1.6.2 Vascular function predicting Cardiovascular disease
Endothelial dysfunction, by these methods, correlates with cardiovascular risk factors (Chan,
Colhoun et al. 2001), and may be predictive of incident cardiovascular events (Perticone,
Ceravolo et al. 2001;Lerman and Zeiher 2005;Yeboah, Crouse et al. 2007). Brachial artery
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median FMD independently predicts long-term adverse cardiovascular events in healthy
subjects in addition to traditional risk factor assessment (Shechter, Issachar et al. 2009). The
endothelial function of the brachial artery measured by this FMD method has shown a good
correlation with the coronary artery response implicating the brachial artery as a "surrogate"
for the coronary artery (Anderson, Uehata et al. 1995;Sorensen, Kristensen et al. 1997). An
excellent correlation has been noted with the severity of the vascular lesions, even when they
are asymptomatic and undetectable, by the usual clinical methods. It has also been reported
that patients without CVD but with risk factors, had a diminished brachial artery
vasodilatation response when compared with a normal population. Furthermore, if they had
peripheral artery disease, the response was even more diminished compared with the positive
risk factor population. This leads us to the assumption that, as the severity of the lesions
increases, so does the endothelial dysfunction (Yataco, Corretti et al. 1999;Esper, Nordaby et
al. 2006). Therefore attenuated brachial artery FMD correlates with the presence of coronary
endothelial dysfunction and atherosclerosis, as assessed by angiography, highlighting the
systemic nature of vascular disease (Anderson, Uehata et al. 1995) and demonstrating that the
technique is both reproducible and reliable (Sorensen, Celermajer et al. 1995).
The FMD technique in the brachial artery could also be used to monitor treatment benefit
(Ceriello, Taboga et al. 2002), in addition to its value in predicting future CVD. FMD as a
tool, also appeared to have been utilised to independently predict postoperative cardiac events
in patients undergoing vascular surgery (Gokce, Keaney et al. 2002). A study from Japan
published in 2006showed that cardiac patients who had low values for the FMD brachial
artery had twice the number of cardiac events on 5 year follow up compared with higher
FMD values (Yoshida, Kawano et al. 2006).
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1.7 Aims ofthesis
W hilst it is clear that endothelial dysfunction in obesity, IGT and T2DM is an important
primary event leading to increased risk of developing CVD, the non-invasive vascular
assessments in different peripheral vessels and vascular beds creating varied risk are not fully
established or understood. W ith increasing prevalence of these risk groups across the world, it
is becoming very clear that primary prevention in the way of screening and identifying the
risk groups within this population should pay dividends in the form of reduced incidence of
CVD.
Therefore, understanding the molecular (biomarkers) and physiological mechanisms of
endothelial function at different vascular beds will help in identifying the early features of the
disease process and, in turn, provide an opportunity to initiate strategies for its reversal.
Finally, effect of Metformin therapy in diabetic patients will be assessed on its effect on
biomarkers and in turn cardiovascular risk.
This thesis will, therefore, aim to:
1. Study the impact of diet, specifically acute hyperglycemia and acute hyperlipidemia
on serum biomarkers of inflammation and endothelial dysfunction including TNF-α, 
Leptin and Endotoxin. The acute effects of hyperglycemic and hyperlipidemic will
also be studied on the functioning of the endothelium at the macrovascular level in
healthy subjects and compare and contrast it with CVD risk groups (T2DM and
Obesity including obesity in children).
2. To study prospectively the microvascular function as measured by Microvascular
reactivity at the level of retina in healthy subjects and above high risk groups using
physiologic stress as detailed above.
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3. For the first time, compare and contrast both modalities (microvascular and
macrovascular function) in healthy subjects and high risk groups in their ability to
measure endothelial dysfunction.
4. Finally, investigate the protective effects of Metformin therapy on lipoprotein damage
in T2DM subjects compared with healthy subjects.
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Chapter 2
Generalmaterials and methods
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2.1 Generalmaterials and methods
This section covers in detail all the methods that are used in this thesis. More detailed
information regarding any specific methodology used in a particular chapter will be covered
in more detail in that relevant chapter. Further details on specific detailed methodology will
be covered in appendices at the end of the thesis.
2.1.1 Patient selection and recruitment
The recruitment of subjects for the study was conducted both in primary care centres/general
practices as well as University Hospital Coventry and W arwickshire (UHCW ) NHS Hospital,
in Coventry. The general practice surgeries which were participating in our study identified
the patients who would qualify for the study, (depending on detailed inclusion and exclusion
criteria) from their databases. Once they were identified, all qualifying patients were invited
to attend the research clinic. They were contacted by telephone to confirm their willingness to
partake in a research project, which could potentially be relevant to them. After they had
given consent to participate, patient information sheets (AppendixI, 1a) were posted to their
home address. The subjects were subsequently contacted and were invited to the research
clinic following a strict 8-12 hour overnight fasting, which all subjects re-confirmed on the
day.
2.1.2 Research Clinic
The research clinic was conducted at a General practice surgery which was participating in
our study. This surgery was central to the population in the study. The clinic was run,
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initially, once a week and subsequently twice a week until the full number of subjects was
recruited. The clinic was staffed by the research doctor and two female research support
nurses who assisted in patient contact, logistics of posting letters and smooth running of
clinics, in addition to assisting with blood pressure recordings and electrocardiographic
recordings. They were also used as chaperones to ensure patient confidence and assistance.
2.1.3 Selection criteria
Patients were identified on the database after matching for strict criteria, as detailed below.
Age criteria were used in this study in view of mounting evidence of advancing age
influencing and, in most circumstances, depressing the endothelial function (SIEKER and
HICKAM 1953;Celermajer, Sorensen et al. 1994;Gerhard, Roddy et al. 1996).
2.1.3.1 Inclusion criteria
Type 2 diabetes mellitus (T2DM) less than 65 years old.
Non diabetic subjects (ND) less than 65 years old.
2.1.3.2 Exclusion criteria
Acute illness
Pregnancy
Uncontrolled hypertension
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Any history of vascular disease [including Cerebrovascular accidents (CVA), Transient
ischaemic attacks (TIA), Myocardial infarction (MI), Ischaemic heart disease (IHD),
Peripheral vascular disease (PVD), Intermittent claudication (IC) etc]
Abnormal resting Electrocardiogram (ECG)
Smoking
Subjects taking aspirin, statins or supplemental vitamins
Body mass index(BMI) >50
2.2 ClinicVisit
The initial clinic visit was undertaken in the mornings to facilitate taking fasting blood tests.
Some clinics were also conducted in the afternoon for subsequent visits. Once at the clinic,
the study was explained to the subjects’in the appropriate language, with the use of
interpreters when it was deemed necessary. After confirming that the study was fully
understood, participating subjects had an opportunity to ask further questions;following this
they signed an informed consent form (Appendix I, 1 b). After enrolling into the study,
fasting blood and urine samples were obtained. The blood tests conducted included renal
function tests, blood glucose, glycated haemoglobin (HbA1C), full cholesterol profile and C-
reactive protein (CRP). These tests were analyzed at the UHCW biochemistry laboratory
within the hospital. Baseline demographic profile was obtained including relevant history
using a standardized proforma and checklist (AppendixI, 1 c). All subjects had their height,
weight, abdominal circumference and body mass index(BMI) measurements taken using the
same equipment to standardise measurements. Blood samples were taken, either from the
47
right or left ante-cubital vein, in a sitting position. Blood pressure was checked with a Blood
pressure (BP) monitor (Omron Intellisence M7 BPM Blood Pressure Monitor with Multi
Cuff) on the left arm and re-checked after 2 min. Finally a 12 Lead ECG was performed using
the same machine (Seca CT3000i) for the duration of the study. Female chaperones were
present during the clinics for female subjects.
The control group of healthy ND subjects was identified in the same manner as subjects with
T2DM, by the same practice managers of the General practice. The criteria used to identify
these subjects were identical. Subjects in this group were matched for age, gender, ethnicity
and BMI of the already enrolled diabetic population. Again, only non-smoking subjects with
a normal resting ECG, normal BP and no history of vascular disease were selected. Subjects
on aspirin, lipid-lowering agents, or supplemental vitamins were excluded as they can
influence endothelial function. All subjects, both T2DM and ND, were recommended to
consume their habitual diet during the entire period of the study. On the first day of
physiological testing, a validated dietary questionnaire was used to obtain dietary habits of all
participants. (Appendix I,1d). This copy righted product from Tinuviel software was
purchased with Research funds.
At the end of the visit to the clinic, patients were offered a drink prior to leaving. A telephone
appointment was booked a few weeks before the start of the physiological tests. They were
asked to attend the UHCW first thing in the morning on the day of their appointment,
preceded by an 8hr overnight fast. As detailed in the patient’s information sheet (AppendixI,
1 a) and study protocol, (AppendixI, 1d), the subjects attended the UHCW on 3 different
days, each day following an overnight fast of a 8hr minimum. The tests were finished by
lunchtime, as detailed in Appendix1I, figure 2 a.
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2.2.1 Patient Recruitment
In order to recruit naive T2DM subjects, efforts were made to screen and identify at-risk
people, not only at participating surgeries but also at non-traditional places like health
awareness camps and at cultural fairs. At-risk groups were defined as people with a family
history of ischaemic heart disease and T2DM, obese people and people of South Asian origin.
After informed consent and the same standardized procedure, this healthy group was similarly
recruited into the study.
2.2.2 Serum and plasma isolation
The following procedure to isolate serum and plasma was immediately performed at the clinic
visit. Once blood was drawn into separate tubes, the tube collecting serum was spun
immediately in a centrifuge (Capricon Laboratory Equipment, model CEP2000) at 3000
revolutions per minute (RPM) (1500×g) for 15 min. Then the tube was placed upright in ice
until it reached the research laboratory. The tube collecting plasma was left to clot for 20 min
and subsequently spun in a centrifuge at 1500×g for 15 min and then this tube was also placed
on ice until it reached the research laboratory. Similarly, the two tubes containing whole
blood and urine, respectively, were appropriately stored in a cold container until it reached
the storage freezers in the laboratory based at Clinical Services Research Institute
Laboratories (CSRI) at University Hospital Coventry. Once at the laboratory, all samples
were appropriately coded, fully anonymised, labelled and stored at –80ºC.
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2.3 PhysiologicalTests
2.3.1 Study Outline
Physiological tests were performed at UHCW over a period of 3 days. Patients were required
to attend all 3 days, preferably, consecutively, where they were subjected to a glucose
challenge as part of an oral glucose tolerance test (OGTT) on day 1, fat stress on day 2 and
lastly combined stress involving both oral glucose and fat stress on day 3 (Ceriello, Taboga et
al. 2002;Ceriello, Quagliaro et al. 2004). All subjects were required to complete the 3 days of
the studies within 4weeks of the first day of the study. On the day of the test, the subjects
attended the UHCW centre early in the morning, after an 8hr overnight fast. T2DM subjects
omitted their morning insulin or metformin medication, as they were fasting. Patients on anti
hypertensives omitted their previous night’s dose and all subjects were advised to bring their
medications with them on the morning of their tests. Once at the study centre (AppendixI,
Figure 1 f ), patients’details, date of birth, fasting status, drugs history, consent and signature
were confirmed. Following this, the patients were given a further detailed briefing about the
study protocol and procedures (AppendixII, Figure 2 a) to ensure they were comfortable to
proceed with the study.
2.3.2 Study protocol
Blood samples were drawn at 0 (fasting state), 1 (1 hr post-stress), 2 (2 hr-post stress), 3, and
4 hr-post stress. Glucose, full lipid profile, insulin, inflammatory and endothelial markers
were analyzed for each time period. Along with the blood tests, endothelial function, at the
level of the arm and retina, was measured. Ultrasound technique to measure flow-mediated
vasodilatation (FMD) of the brachial artery and retinal vessel analyser (RVA), to measure
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retinal vessel reactivity (RVR), was undertaken at same the time points, along with the blood
tests. On the first day, standard OGTT with 75g glucose was consumed as physiological
stress for measuring endothelial function. The next day high fat meal consisting of 158ml of
double whipping cream (ASDA supermarket) standardized to contain 75g of fat was
consumed before physiological testing. On the final day both glucose and fat, at the same
doses as previously described, were given as a meal (AppendixI, study protocol 1 e). The
nutritional value of the double cream is shown below.
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Typical values Per 100ml
Energy 1831kJ
445kcal
Protein 1.7g
Carbohydrate 2.6g
of which sugars 2.6g
Fat 47.5g
of which saturates 29.7g
Fibre Nil
Sodium Trace
equivalent as salt 0.1g
Table 2.3.2 ASDA fresh double cream: Nutritional content.
2.3.3 Endothelial Function at Macrovascular level
Endothelial function was evaluated by measuring flow-mediated vasodilatation (FMD) of the
brachial artery. It was a non-invasive method of assessing the endothelial function at the
macrovascular level. Endothelial dependant vaso-reactivity has been a routinely used clinical
endpoint for assessment of endothelial function (Deanfield, Halcoxet al. 2007). Endothelial
dysfunction reflective of cardiometabolic changes appears to be an early risk marker for
catastrophic CV events (Gupta, Ravussin et al. 2012). FMD brachial artery scan
measurements were considered as surrogate for atherosclerosis and therefore the foundations
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of cardiovascular risk (Anderson, Uehata et al. 1995;Sorensen, Kristensen et al. 1997). The
examination was carried out in a temperature and light controlled room on subjects who were
lying comfortably flat on a couch (AppendixI, Figure 1 f ). The subject’s left arm was resting
by their side whilst the right arm was placed comfortably on a height adjustable special table
(Appendix I, Figure 1 f). In this study, the temperature in the study room was constantly
maintained at 21ºC using an efficient central air conditioner. The room temperature was
monitored daily using a room thermometer, apart from occasional cross checking using an
efficient sensor and storage device (this continuously tracks the temperature by the minute for
a period of time which then gets downloaded to a computer to analyze accurate findings). The
conditions in the room were kept as quiet as possible with only researchers and subjects
present. Usually, there were two subjects, 2 operators and another female research assistant as
a chaperone. A BP cuff was placed on the left arm which was connected to an automated
quality checked and a National Health Service (NHS) approved BP machine (Model DASH
3000- GE Medical systems) which was used to check systolic and diastolic BPs at various
times during the study protocol. The same machine was used from the beginning to the end of
the study, to reduce any possible variations between machines.
ECG tracing was obtained by 3 leads connected to the VIVID 7 ECHO machine (GE
Vingmed System V) (AppendixI, 1 g). Similar tracing on the studied subjects was used to
monitor the heart rate continuously throughout the study. A 12 MHzflat linear array probe
was connected to the Ultrasound machine which was used to scan a longitudinal section of
the brachial artery. The probe was held in the same position during the scan, using a specially
designed stereo-tactic clamp. The clamp was used to position the relaxed, rested, right arm in
place from the beginning to the end of the study. An electronic dual tourniquet
microprocessor device was used to instantly inflate an appropriate cuff placed on the distal
arm below the transducer position. The study was designed to measure endothelial function
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proximal to the pressure cuff. This was in contrast to other methods, such as the upper arm
pressure cuff and distal scanning. The forearm compression was the favoured approach not
only in guidelines (Corretti, Anderson et al. 2002), but also because it held statistical
advantages over upper arm compression (Peretz, Leotta et al. 2007). Forearm compression
was also more likely to represent NO mediated endothelial response than upper arm proximal
compression (Tschakovsky and Pyke 2005). This tourniquet device inflates the cuff to supra-
systolic pressures, typically 200mmHg to produce ischaemia in the forearm. The cuff was
then deflated after 5 min thus causing a reactive hyperaemia, which, in turn, produced a shear
stress stimulus that induces the endothelium to release NO, a vasodilator. FMD, which
reflects endothelium dependent vasodilatation, was calculated as the percentage increase in
diameter from baseline to the value obtained at 50 sec after the cuff deflation.
2.3.4 Flow mediated dilatation (FMD) Measurements
FMD is an established non-invasive technique for assessing endothelium function using high
resolution ultrasonography. Endothelial function in this study was evaluated by measuring
FMD of the brachial artery. The traditional method of measuring FMD broadly follows the
technique as described below, by Celermajer in 1992 (Celermajer, Sorensen et al. 1992). A
more recent systematic review in 2012 appears to indicate that brachial artery FMD predicts
cardiovascular risk (Garcia, Lima et al. 2012). Vasodilatation responses of the brachial
arteries are usually measured using ultrasound technique by a qualified examiner. The
diameter of the brachial artery was measured from B-mode ultrasound images with a 7-12
MHzlinear array transducer probe. Flow velocity in the brachial artery was measured with a
pulsed Doppler signal at a 70°angle to the vessel. The brachial artery was scanned in the
antecubital fossa in a longitudinal fashion. Depth and gain settings were optimized at the
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beginning of the study and were kept constant throughout the recording period. W hen a
satisfactory transducer position was noted, the surface of the skin was marked, and the arm
remained in the same position throughout the study. Each subject lay quietly for 10 min
before the first scan. At the end of each test, the subjects lay quietly for 15 min. Finally,
sublingual nitroglycerin (GTN) was administered and 3 min later, the last measurements were
performed. Response to GTN was used as a measure of endothelium-independent
vasodilatation. All studies were performed in a quiet and temperature controlled room (22°C
to 23°C).
After baseline measurements of the diameter and flow velocity including pulse wave Doppler
in the brachial artery were obtained, a sphygmomanometer cuff placed around the forearm
was inflated to a pressure up to 200mm Hg and released after 5 minutes. The arterial diameter
was continuously monitored and recorded during the whole scanning time. The ultrasound
images were recorded on a VHS video cassette recorder and the arterial diameter was
measured with ultrasonic calipers, by two independent qualified observers (M. C. Corretti
1995). Diameter measurements for the reactive hyperemia were taken 45 to 90 sec after cuff
deflation to measure peak diameter. Responses of the vessel diameters to the reactive
hyperaemia and GTN were expressed as the percent increase above the baseline value of the
diameter. Blood flow was calculated by multiplying the velocity-time integral of the doppler
flow signal by heart rate and the vessel cross-sectional area. The increase in the blood flow
was calculated by dividing the maximum flow within the first 15 sec after the cuff deflation
by the flow at baseline (M. C. Corretti 1995).
As this technique had a potential to involve significant observer variability, guidelines were
created in 2002 to standardise the technique (Corretti, Anderson et al. 2002). Even though this
improved the issue of variability, the procedure still continued to have significant drawbacks
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which limited the confidence of values and results obtained from using the above described
technique. Retrospective analysis, in short, gave rise to several problems (Newey and Nassiri
2002) which are discussed in more detail in later chapters.
Many of these potential problems were resolved when the data was analyzed online (Newey
and Nassiri 2002). The system used for this study allowed live on-line analysis with a single
operator. The tracking and optimisation for most part was done automatically by the system
software. In view of live analysis, high image acquisition rate was possible and results were
obtained instantly. This obviated the need for retrospective analysis. Finally, this system did
not require the need for continuous ECG monitoring for cardiac cycle changes, as it could
analyse changes of cardiac cycle from monitoring the arterial wall motion. Artery diameter
was calculated by detecting the vessel walls within a user-defined image region, using an
automated computer algorithm. These automated systems were developed to overcome the
specific problems associated with previous retrospective data analysis and to improve the
evaluation of FMD from ultrasound data (Newey and Nassiri 2002).
This study utilised all the accepted criteria for best acquisition of FMD images. The usage of
these criteria resulted in an effective and reliable NO mediated response (Pyke and
Tschakovsky 2005). The criteria included distal placement of the occlusion cuff to the site of
FMD measurement, 5 min or less occlusion duration and obviating the need for ischaemic
hand grip exercise for measuring FMD of brachial arteries (Pyke and Tschakovsky 2005).
This software was loaded onto a personal computer and connected to a standard ultrasound
machine using a frame grabber. The network design and technology involved in designing
such an on-line system was clearly described by Newey in 2002 (Newey and Nassiri 2002).
This system involved using specially designed software on a personal computer that
automatically located the correct vessel walls within a user-defined region-of-interest (ROI)
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and measured vessel diameter online throughout an FMD study. The system was designed to
minimise operator workload. The only user input normally required was to drag an
orthogonal ROI over the required vessel section and to press a start button (Newey and
Nassiri 2002).
Another important dimension to the newer system was the wall tracking ability. The tracking
system was designed to identify the vessel walls in the first image by searching the entire ROI
pixel-by-pixel with each network in turn, with the input line section centered on the current
search location. This search generated matrices containing the probability of each ROI point
being a vessel wall. The matrices were examined to select the most likely vessel wall starting
points, using a range of criteria. These included the wall probability level, wall order (i.e.
anterior before posterior), wall separation distance and the mean intensity levels above and
below the starting points. W alls are then propagated laterally from the starting points to create
a vessel wall pair. Lateral propagation consisted of a small sideways step followed by a
vertical search with the appropriate network to find the point at the new step with the highest
probability of being a wall. This process was repeated from the highest probability point at
each step until the edges of the ROI were reached. The detected walls were then overlain on
the image and then vessel diameter was calculated relative to each point along the vessel axis.
The highest probability point on each wall was then used as the focus for wall propagation in
the following image (Newey and Nassiri 2002). The tracking process was entirely automatic,
except for selection of the ROI. Controls were provided for minor ROI adjustments, and wall
tracking could be manually overridden on-line by pointing and clicking.
In FMD studies, it was necessary to measure artery dilatation changes at diastole. This was
undertaken to avoid inaccurate and inconsistent measurements when the cardiac cycle was
not taken into account. This required synchronisation of the scanner image to one point in the
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ECG. The scanner image was, therefore, only updated once in every heartbeat so that
information that was potentially useful (e.g. in vessel elasticity studies) was not lost. In the
study, by continuously updating the scanner image and measuring the vessel diameter at 25
images every second, it was possible to recover vessel diameter changes over the cardiac
cycle as the vessel expanded and contracted with BP changes. Cardiac events were detected
using a cross-correlation search technique that located the most highly correlated events. The
detected events were averaged after normalisation to heart rate, and the search was directed to
maximise the systolic-to-diastolic difference by fine-tuning the correlation window width and
position. The diameter changes over the cardiac cycle could be recovered reliably by this
method (Sidhu, Newey et al. 2002).
The above described method of brachial artery imaging could represent this technique as a
gold standard for clinical research on conduit artery endothelial biology like the brachial
artery (Deanfield, Halcoxet al. 2007). It is highly likely future studies would be based on
similar instant semi-automated analysis rather than operator dependant off line retrospective
video editing methods. In this study, brachial arteries were imaged with a standard ultrasound
system (VIVID 7 ECHO machine (GE Vingmed System V) connected with a 12 MHzlinear
transducer probe. The ultrasound system was connected to a personal computer equipped with
a frame grabber and artificial neural network wall detection software (vessel image analysis)
(VIA) (Sidhu, Newey et al. 2002), as described previously. This system was developed by
Val Newey’s group at St. George’s Hospital, London. The VIA software automatically
detects and tracks the anterior and posterior walls within a user defined region of interest
(Figure 2.3.4.1 below) (Sidhu, Newey et al. 2002).
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Figure 2.3.4.1 VIA software detecting anterior and posterior walls in the ROI (Sidhu,
Newey et al. 2002)
The white boxin the bottom half of the picture was the ROI. The brachial artery walls were
clearly visible within the ROI as two parallel white lines across the picture, which
corresponds to anterior and posterior walls.
The software could also accommodate angulations of the artery (up to 20°) relative to the
perpendicular. The B mode images were processed at 25 frames every sec and the vessel
diameter, including diameter changes over the cardiac cycle, was displayed in real time
(Figure 2.3.4.2) (Sidhu, Newey et al. 2002).
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Figure 2.3.4.2 VIA software displaying real time diameter changes over cardiac cycle
(Sidhu, Newey et al. 2002).
The image reveals the acquisition rate of pictures from the ultrasound machine to the
computer with VIA software for this analysis. This is depicted as pixels per min. The display
on the figure shows cardiac cycle changes as a monitored graph.
This method of instant and accurate monitoring of the endothelial boundaries allowed
ultrasound imaging parameters to be optimized at the start of the scan and the transducer
position to be adjusted immediately for optimum tracking performance during the entire test.
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The brachial artery was scanned longitudinally 2–10 cm above the elbow, until the clearest
possible image of the anterior and posterior wall media was obtained. Depth and gain settings
were kept constant during the rest of the study. A custom made stereotactic clamp was used to
hold the transducer in a fixed place and a screw gauge was used to make small compensatory
movements of the transducer to accommodate subject movement during the test (AppendixI,
1 f). The distance of the probe from the antecubital fossa was noted and a two dimensional
image of the brachial artery was saved on the computer’s hard drive for reference in repeat
studies. Brachial artery FMD was determined according to a conventional protocol (Ceriello,
Taboga et al. 2002;Sidhu, Newey et al. 2002;Arroyo-Espliguero, Mollichelli et al. 2003;
Masci, Laclaustra et al. 2005). The right brachial artery was scanned continually throughout
the test.
Pulse wave doppler was used to assess arterial flow at rest and a few sec after tourniquet
deflation. Firstly, a baseline scan was performed for 2 min. During this time, the ECHO
machine not only monitors the stable brachial artery endothelial walls, but also helps in
measuring brachial artery diameter at regular intervals. Using pulse wave Doppler, the flow
velocity and, subsequently, the blood flow could be calculated. At the same time, various
cardiovascular parameters were monitored. Heart rate and regular BP checks were also
monitored on a continuous basis. At the end of 2 min, the cuff placed on the distal right
proximal forearm was inflated to a pressure of 200 mmHg almost instantly and left at that
level of compression for 4min 30 sec. During this transition, and also during the compression
phase, both ultrasound parameters via ECHO and VIA parameters were continuously
monitored on-line (AppendixII, Figure 2 b). Cardiovascular parameters were also monitored
during this time. At 4min 30 sec of compression, pulse wave doppler flow monitoring was
started and at 5 min compression, the cuff pressure was released to zero. Pulse wave doppler
was continued during the time when the cuff was released so that the velocity integral at the
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time of release could be recorded and measured. After 30 sec of release, 2D ultrasound
scanning was re-started to last until 5 min of recovery. Brachial artery dilatation (FMD)
following reactive hyperaemia was measured at 50 sec following release of cuff pressure. The
print out with the FMD result, along with all the cardiovascular data, was obtained
immediately when the scanning ended. At the end of the last scan for the day, 250 grams of
sublingual GTN was administered. Imaging was performed for another 5 min to determine
endothelium independent vasodilatation (Figure 2.3.4.3 below).
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Figure 2.3.4.3 Protocol for Brachial artery scan using VIA software
The above picture shows the protocol used to scan the brachial artery, in the study. The white
line is the time line showing 2 min of baseline scanning followed by 4 min 30 sec of
compression. Finally, there is a further 2 min of scanning post release of compression. The
FMD value was measured at 50 sec after release. The bottom blue line shows the artery
diameter showing increased measurements at 50 sec point confirming the FMD percentage
value.
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At the end of the study a graph of diameter against time was immediately displayed. The
FMD (defined by the percentage increase in mean diameter over a 10 sec period, 50 sec after
tourniquet deflation) was automatically calculated by VIA from diastolic vessel diameters
(Figure 2.3.4.4and Figure 2.3.4.6below).
18.4
5.7
7.0
8.0
9.0
10.0
11.0
12.0
13.0
14.0
15.0
16.0
17.0
10:21:3610:11:29 10:12:30 10:13:20 10:14:10 10:15:00 10:15:50 10:16:40 10:17:30 10:18:20 10:19:10 10:20:00 10:20:50
Peak start
Base endBase start
Diastolic dia
Figure 2.3.4.4 VIA software displaying real time diameter changes over time.
The Y axis displays arterial diameter in mm. The X axis displays time in minutes and
seconds. The first and second green lines represent the time points at which the BP cuff
inflated and then deflated, respectively. Purple lines represent the 50 sec FMD peak dilation
point post deflation.
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Figure 2.3.4.5 VIA software final reports on an FMD scan
The above figure shows the FMD % dilatation along with cardiovascular and elasticity
parameters on a subject’s scan.
The graph at the centre shows the dilatation at 50 sec in response to release of pressure on the
arterial wall. The cardiac cycle is represented at the bottom right of the picture.
The endothelium independent dilatation was calculated similarly to the percentage increase in
mean diameter 5 min after GTN administration. On-line image analysis and continuous
display of vessel diameter allowed wall tracking to be optimized throughout the study,
avoiding loss of data because of poor image quality. Using VIA software, the FMD was
calculated and displayed within seconds of completing the study. It had already been shown
that this new technique minimised the variability of measurement. The mean day to day
variability of FMD measurements was 0.9(0.5)% in subjects with a wide range of measured
FMD and baseline arterial diameters in a previous study (Sidhu, Newey et al. 2002). Using a
reference two dimensional image of the artery for comparison in repeat studies also ensured
that the same section of artery was scanned every time each day and on subsequent days. The
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magnitude peak FMD response could be influenced by any variability of occlusion cuff
position, duration of occlusion, occlusion pressure and time of peak dilatation measurements
(Pyke and Tschakovsky 2005). As noted above, all systems were standardized to minimize
variability in the scanning procedures. Similar measurements to detect endothelial function
were undertaken in the retinal vasculature to study microvascular function. The following
procedure was used.
2.3.5 Retinal Vessels Reactivity (RVR) Measurements
Retinal vessels facilitate for observations and measurements of microvascular changes in a
direct and non-invasive method. This method is used by clinicians using an opthalmoscope to
identify changes in the vascular bed relating to diabetes, hypertension and other
cardiovascular risk parameters but early functional vascular changes of T2DM and
hypertension could occur without any identifiable or obvious lesions on traditional
opthalmoscopic examination (HICKAM and SIEKER 1960). Similarly, early functional
changes in the retinal vascular bed may not be identifiable on current retinal screening
programmes based on identifying structural abnormalities. Therefore, in order to identify
these early functional vascular changes of vasosclerosis (when there is little or no change on
opthalmoscopic (HICKAM and SIEKER 1960) or retinal screening fundal photographs),
RVA, with its ability to objectively measure vascular function, was utilized to measure
microvascular function in this study.
RVR was measured using the retinal vessel analyzer (RVA, Imedos, GmbH). The
fundamental components of this system consisted of a fundus camera (field of 50°;model FF
450;Zeiss, Jena, Germany), a video camera, a real-time monitor and a computer with image-
analysis software for the accurate determination of retinal arterial and venous diameter.
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Retinal vessel diameter was analysed in real time with a maximum frequency of 40 Hz, so
that every second a maximum of 25 readings of vessel diameter could be obtained. For this
purpose the fundus was imaged onto the charge-coupled device (CCD) (camera with an
apparatus which was designed to convert optical brightness into electrical amplitude signals
using a plurality of CCDs, and then reproduce the image using the electrical signals without
time restriction) chip of the video camera (AppendixI, Figure 1 h). The consecutive fundal
images were digitised with a frame grabber. Evaluation of the retinal venous and arterial
diameter was performed on-line. These pictures could also be reviewed and re- analysed off-
line, from the recorded videotapes (Seifertl and Vilser 2002).
2.3.6 Mechanism of wall motion detection-Retinal Vessel Analyser (RVA)
The RVA system, as a method suitable for quantitative examination of retinal vessel function
and changes of atherosclerosis, was first reported in 2004in a clinical methodological study
by Nagel (Nagel and Vilser 2004). The RVA measured the diameter of the retinal vessel.
Each blood vessel has a specific transmittance profile due to the absorbance properties of
haemoglobin. Measurement of retinal vessel diameter was based on adaptive algorithms that
used those specific profiles. W henever a specific vessel profile was recognised, the RVA
system followed this vessel, as long as it appeared within the measurement window (Seifert l
and Vilser 2002). The system corrected automatically for alterations in luminescence that
were induced, for instance, by slight eye movements. If the requirements for the assessment
of diameter were not fulfilled temporarily, as occurred during blinks, the system
automatically stopped the measurement of diameter. As soon as an adequate fundus image
was achieved again, measurement of diameter restarted automatically. An opto-electronic
shutter controlled by a special program running on the RVA computer, inserted in the camera,
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interrupted the observation light (530–600 nm, irradiance at the fundus 1.96x10–4W /cm2)
over the entire 30°visual field of the retinal camera and produced a bright-to-dark contrast
ratio of at least 25:1 (flicker provocation) (Seifertl and Vilser 2002). This created the flicker
light by means of rectangular interruption of a green observation light of the RVA. Flicker
provocation increased metabolic rate of the retinal vasculature and, in turn, acted as an
indirect stimulant. The flicker stimulated retinal photoreceptors, which have a higher
metabolic demand and influence vascular reactivity through neurovascular coupling. An ROI
could be selected as a rectangle that included the particular vessel. Diameter was calculated
along the arterial or venous segment, or both, that were located within the rectangle. As long
as the vessels under study were within the selected rectangle during the eye movements, the
system automatically corrected for the eye movements. This was again permitted by the
adaptive nature of the diameter analysis software. In contrast with other procedures which
had been proposed for the determination of retinal vessel size, this system measured
diameters only in relative units (Polak, Dorner et al. 2000). RVA, as described previously and
as used in this study, had been proven in a methodological study in 2004(Nagel and Vilser
2004) as a method to observe light induced diameter changes.
2.3.7 Retinal Vessel Analyser (RVA) Protocol
All subjects were given topical 1 % Tropicamide applied to the right eye, at least 20-30 min
before the actual scanning for pupillary dilatation. The subjects were seated comfortably for
a few min and the stool height adjusted so that the subject was extremely stable and
comfortable for the duration of the study. The left eye was covered to improve fixation of the
right eye during imaging with the fundus camera. The image of the retina was adjusted on the
screen of the real-time monitor after adjusting the camera to the dilated pupil, and a suitable
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area in the retina was picked. The best area for scanning was picked based on the course of
artery and vein, distance from the fundus and lack of branches. The superior or inferior
quadrant of the temporal region was the usual area picked (AppendixI, Figure 1 i). BP and
pulse-rate readings were taken before the start of the scan. The recordings were stored on a
storable medium and could be evaluated off-line. After obtaining a clear fundus image with
good contrast and no reflections, the scanning was started according to a fixed protocol. The
fundus of the eye was examined under green light. After the baseline recording of 50 sec,
where both artery and vein in the chosen segment were continuously monitored, three flicker
periods of 20 sec each were applied, interrupted with 80 sec of still illumination. The flickers
were created by interrupting the green light. The maximum vaso-motion, in response to
flicker stimulation, was measured in two chosen segments of the major temporal inferior
branch of the arteriole and venule. The point of maximum dilation was determined as the
highest 1 sec mean vessel diameter during the period of 50 sec, after the beginning of the
corresponding flicker stimulus (Gugleta, Zawinka et al. 2006). Three points of maximum
dilation were obtained in all measuring sites (proximal and distal in arterioles and venules)
and expressed as a percentage of the corresponding first baseline value. A graph was
generated which described the measure of vessel dilatation (Appendix II, Figure 2 c and
Figure 2 d).
2.3.8 Arterio-venous Ratio (A/V Ratio) on RVA
Apart from the reactivity measurements of retinal vessels, the RVA contained software to
measure other parameters including “vessel map basic” which enabled A/V ratios to be
determined in line with the Atherosclerosis risk in communities study (ARIC) (W ong, Klein
et al. 2001). The A/V ratio was a quantitative parameter to determine vascular risk. In
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combination with an individual’s medical history and an evaluation of micro-vascular fundus,
this can result in a valuable vascular predictive tool. The result was obtained automatically
once the set number of arteries and veins were identified on the fundal pictures (AppendixII,
Figure 2 e).
2.4 Molecular Analysis
2.4.1 Immediate bed-side plasma and serum isolation
Serum and plasma from blood of participants was separated immediately after collection.
Plasma was collected after spinning a column of blood in a mobile centrifuge (Capricon
Laboratory Equipment, model CEP 2000) at 1500×g for 15 min. Then the sample was
immediately placed in a special container and then stored in a freezer straight away. Similarly
serum from the blood was separated after collecting the blood in a collection tube which
aided coagulation. Initially, up to 30 min of standing was allowed before spinning to aid
coagulation. Once the blood was coagulated inside the collecting tube, the tube was placed in
a centrifuge and spun at 1500 ×g for 15 min. This separated the serum at the top. Again the
sample was immediately placed in a special container and then stored in a freezer straight
away. Long term storage of serum, plasma and urine samples was carried out in 1.5 ml
collection tubes and stored at -80°C until further analysis. A detailed database was created in
accordance with ethics procedures for long term storage of all the samples (Appendix II,
Figure 2 f).
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2.4.2 MultiplexImmunoassay
Serum endotoxin concentrations were assessed using a Chromogenic Limulus Amebocyte
Lysate test (Cambex, New Jersey, USA), with a sensitivity of 0.1 EU/ml and an intra- and
interassay CV of 3.9±0.46 and 9.6±0.75, respectively. Our previous studies confirmed the
specificity of the endotoxin assay (Baker, Harte et al. 2009). A multiplexed CVD Panel 1
immunoassay (Linco Research, Missouri, USA) was utilised to examine the circulating
concentrations of the following inflammatory and CVD risk biomarkers: TNF-α, PAI-1 
(tPAI-1, total) CRP, soluble intercellular adhesion molecule type-1 (sICAM-1), soluble
vascular cell adhesion molecule-1 (sVCAM-1), MMP-9, MPO, VEGF and soluble endothelial
selectin (sE-Selectin). The CVD Panel 1 immunoassay had a sensitivity of 16-50,000 pg/ml
for MMP-9, MPO and PAI-1 and further, a sensitivity of 80-250,000 pg/ml for sICAM-1,
sVCAM-1 and sE-Selectin;with an intra- and interassay CV of 4.5-12.3% and 8.5-16.3%,
respectively. Plasma glucose was measured using an automated glucose analyser (Roche
Diagnostics, Mannheim, Germany). Serum insulin levels were measured by a
chemiluminescent assay (DPC, Los Angeles, USA) with a sensitivity of 14.3 pmol/l and
intra- and interassay CV of 3.7% and 6.7%, respectively.
2.4.3 Protein Glycation and oxidation damage to LDLproducts
2.4.3.1 Isolation of LDL
LDLwas isolated from the stored plasma samples. For rapid, same-day preparation of LDL, a
self-generating gradient of iodixanol in a vertical rotor (S120VT) was used in a Sorvall MTX
150 micro ultra centrifuge (Hitachi). The density of plasma was increased to 12% using 60%
iodixanol solution (OptiPrep;Axis-Shield). Plasma (0.9ml) was layered under 0.9ml of 9%
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iodixanol in a 2ml ultracentrifuge tube (polyallomer, no. S302897A;Hitachi) and further void
filled with 0.2ml nitrogen-purged PBS. The sample was centrifuged (501,000g, 16°C, 2.5 hr)
with low acceleration and deceleration. LDL was washed with nitrogen-purged water (4ml ×
3) over 100-kDa microspin filters (Amicon) to remove iodixanol. The LDL was stored at
−20°C until further analysis. Sample handling was performed under subdued light. Protein 
concentration was measured by Bradford assay (Rabbani, Chittari et al. 2010). Lipid
peroxidation of LDL was assessed by measuring thio-barbituric acid reactive substances
(TBARS). TBARS were quantified by reference of the chromophoric response to a standard
curve constructed from malondialdehyde tetramethyl acetal and expressed as
malondialdehyde equivalents (Rabbani, Chittari et al. 2010). The purity of LDLwas assessed
by SDS-PAGEdenaturing and agarose non-denaturing electrophoresis.
2.4.3.2 In vitro modification of LDL
LDL was glycated minimally by methylglyoxal and glucose in vitro to assess the major
glycation adducts formed. LDL glycated minimally by methylglyoxal (MGmin-LDL) was
prepared by incubation of methylglyoxal (200μmol/l) with LDL (4.2mg/ml) in PBS (0.4 
mmol/l diethylenetriaminepentaacetic acid [DETAPAC], pH 7.4) at 37°C for 6 hr. The
glycated and control LDL was washed extensively with argon-purged ice-cold water using
ultra-spin filters (Amicon 100-kDa cutoff membrane from Millipore) at 4°C, and stored at
4°C under argon and used within 2 weeks. LDL glycated minimally by glucose (AGEmin-
LDL) was prepared by incubation of glucose (25mmol/l) with LDL (3mg/ml) in PBS
(0.4mmol/l DETAPAC, pH 7.4) under argon (0.5ml) at 37°C for 7 days under sterile
conditions. Control LDL was incubated without glucose. The glycated and control LDL was
washed with argon-purged water ultrafiltrate at 4°C, and stored at 4°C under argon until
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further analysis. Electrophoretic mobility of native and modified LDL on agarose gel
electrophoresis was performed using a gel lipoprotein electrophoresis kit ( Helena kit) using
barbital buffer, pH 8.6.
2.4.3.3 Delipidation of LDL
An aliquot of LDL solution (20μl, 100μg) was transferred into a glass tube (50 × 7.5mm) 
containing butylated hydroxytoluene in methanol (5μl, 2mg/ml), 20% trichloroacetic acid 
(100μl), and water (75μl), mixed well, left on ice for 10 min, and then centrifuged (10,000g,
15 min, 4°C). The supernatant was removed and the pellet washed with acetone (200μl) and 
diethyl ether (200μl) and dried under argon. 
2.4.3.4 Enzymatic digestion of apoB100
Delipidated protein was hydrolyzed exhaustively by modification of our collaborators
previous work (Ahmed, Argirov et al. 2002). Protein was suspended in 100mmol/l potassium
phosphate buffer, pH 7.4 (50μl). Pronase E (20μl, 2mg/ml in 10mmol/l KH2PO4 buffer, pH
7.4) and 10μl penicillin (50units/ml) and streptomycin (50μg/ml) were added and the samples 
incubated at 37°C for 24 hr. Thereafter, 10μl each of prolidase and aminopeptidase solutions 
(2mg/ml in 10mmol/l KH2PO4 buffer, pH 7.4) was added, and samples were incubated for a
further 48hr. All steps were performed under argon.
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2.4.3.5 Protein biomarker determination by LC-MS/MS
Fructosyl-lysine (FL), advanced glycation end products (AGE) and oxidation and nitration
markers were determined in enzymatic hydrolysates of delipidated lipoprotein by stable
isotopic dilution analysis LC-MS/MS (Thornalley, Battah et al. 2003;Rabbani, Chittari et al.
2010). This work was published in Diabetes journal in 2010 (Rabbani, Chittari et al. 2010).
2.5 StatisticalAnalysis
Statistical analyses for these studies were performed using SPSS 17 programme. Initially,
Kolmogorov-Smirnov test was used to determine whether variables had a normal distribution
(AppendixIII, Table 2.5.1 and 2.5.2). These results showed that the variables were normally
distributed. Paired student’s t test was subsequently used to compare parameters before and
after intervention within the same group. In the healthy subjects, this test was performed to
check whether the differences in values obtained after OGTT were significantly different
from the fasting levels in the variables tested. Further, the non-parametric test, W ilcoxon
signed ranks test, was used to confirm data comparisons within the same groups. Finally,
baseline data comparisons between different groups were performed using an unpaired
student’s t test. Statistical significance was defined as P<0.05.
2.6 Validation ofvascular tests
The results obtained from both scanning parameters were validated by the high levels of
validity measurements recorded for each scan. On the FMD software, the obtained values
were validated by the low levels of noise recorded for each scan. Accuracy of the results
73
depended on the scans generating less than 40% as noise levels for each study. This figure
was reached whilst validating the software by the manufacturer of the software program
(Sidhu, Newey et al. 2002). This study consistently recorded noise levels less than 40 % at
each point of the study confirming the validity of the results obtained (AppendixIII, 2.6.1 and
2.6.2). On the RVA software, the validity measurements of more than 40% (valid cycles)
were considered as a reliable indicator for accuracy of the study results (Seifertl and Vilser
2002). This study recorded valid cycles higher than 50 % at each point confirming the
validity of the RVR values obtained (AppendixIII, 2.6.3 and 2.6.4).
2.7 Summary
The above tests summarize the various techniques and tests performed in this thesis in
different chapters. A summary sheet was created for each subject with collated results from
the tests outlined in this chapter (AppendixII, Figure 2 g). A detailed summary of specific
tests and methodology was shown in the relevant chapters.
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Chapter 3
Impact ofAcute Lipid ingestion on Circulatingendotoxin
Levels withassessment ofvascular function
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3.1 Introduction
The interrelationships between inflammation, insulin resistance and adipose tissue (AT) are
critical in explaining increasing risk of developing T2DM (Laaksonen, Niskanen et al. 2004)
(Tuttle, Davis-Gorman et al. 2004). It is known that low grade chronic systemic inflammation
contributes to this risk, which appears altered by several factors such as increasing age,
gender, ethnicity, genetics and dietary influences. However systemic inflammation appears to
persist in T2DM subjects, despite medication, whilst the mechanisms and mediators of this
continual inflammation appear less clear. Evidently, AT accumulation has a significant
impact on disease risk in type 2 diabetes and inflammation possibly through hypoxia
(Landini, Honka et al. 2015) but may merely act in response to systemic primary insults
(Baker, Harte et al. 2009;Tabak, Brunner et al. 2009;Youssef-Elabd, McGee et al. 2011).
One potential cellular mechanism for increased inflammation may arise through activation of
the innate immune system in human AT (Brun, Castagliuolo et al. 2007;Cani, Amar et al.
2007;Cani, Neyrinck et al. 2007;Creely, McTernan et al. 2007). Previous studies have
shown that increased activation of the innate immune pathway may arise through excess
circulating lipopolysaccharide (LPS) or endotoxin;which represents the outer cell wall
membrane of gram-negative bacteria likely from the gut (Lin, Lee et al. 2000;Brun,
Castagliuolo et al. 2007;Creely, McTernan et al. 2007;Dixon, Valsamakis et al. 2008;Al-
Attas, Al-Daghri et al. 2009;Miller, McTernan et al. 2009). Our previous work has shown
that endotoxin has an immediate impact on the innate immune pathway in human AT, acting
via key receptors known as the toll like receptors (TLRs) which recognize antigens, such as
the LPS component, to initiate an acute phase response to infection (Creely, McTernan et al.
2007;Baker, Harte et al. 2009). Stimulation of the TLRs leads to intracellular activation of
NFκB, a key transcription factor in the inflammatory cascade that regulates the transcription 
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of numerous pro-inflammatory adipokines (Creely, McTernan et al. 2007;Youssef-Elabd,
McGee et al. 2011). Therefore in vitro endotoxin may act as a mediator of inflammation
through activation of NFκB, leading to a rapid response within AT that may be exacerbated 
by increased AT mass (Lin, Lee et al. 2000;W ellen and Hotamisligil 2005;Song, Kim et al.
2006;Kopp, Buechler et al. 2009;Shoelson and Goldfine 2009).
However clinical studies have also implicated gut derived endotoxin as a ‘primary insult’to
activate the inflammatory state, contributing to metabolic disease, with current cross-sectional
data showing elevated systemic endotoxin levels in conditions of obesity, T2DM and
coronary artery disease (Brun, Castagliuolo et al. 2007;Creely, McTernan et al. 2007;Dixon,
Valsamakis et al. 2008;Al-Attas, Al-Daghri et al. 2009;Baker, Harte et al. 2009;Miller,
McTernan et al. 2009). W ithin these studies circulating endotoxin is observed to be positively
associated with waist circumference, waist-hip-ratio, insulin levels, inflammatory cytokines,
as well as lipids including total cholesterol, triglycerides (TGs), LDL-cholesterol and
negatively associated with HDL-cholesterol (Brun, Castagliuolo et al. 2007; Creely,
McTernan et al. 2007;Dixon, Valsamakis et al. 2008;Al-Attas, Al-Daghri et al. 2009;Baker,
Harte et al. 2009;Miller, McTernan et al. 2009). A recent review summarized endotoxin as a
model to induce transient systemic inflammation even in healthy human subjects
(Schedlowski, Engler et al. 2014).
Lipids present another important mediator of inflammation in CVD and T2DM, as human
dietary studies have noted that cholesterol, trans-fatty acids (TFAs) and saturated fatty acids
(SFAs) all increase the levels of atherogenic lipoproteins. Specifically, SFAs are noted to
adversely affect vascular function whilst polyunsaturated fats (PUFAs;such as linoleic acid
(18: 2n-6) and n-3 PUFA) appear beneficial (Hall 2009). As such the combined importance of
dietary lipids and endotoxin in determining inflammatory and CVD risk may arise as
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endotoxin has a strong affinity for chylomicrons (lipoproteins that transport dietary long
chain SFAs through the gut wall) as endotoxin crosses the GI mucosa (Amar, Burcelin et al.
2008; Ghoshal, W itta et al. 2009; Moreno-Navarrete, Manco et al. 2010). As such,
atherogenic and inflammatory risk may arise through a combination of dietary lipoprotein
patterns and an increase in circulating endotoxin, exacerbated by feeding patterns (Hall 2009;
W yness 2009).
To address whether endotoxin might possess an associated vascular risk, previous work has
examined whether endotoxin could represent a biomarker of atherosclerotic and
cardiovascular risk. This prior cross sectional study (n=193) sought to address the impact of
gender and ethnicity and relationship between lipoprotein patterns and circulating endotoxin.
Age-adjusted endotoxin levels identified men to have a higher circulating endotoxin level
than women (p=0.002). Further that in examining ethnicity the study observed that endotoxin
levels were highest in South Asians (13.3 EU/mL [95% CI 12.0 to 14.7]), who are at raised
metabolic risk, followed by white Caucasians (12.5 (10.8to 14.6) and lowest in individuals of
African origin (10.1 EU/mL[9.1 to 11.1]).
Additionally that endotoxin levels were positively associated with waist circumference, waist-
hip-ratio, total cholesterol, serum TGs and serum insulin levels and negatively associated
with serum HDL-cholesterol;with circulating endotoxin appearing to represent a novel
marker of atherosclerotic and CVD risk (Miller et al, 2009). Furthermore prior data has also
highlighted that endotoxin levels fall with treatment with rosiglitazone, which also reduces
blood pressure. Both inflammation and vascular injury impact on the risk of elevated blood
pressure as noted in numerous previous studies (W ei et al, 2007, Bautista et al, 2005, Harte et
al, 2005, Chae et al, 2001). However limited data has examined the potential impact of
endotoxin to affect blood pressure (W ei et al, 2007), although it remains unclear whether this
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could be viewed as a consequence of endotoxin levels or a marker of such an occurrence. In
spite of this, previous data has assessed the prenatal exposure of endotoxin in Sprague-
Dawley rats and the link with blood pressure. The Sprague-Dawley rats in this study were
injected intraperitoneally with endotoxin/LPS (0.79mg/kg) between 8-12 days gestation. The
findings from these studies noted that prenatal exposure to endotoxin led to an increase in
blood pressure, independent of body weight, and, as such, may suggest that systemic levels of
endotoxin in obese children and adolescents may contribute to its aetiology. This gives us
encouraging evidence that endotoxin may affect the circulation and the vasculature.
Examining this, post-prandially, through a fat loaded meal may have specific systemic and
vascular impact which may be altered and further influenced due to different gut
compromised metabolic states.
Therefore altering the lipid profile through dietary intervention may reduce endotoxin and the
arising inflammatory and vascular response. Recent human studies have explored dietary
effects of a high SFA, high carbohydrate meal on circulating endotoxin levels in healthy
individuals. The findings revealed a substantial increase in circulating endotoxin, in subjects
given a high fat meal, in conjunction with markers of inflammation - as noted from
mononuclear blood cells (Cani, Amar et al. 2007;Ghanim, Abuaysheh et al. 2009).
Murine studies have also identified an association between endotoxin and insulin resistance,
through infusion of endotoxin, with the same effect also noted by a high fat diet (Cani,
Neyrinck et al. 2007);with insulin resistance and weight gain both impacting on gut
permeability (Brun, Castagliuolo et al. 2007;Ghanim, Abuaysheh et al. 2009). In studies, to
date, using either infused endotoxin as a bolus or derived from the gut due to dietary changes,
both methods suggest endotoxin has the capacity to impact on the inflammatory pathways
(Ghanim, Abuaysheh et al. 2009;Deopurkar, Ghanim et al. 2010).
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However, it remains to be established whether diets in different metabolic states affect
absorption of endotoxin. Also do such post-prandial circulating endotoxin levels correlate
with systemic lipid changes post-prandially, being compounded in more insulin resistant
states?
Therefore the study in this chapter sought to establish whether a high fat rich meal increased
circulating endotoxin levels and whether this is altered in different metabolic disease states.
Further whether a lipid meal may affect micro and macro-vascular reactivity in the different
metabolic states and, finally, whether such an acute effect may, in part, be mediated through
changes in circulating endotoxin levels as well as lipid profiles.
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3.2 Patients and Methods
3.2.1 Study subjects
Non-obese controls (NOC, n=9), obese subjects (n=15), patients with impaired glucose
tolerance (IGT;n=12) and T2DM (n=18) were included in the study. The details are shown in
Table 3.2.3 below. Obesity and body weight was categorized in Table 3.2.1 as below
according to The W orld health Organization (W HO).
Table 3.2.1.1 The International Classification of adult underweight, overweight and obesity
according to BMI. The W orld health Organization (W HO) –2009
Classification BMI(kg/m)
Underweight <18.50
Normal range 18.50 - 24.99
Overweight ≥25.00 
Pre-obese 25.00 - 29.99
Obese ≥30.00 
Obese class I 30.00 - 34-99
Obese class II 35.00 - 39.99
Obese class III ≥40.00 
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All subjects with T2DM were of South Asian origin except 1 subject, who was Afro-
Caribbean in origin. Similarly all healthy controls were South Asian in origin except one who
was Afro-Caribbean. South Asians have a significantly higher risk of developing Type 2
diabetes and its associated complications (Yudkin 1996{Chowdhury, 2006#353;Chowdhury,
Lasker et al. 2006). It is an emerging epidemic for the healthcare of people in the UK and
globally. South Asians have a six-fold increase in their risk of developing type 2 diabetes
compared to age matched Caucasian populations (Raleigh and Kiri 1997). South Asians
present with diabetes at a younger age;they are therefore exposed to diabetes for a longer
period than Caucasians, and this in turn leads to a greater risk of cardiovascular and
microvascular complications (Barnett, Dixon et al. 2006).
All subjects were non-smokers. Screening blood tests were performed for both baseline
measurements to qualify for the study, as well as to assess their glucose control. Routine
blood tests included renal function, glucose, HbA1C and full cholesterol profile. All subjects
had their height, weight, abdominal circumference and BMI measurements taken using
standard equipment. Blood samples were taken either from the right or left ante-cubital vein
in a sitting position. Blood pressure was checked with a blood pressure monitor on the left
arm and rechecked after 2 minutes.
Finally a 12 Lead ECG was performed using the same machine for the duration of the study.
Subjects included in the study had a normal resting ECG, normal renal function tests and
blood pressure and no history of vascular disease. Detailed medical drug histories were taken
on medications and those subjects on medication considered to lead to a change in
inflammatory status were excluded, including the thiazolidinediones. Ethical approval was
obtained from the Local Research Ethics Committee and all patients gave written consent.
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Table 3.2.1.2 The table presents the anthropometric data for the different cohorts. Data are
presented as mean±SD. # denotes data with a non-Gaussian distribution that were
transformed prior to statistical analysis, significance values are noted.
Normal Group Obese Group IGT Group Type 2 Diabetes
Group
p value
Parameters
N 9 15 12 18
Age (Years) 39.9±11.8 43.8±9.5 41.7 ±11.3 45.4±10.1 NS
Sex(M:F) 6:3 10:5 7:5 11:7
Ethnicity Asian: n=8 Afro-
Caribbean: n=1
Asian n=15 Asian n=12 Asian: n=17
Afro-Caribbean:
n=1
#BMI (kg/m2) 24.9±3.2 33.3 ±2.5 32.0 ±4.5 30.3 ±4.5 Normal Vs obese: p<0.001;
Normal Vs IGT: p=0.001;
Normal Vs T2DM: p=0.003;IGT
Vs Obese: NS;IGT Vs T2DM:
NS;Obese Vs T2DM: p=0.019
W aist
Circumference (cm)
86.9±8.25 108.9±17.9 106.4±10.37 100.1 ±10.2 Normal Vs obese: p=0.001;
Normal Vs IGT: p<0.001;
Normal Vs;T2DM:p=0.002;IGT
Vs Obese: NS;IGT Vs T2DM:
NS;Obese Vs T2DM: NS
#Estimated
Glomerular
Filtration Rate
105.62±19.71 91.07±17.40 105.92±19.77 92.28±24.36 NS
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All research subjects (n=54) with and without T2DM were given a high-fat meal
(standardized meal: 75g fat, 5g carbohydrate, 6g protein) following an over-night fast of 12-
14hours, as previously described (Ceriello, Assaloni et al. 2005). The cohort consisted of
non-obese controls (ND): age: 39.9 (mean±SD) 11.8yr, BMI: 24.9 (mean±SD) 3.2Kg/m2;
n=9;Obese: age: 43.8±9.5yr;BMI:33.3±2.5Kg/m2;n=15;impaired glucose tolerance (IGT):
age: 41.7± 11.3yr; BMI: 32.0±4.5 Kg/m2; n=12; type 2 diabetes: age: 45.4±10.1yr;
BMI:30.3±4.5Kg/m2;n=18. Blood samples were drawn at baseline (0hr), and post-prandially
(1hr, 2hr, 3hr, 4hr,) and endotoxin and lipid levels measured.
3.2.2 In vivo Assessment of the Biochemical profile
On the assigned date, fasting blood samples were collected from participating subjects and
lipid profiles and fasting plasma glucose determined using routine laboratory methods
undertaken in the biochemistry laboratory at University Hospital Coventry and W arwickshire
(UHCW ). In brief, the routine blood tests included renal function, glucose, HbA1C and full
cholesterol profile [Triglycerides(TG), high density lipoproteins (HDL) and low density
lipoproteins (LDL)], as noted in Table 3.2.2.
Insulin measurements were performed by a solid phase enzyme amplified sensitivity
multiplex immune assay (Millipore, Hertfordshire, UK), and glucose was measured by a
glucose oxidase method (YSL 200 STAT plus). Homeostasis model assessment for Insulin
resistance (HOMA-IR) was calculated for all patients using the HOMA formula: HOMA-IR
=Fasting insulin (mU/l) xplasma glucose (mmol/L) /22.5.
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Normal Group
Parameters Baseline 1-hour 2-hour 3-hour 4-hour
#TGs (mmol/L) 1.1 ±0.07 1.3 ±0.08* 1.8±0.08*** 2.2 ±0.2** 2.4±0.27**
Total Cholesterol (mmol/L) 4.9±0.95 5.1 ±0.85 5.1 ±0.73 5.1 ±0.94 5.2 ±0.81
#LDL-Cholesterol (mmol/L) 3.2 ±0.04 3.2 ±0.03 3.1 ±0.03 2.82 ±0.04* 2.79±0.04
#HDL-Cholesterol (mmol/L) 1.1 ±0.004 1.1 ±0.004 0.98±0.03 1.06±0.004 1.03 ±0.008
#TNF-α (pg/ml) 8.0 ±2.3 8.1 ±2.2 7.4±2.0 7.4±1.8 8.0 ±2.0
#Leptin (ng/ml) 16.8±4.8 17.0 ±5.3* 14.6±4.0* 13.6±3.5* 14.7 ±4.4
#Endotoxin (EU/ml) 3.3 ±0.15 4.0±0.17* 4.32±0.19 5.5±0.64 6.3±1.4
Obese Group
Parameters Baseline 1-hour 2-hour 3-hour 4-hour
#TGs (mmol/L) 1.6±0.08 1.7 ±0.08 2.3±0.10 *** 2.7 ±0.12*** 3.0 ±0.14***
Total Cholesterol (mmol/L) 5.3 ±0.80 5.1 ±0.67 5.1 ±0.99 5.3 ±1.0 5.2 ±0.76
#LDL-Cholesterol (mmol/L) 3.56±0.04 3.34±0.02 3.0 ±0.05*** 3.0 ±0.06*** 2.9±0.04***
#HDL-Cholesterol (mmol/L) 0.92 ±0.01 0.90 ±0.01 0.84±0.01* 0.85±0.008** 0.81±0.01***
#TNF-α (pg/ml) 8.4±1.3 8.4±1.4 7.8±1.6 7.5 ±1.4* 7.5 ±1.4*
#Leptin (ng/ml) 25.6±3.1 23.3±2.7*** 20.7 ±2.3 21.7 ±2.6 21.4±2.9***
#Endotoxin (EU/ml) 5.1 ±0.94 4.2 ±0.71 6.2 ±0.49 7.8±0.76** 7.7 ±0.58**
IGT Group
Parameters Baseline 1-hour 2-hour 3-hour 4-hour
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Table 3.2.2 The table presents the variable data for the different cohorts over time, which
were presented as mean±SD, * denotes significant difference compared with baseline;#
denotes data with a non-Gaussian distribution that were transformed prior to statistical
analysis. Significance values *p <0.05, **p <0.01, ***p <0.001
#TGs (mmol/L) 1.3 ±0.03 1.5 ±0.04*** 1.9±0.07 *** 2.5±0.15 *** 2.5±0.15 ***
Total Cholesterol (mmol/L) 4.9±0.80 4.7 ±0.74 4.8±0.74 4.8±0.77 4.8±0.77
#LDL-Cholesterol (mmol/L) 3.24±0.04 3.08±0.03 2.9±0.03** 2.6±0.04** 2.66±0.05**
#HDL-Cholesterol (mmol/L) 0.88±0.008 0.86±0.008 0.82±0.006*** 0.81±0.008*** 0.77±0.01***
#TNF-α (pg/ml) 4.4±2.1 4.3 ±2.0 4.3 ±2.0 4.1 ±2.0 4.3 ±2.1
#Leptin (ng/ml) 37.0 ±2.7 32.6±2.7*** 32.0 ±2.7* 31.1 ±3.0** 33.0 ±3.3**
#Endotoxin (EU/ml) 5.7 ±0.10 5.8±0.22 5.5 ±1.0 7.4±0.26* 7.5 ±0.20 *
T2DM Group
Parameters Baseline 1-hour 2-hour 3-hour 4-hour
#TGs (mmol/L) 1.4±0.03 1.6±0.05*** 2.2 ±0.08*** 2.8±0.12*** 3.1 ±0.13***
Total Cholesterol (mmol/L) 5.0 ±1.0 4.8±0.95* 4.8±0.91 5.0 ±1.0 4.9±0.93
#LDL-Cholesterol (mmol/L) 3.17±0.11 2.9±0.07*** 2.6±0.10*** 2.4±0.16** 2.4±0.14***
#HDL-Cholesterol (mmol/L) 1.0 ±0.02 1.0 ±0.02 0.94±0.02*** 0.92±0.02*** 0.86±0.02***
#TNF-α (pg/ml) 8.6±2.0 8.4±2.0 8.4±2.0 8.3 ±1.8 8.1 ±2.3
#Leptin (ng/ml) 18.1 ±3.5 20.0 ±5.0*** 18.7 ±3.7 18.2 ±3.4 15.2 ±3.3
#Endotoxin (EU/ml) 5.3 ±0.54 5.5 ±0.44 5.8±0.34 9.8±1.2** 14.2±3.0 **
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3.2.3 Analysis of circulating endotoxin levels
Serum endotoxin was analysed using a commercially available QCL-1000 LAL Endpoint
Assay (Lonza, New Jersey, USA). The assay, and the values given by the manufacturer for
intra-assay CV (3.9±0.46) and inter-assay CV (9.6±0.75), have been validated in our
laboratory, as detailed previously (Creely, McTernan et al. 2007).
3.2.4 FMD Methodology
In brief, vascular reactivity measurements were evaluated using the flow-mediated
vasodilatation (FMD) of the brachial artery. Vasodilatation responses of the brachial artery
have been measured by ultrasound technique, the validity of which has been previously
confirmed (M. C. Corretti 1995). Brachial artery FMD was determined according to a
conventional protocol (Ceriello, Taboga et al. 2002;Sidhu, Newey et al. 2002;Arroyo-
Espliguero, Mollichelli et al. 2003;Masci, Laclaustra et al. 2005).
The system used for this study allowed live on-line analysis with a single operator. The
tracking and optimisation for most part was done automatically by the system software. In
view of live analysis, high image acquisition rate was possible and results were obtained
instantly. This obviated the need for retrospective analysis (Newey and Nassiri 2002).
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3.2.5 RVA Methodology
Retinal vessel reactivity was measured using the retinal vessel analyzer (RVA, Imedos,
GmbH). The fundamental components of this system consisted of a fundus camera (field of
50°;model FF 450;Zeiss, Jena, Germany), a video camera, a real-time monitor, and a
computer with image-analysis software for the accurate determination of retinal arterial and
venous diameter. Retinal vessel diameter was analyzed in real time with a maximum
frequency of 40 Hz, so that every second a maximum of 25 readings of vessel diameter could
be obtained. This method was detailed in chapter 2.
The consecutive fundus images were digitized with a frame grabber. Evaluation of the retinal
venous and arterial diameter was performed on-line. These pictures could also be reviewed
and re- analyzed off-line, from the recorded videotapes (Seifertl and Vilser 2002).
Measurement of retinal vessel diameter was based on adaptive algorithms that used those
specific profiles. W henever a specific vessel profile was recognized, the RVA system
followed this vessel as long as it appeared within the measurement window (Seifertl and
Vilser 2002).
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3.2.6 Statistical analysis
For assessment of the different variables, statistical analysis was undertaken using a paired
student t-test, for intra-comparison of hourly time points versus baseline, and an unpaired
student t-test for inter-comparisons. The threshold for significance was p<0.05. Data in the
text and figures are presented as mean±SD or mean±SEM. Correlations were determined with
a Pearson correlation for continuous variables and Spearman correlation coefficient for non-
continuous variables. Once a non-Gaussian distribution was logarithmically or square root
transformed, statistical analysis was undertaken. All statistics were performed on SPSS
version 17.0.
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3.3 Results
3.3.1 Baseline characteristics across Groups
Table 3.2.2 revealed the metabolic baseline and hour time point characteristics of the 4
groups analysed in this study. Age did not differ significantly between the groups whereas
BMI was altered across the groups, with the non-obese control (ND) group possessing the
lowest BMI (24.9±3.2 Kg/m2;Table 3.2.1). The other 3 groups (Obese: 33.3±2.5Kgm2***↑; 
IGT: 32.0±4.5Kgm2***↑ and T2DM: 30.3±4.5Kgm2**↑ subjects; p value; ***p<0.001, 
**p<0.01) differed significantly compared with ND subjects, whilst the T2DM group
exhibited a significantly lower BMI than the obese cohort (p<0.05). W aist Circumference
(wc) followed a similar pattern to the BMI data. ND subjects’wc was 86.9±8.25cm versus
Obese 108.9±17.9cm***↑; IGT: 106.4±10.37cm***↑ and T2DM: 100.1±10.2cm**↑ subjects
(Table 3.2.1). The mean systolic blood pressures (SBP) of the groups were similar across all
groups and did not change significantly over the 4hr duration, which was also noted for the
diastolic blood pressures (DBP), (ND subjects: SBP: 128.2±9.7mmHg, DBP:
72.3±10.0mmHg; Obese: SBP: 128.2±10.7mmHg, DBP: 73.4±7.8mmHg; IGT: SBP:
127.3±10.1mmHg, DBP: 75.1±8.8mmHg and T2DM: SBP: 129.1±10.1mmHg, DBP:
74.5±6.9mmHg).
As anticipated, the baseline ND group had significantly lower fasting plasma glucose levels
compared with the T2DM group, whilst showing similar glucose levels to the obese and IGT
cohorts (ND: 4.7±0.69 mmol/L Vs T2DM: 8.1±1.8 mmol/L***↑; IGT: 5.6±1.2 mmol/L; 
Obese : 4.9±0.93 mmol/L;p values;***p<0.001). Hb1Ac was similar in the obese and ND
groups but significantly higher in the IGT and T2DM groups (ND: 5.9±0.31% Vs T2DM:
7.5±1.12 %***↑; IGT: 6.3±0.47 %*↑; Obese: 5.9 ± 0.49%; p values; ***p<0.001, *p<0.05). 
W ithin each cohort, glucose levels did not significantly alter over the 4hr post-prandial time
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period. The baseline lipid profile across the groups was comparable. Serum endotoxin levels
were significantly lower in the baseline ND group compared with the IGT and T2DM groups
(ND: 3.3±0.15 EU/ml, Vs Obese: 5.1±0.94 EU/ml↑; IGT 5.7±0.10 EU/ml**↑; T2DM: 
5.3±0.54EU/ml*↑; **p<0.01, *p<0.05; Figure 5.3.2.1).  
3.3.2 Post-prandial Change in Endotoxin levels over time in individual groups
Post-prandial exposure to a high-fat meal led to a significant rise in endotoxin levels in obese
(baseline: 5.1±0.94 EU/ml;1hr: 4.2±0.71 EU/ml;2hr: 6.2±0.49* EU/ml: 3hr: 7.8±0.76**
EU/ml;4hr: 7.7±0.58** EU/ml;**p<0.01, *p<0.05 Figure 3.3.2.1);IGT (IGT: Baseline:
5.7±0.10 EU/ml;1hr: 5.8±0.22 EU/ml;2hr: 5.5±1.0 EU/ml: 3hr: 7.4±0.26* EU/ml;4hr:
7.5±0.20*EU/ml;*p<0.05 Figure 5.3.2.1) and T2DM subjects (Baseline: 5.3±0.54EU/ml;
1hr: 5.5±0.44EU/ml;2hr: 5.8±0.34EU/ml: 3hr: 9.8±1.2**EU/ml;4hr: 14.2 ±3.0**EU/ml;
**p<0.01 Figure 3.3.2.1) over the 4hr time period. In the non-obese control (ND) group,
whilst there was a rise in circulating endotoxin over the 4hr period this trend did not reach
significance past 1hr (Figure 3.3.2.1). Fasting endotoxin levels showed a positive correlation
with fasting TG levels in the whole cohort (r=0.303, p=0.026). Further examination of this
relationship post-prandially identified the positive correlation strengthened over time, with
the strongest relationship between endotoxin and TG noted at 2 and 3hr, respectively (2hr
time point: r=0.531, p<0.001;3hr time point: r=0.498, p<0.001) with a decline by 4hr post
feeding (r=0.434, p=0.001). No further correlations between endotoxin and any other
parameters were observed, and those noted were not influenced by age or gender.
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Figure 3.3.2.1 Endotoxin levels in NOC, IGT, obese and T2DM subjects
Figure 3.3.2.2
These figures show the changes in circulating endotoxin levels (3.3.2.1) and TG levels
(3.3.2.2) in non-obese control (NOC), IGT, obese and T2DM subjects. Endotoxin and TG
levels were measured at baseline and following a high SFA meal, at each hour post-prandially
over a 4hr duration. Each point on the graph represents the mean value for each cohort
(±SEM).
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3.3.3 Post-prandial Change in endotoxin levels between groups
Fasting endotoxin levels were significantly higher in IGT and T2DM subjects compared with
ND (72.7%**and 60.6%* increase, respectively; **p<0.01, *p<0.05 Figure 3.3.3.2 &
3.3.3.3). However, during the post-prandial 4hr time period, the circulating endotoxin levels
in both obese and IGT subjects diminished to approximately 20% higher than that of the ND
(4hr, Figures 3.3.3.1 & 3.3.3.2), whilst circulating endotoxin levels were sustained at
significantly higher levels in the T2DM subjects than the ND (4hr, Figure 3.3.3.3, p<0.05).
Figure 3.3.3.1 Endotoxin levels between the non-obese and obese subjects on fat stress
This figure shows the increase in endotoxin levels between the non-obese control (NOC)
subjects and the obese subjects from baseline to 4hr post high fat meal. Endotoxin is
measured in EU/mLand the percentage increase compared with NOC is also shown.
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Figure 3.3.3.2 Endotoxin levels between the non-obese subjects (NOC) and IGT on fat
stress
Figure 3.3.3.3 Endotoxin levels changes between NOC and T2DM subjects on fat stress
These figures show the increase in endotoxin levels between the non-obese controls (NOC)
subjects, IGT (3.3.3.2) and T2DM (3.3.3.3) subjects from baseline to 4hr post high fat meal.
Endotoxin is measured in EU/mL and the percentage increase compared to NOC is also
shown.
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3.3.4 Post-prandial Changes in lipids over time in individual groups
Post-prandial exposure to a high-fat meal led to a significant rise in TG levels in ND, IGT and
T2DM subjects post 1hr (p<0.05), whilst the obese subjects followed the same trend, TG
levels were only significantly altered post 2hr feed (p<0.05;Figure 3.3.2.2).
Total cholesterol remained relevantly unaltered over the 4hr period within all 4groups (Table
3.3.1.1). In addition, no change was noted in LDL and HDLCholesterol for the ND subjects
over the 4hr period (Table 3.3.1.1). LDLand HDLin the other 3 groups did show significant
individual group changes over time. For all metabolic states, LDL and HDL significantly
changed (increased and reduced, respectively;p<0.05;Table 3.3.1.1), whilst levels in ND
subjects did not alter.
3.3.5 Post-prandial Changes in lipid levels between groups
Fasting total cholesterol, TG, LDL-Chol and HDL-Chol levels were comparable at baseline
within the 4 groups and did not differ significantly throughout the 4hr duration (Figure
3.3.5.1;Table 3.3.1.1).
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Figure 3.3.5.1 TG levels between the non-obese and obese subjects on fat stress
Figure 3.3.5.2 TG levels between the non-obese subjects and IGT on fat stress
These figures show the increase in TG levels between the non-obese control (NOC) subjects
and the obese (3.3.5.1) and IGT (3.3.5.2) subjects from baseline to 4hr post high fat meal.
TG levels are measured in mmol/L and the percentage increase compared to NOC is also
shown.
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Figure 3.3.5.3 TG levels between the non-obese subjects and T2DM on fat stress
This figure reveals the increase in TG levels between the non-obese control (ND) subjects
and T2DM subjects from baseline to 4hr post high fat meal. TG levels are measured in
mmol/Land the percentage increase compared to ND is also shown.
3.3.6 Post-prandial Changes in FMD levels between groups
Post-prandial exposure to a high-fat meal led to a significant reduction in FMD % levels in all
groups including ND, obese and T2DM subjects post 1hr (p<0.05) ( Tables 3.3.6.1, 3.3.6.2,
3.3.6.4), whilst the IGT subjects had similar significant depressed affect at 2 hours (p<0.05)
(Table 3.3.6.3). These changes were mirrored by significant increase in endotoxin and
triglyceride levels in all groups (Figure 3.3.2.1 and 3.3.2.2).
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Table 3.3.6.1 FMD of brachial artery in response to fat stress in ND subjects
The table presents the FMD data for the different NOC subjects over time (baseline and post
meal), which are presented as mean±SEand mean±SD,
*denotes significant difference compared with baseline. Significance values *p <0.05.
Table 3.3.6.2 FMD of brachial artery in response to fat stress in T2DM subjects
The table presents the FMD data for the different T2DM subjects over time (baseline and post
meal), which are presented as mean±SEand mean±SD,
*denotes significant difference compared with baseline. Significance values *p <0.05.
NOC 70 g Fat stress n=9
FMD Brachial % Fasting 1 hr post 2 hr post 3 hr post 4hr post
Mean ±std. Error 4.00 ±1.15 2.31 ±0.87* 2.21 ±0.67 1.19±0.58* 2.37 ±0.72*
Median±Std.
deviation 2.07 ±3.64 1.13 ±2.75 2.19±1.90 0.67 ±1.84 2.17 ±2.30
T2DM 70 g Fat stress n=18
FMD Brachial % Fasting 1 hr post 2 hr post 3 hr post 4hr post
Mean ±std. Error 2.30 ±0.37 1.47 ±0.37* 1.04±0.64 1.04±0.34* 2.42 ±0.61
Median±Std.
deviation 2.29±1.63 0.88±1.62 0.59±2.88 0.84±1.59 1.44±2.83
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Table 3.3.6.3 FMD of brachial artery in response to fat stress in IGT subjects
The table presents the FMD data for the different IGT subjects over time (baseline and post
meal), which are presented as mean±SE and mean±SD, * denotes significant difference
compared with baseline. Significance values *p <0.05.
Obese 70 g Fat stress n=15
FMD Brachial % Fasting 1 hr post 2 hr post 3 hr post 4hr post
Mean ±std. Error 3.31 ±0.67 1.47±0.80* 1.77 ±0.48* 1.85 ±0.33 3.36±0.52
Median±Std. deviation 2.30 ±2.52 1.76±2.77 1.37 ±1.87 1.69±1.20 3.06±2.03
Table 3.3.6.4 FMD of brachial artery in response to fat stress in obese subjects
The table presents the FMD data for the different obese subjects over time (baseline and post
meal), which are presented as mean±SE and mean±SD, * denotes significant difference
compared with baseline. Significance values *p <0.05.
Mean baseline (fasting) flow mediated dilatation (FMD) of brachial artery in NOC subjects
(4.00 %) was significantly higher than the mean baseline levels noted in T2DM subjects
IGT 70 g Fat stress n=12
FMD Brachial % Fasting 1 hr post 2 hr post 3 hr post 4hr post
Mean ±std. Error 3.97 ±1.05 2.70 ±0.72 1.60*±0.88 3.45 ±0.97 2.34±0.96
Median±Std. deviation 3.75 ±3.33 2.63 ±2.49 1.00 ±3.05 2.97 ±3.24 0.92 ±3.34
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(2.30 %). Similarly, mean baseline level in NOC subjects was slightly higher than both obese
subjects (3.31 %) and IGT group (3.97 %). After a high fat meal (70 grams equivalent), the
mean FMD levels depressed significantly (P < 0.05) in all groups as evidenced in tables
3.3.6.1-3.3.6.4.
These depressive effects seem to be more profound in T2DM compared with any other group
even though it did not reach statistical significance (Table 3.3.6.5). Similarly, compared with
healthy controls, IGT subjects had statistical significant variation in FMD levels by hour 3 on
fat stress ( p<0.05- Table 3.3.6.5). By 4hr after the fat stress, the FMD levels in all groups
start to recover and reach the previous baseline values.
Figure 3.3.6.5 FMD changes between cohorts pre and post meal
Intra-group analysis, assessed flow mediated dilation (FMD) post-prandial percentage (%)
changes;a*=NOC (normal) vs IGT. #=Normal vs fasting;¶=Obese vs fasting;¥=IGT vs
fasting;§=T2DM vs fasting. P-values are noted in graph as follows: *p<0.05, **p<0.01,
***p<0.001.
100
3.3.7 Post-prandial Changes in RVA levels between groups
Mean baseline retinal vessel reactivity (RVR) of the retinal artery in NOC subjects (2.8%)
was significantly higher than the mean baseline levels noted in T2DM subjects (1.64%) and
slightly higher than obese subjects (2.66%). Following the high fat meal, the mean RVR
levels were depressed in T2DM subjects (1.04%), but in NOC, obese and IGT subjects, RVR
levels were higher than their respective baseline levels (Table 3.3.8.1- 3.3.8.4). At 2 hr point,
this divergence in levels between these three groups (NOC, IGT and obese) to T2DM was
significant altered (p<0.05;Table 3.3.8.5). By 4hour post fat stress, the RVR levels appear to
return back to their previous baseline values (Table 3.3.8.1- 3.3.8.4).
NOC 70 g Fat stress n=9
RVA Retinal % Fasting 1 hr post 2 hr post 3 hr post 4hr post
Mean ±std. Error 2.80 ±0.64 2.61 ±0.41 3.12 ±0.61 3.70 ±0.57 3.06±0.65
Median±Std. deviation 3.00 ±2.02 2.65 ±1.31 3.80 ±1.93 4.25 ±1.63 3.50 ±1.96
Table 3.3.7.1 RVA in response to fat stress in NOC subjects
The table presents the retinal vessel reactivity (RVR) data for the different non-obese control
(NOC) subjects over time (baseline and post meal), which are presented as mean±SE and
mean±SD.
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Table 3.3.7.2 RVA in response to fat stress in T2DM subjects
The table presents the RVA data for the different T2DM subjects over time (baseline and post
meal), which are presented as mean±SEand mean±SD.
IGT 70 g Fat stress n=12
RVR Retinal % Fasting 1 hr post 2 hr post 3 hr post 4hr post
Mean ±std. Error 3.68±0.66 2.89±0.62 3.75 ±0.54 2.76±0.44* 3.05 ±0.58
Median±Std. deviation 3.60 ±2.19 3.10 ±2.08 3.40 ±1.89 2.65 ±1.53 2.95 ±2.03
Table 3.3.7.3 RVA of Retinal artery in response to fat stress in IGT subjects
The table presents the RVA data for the different IGT subjects over time (baseline and post
meal), which are presented as mean±SE and mean±SD, * denotes significant difference
compared with baseline. Significance values *p <0.05.
T2DM 70 g Fat stress n=18
RVA Retinal % Fasting 1 hr post 2 hr post 3 hr post 4hr post
Mean ±std. Error 1.64±0.51 1.70 ±0.31 1.04±0.33 1.46±0.42 1.48±0.43
Median±Std. deviation 0.90 ±2.31 1.45 ±1.38 0.70 ±1.51 1.15 ±1.81 1.10 ±1.91
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Obese 70 g Fat stress n=15
RVR Retinal % Fasting 1 hr post 2 hr post 3 hr post 4hr post
Mean ±std. Error 2.66±0.43 2.76±0.60 2.70 ±0.52 3.03 ±0.59* 2.76±0.63
Median±Std. deviation 2.85 ±1.62 2.20 ±2.17 3.00 ±1.97 3.30 ±2.12 3.10 ±2.44
Table 3.3.7.4 RVA of Retinal artery in response to fat stress in obese subjects
The table presents the RVA data for the different obese subjects over time (baseline and post
meal), which are presented as mean±SE and mean±SD, * denotes significant difference
compared with baseline. Significance values *p <0.05.
Figure 3.3.7.5 RVR changes between cohorts pre and post meal
Intra-group analysis, assessed retinal vessel reactivity (RVR) post-prandial percentage (%)
changes;. a=T2DM vs NOC (normal);b=T2DM vs IGT;c=T2DM vs obese. #=normal vs
fasting;¶=Obese vs fasting;¥=IGT vs fasting;§=T2DM vs fasting. P-values are noted in
graph as follows: *p<0.05, **p<0.01, ***p<0.001.
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3.3.8 Correlation between endotoxin levels and vascular function
There was no correlation noted between changes in endotoxin and either FMD or RVR
changes pre or post meal as detailed in Table 3.3.8.1.
Time point Pearson correlation
coefficient for log
endotoxin Vs FMD
P value
(2-tailed
significance)
Pearson correlation
coefficient for log
endotoxin Vs RVA
P value
(2-tailed
significance)
Fasting -0.060 (0.681) -0.045 (0.025)
1 hr post
prandial
-0.059 (0.687) 0.025 (0.045)
2 hr post
prandial
-0.190 (0.187) 0.069 (0.076)
3 hr post
prandial
-0.026 (0.858) 0.125 (0.089)
4 hr post
prandial
-0.160 (0.253) 0.126 (0.002)
Table 3.3.8.1 Correlation between endotoxin and RVR or FMD. This table presents the
Pearson correlation between log endotoxin and FMD and RVA, respectively at fasting and 1-
4hrs post-prandial.
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3.3.9 The effect of cholesterol levels on vascular reactivity
Analysis of FMD versus cholesterol (log transformed) identified a significant negative
correlation at fasting and 1hr post-prandial, although absent at 2hr and 3hr. However, the
strongest relationship between FMD and cholesterol was observed at 4hr, (4hr time point: r=-
0.411, p<0.01;Table 3.3.9.1). No further correlations between FMD and any other
parameters were observed.
Time point Pearson correlation coefficient for log
cholesterol Vs FMD
P value
(2-tailed significance)
Fasting -0.320* 0.025
1 hr post-prandial -0.288* 0.045
2 hr post-prandial -0.253 0.076
3 hr post-prandial -0.243 0.089
4hr post-prandial -0.411** 0.002
Table 3.3.9.1 The table presents the Pearson correlation between log cholesterol Vs FMD in
the whole cohort at fasting and 1-4hrs post-prandial. **Correlation is significant at the 0.01
level (2-tailed). *Correlation is significant at the 0.05 level (2-tailed).
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Analysis of FMD versus cholesterol (log transformed) identified a significant negative
correlation at fasting and 1hr post-prandial, although absent at 2hr and 3hr. However, the
strongest relationship between FMD and cholesterol was observed at 4hr, (4hr time point: r=-
0.411, p<0.01;Table 3.3.9.1). No further correlations between FMD and any other parameters
were observed.
3.4 Discussion
This was the first study to examine the comparative and differential changes in circulating
endotoxin following a SFA (saturated fatty acid) meal from subjects with and without
T2DM, obesity or impaired glucose tolerance (IGT) status. The novel data highlights that a
SFA meal increases circulating endotoxin levels in all subjects irrespective of their metabolic
status, although circulating endotoxin shows dramatic post-prandial changes in the high
metabolic risk groups. More specific comparative analysis of ND subjects versus subjects
with T2DM at 4hr post-prandial, identified that the latter had a mean endotoxin level 125.4%
higher than ND subjects. Cumulative data derived from the fasting state and the SFA post-
prandial state indicate that T2DM subjects are subjected to 336% more circulating endotoxin
than ND subjects over the 4hr duration. In comparison with other metabolic states, the obese
and IGT subjects were still subjected to 167% and 198.5% more circulating endotoxin than
ND subjects. As such, endotoxin, which is considered a potential mediator of chronic low
grade inflammation, is considerably higher in the state of T2DM, with implications for a
continual inflammatory state, as other papers have observed (Al-Attas, Al-Daghri et al. 2009;
Ghanim, Abuaysheh et al. 2009;Miller, McTernan et al. 2009;Deopurkar, Ghanim et al.
2010).
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Our previous studies have shown significant associations between SFA meal and adhesion
molecules, particularly intracellular adhesion molecule (ICAM)-1, vascular cell adhesion
molecule (VCAM)-1 and E-selectin (Ceriello, Quagliaro et al. 2004), all leading to
endothelial dysfunction and association with CVD (Ceriello, Quagliaro et al. 2004). More
recent study from Spain appear to confirm ED due to high fat meal (Garcia-Prieto,
Hernandez-Nuno et al. 2015). Interest has been generated in inflammatory mediation from
factors such as endotoxin, visfatin, TNF-α and Leptin (Eggesbo, Hjermann et al. 1994; Cani, 
Amar et al. 2007;Ghanim, Abuaysheh et al. 2009;Deopurkar, Ghanim et al. 2010;Lassenius,
Pietilainen et al. 2011;Maitra, Gan et al. 2011;Agueda, Lasa et al. 2012;Tian, Chang et al.
2014;Pina, Genre et al. 2015;Xiao, Zou et al. 2015). Elevated levels of these factors have
been reported in T2DM patients leading to new insight into endothelial dysfunction and
cardiovascular risk.
Postprandial hypertriglyceridaemia and hyperglycaemia are considered risk factors for CVD,
and evidence suggests that postprandial hypertriglyceridaemia and hyperglycaemia may
induce an increase in circulating adhesion molecules (Ceriello, Quagliaro et al. 2004).
Previous studies have revealed an independent and cumulative effect of postprandial
hypertriglyceridaemia and hyperglycaemia on ICAM-1, VCAM-1 and E-selectin plasma
levels, suggesting markers of inflammation as a common mediator of such effects (Ceriello,
Quagliaro et al. 2004;Ceriello, Assaloni et al. 2005).
This chapter, therefore, looked at the effects of SFA/high fat meal on markers of
inflammation, including endotoxin and TNF-α. W hilst our previous studies have shown 
significant associations in the fasted state between circulating endotoxin, lipoprotein patterns
and anthropometric data, (Brun, Castagliuolo et al. 2007;Creely, McTernan et al. 2007;
Dixon, Valsamakis et al. 2008;Al-Attas, Al-Daghri et al. 2009;Baker, Harte et al. 2009;
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Miller, McTernan et al. 2009), these current studies sought to establish whether endotoxin
acutely changes post-prandially, and whether this is altered by differing metabolic states. By
undertaking this, our current studies have highlighted subtle but significant differences in how
endotoxin levels change in the post-prandial period. Following the SFA meal, the NOC
endotoxin levels rose over the 4hr duration but circulating levels did not increase
significantly. In contrast, in the obese and IGT groups there was a significant rise in
endotoxin, which appeared to plateau by 4hr. However, at the 4hr time point, both the IGT
and obese groups’endotoxin levels were much lower than the T2DM subjects, as the levels of
endotoxin in the T2DM subjects appeared to be still rising post 4hr SFA meal. Circulating
endotoxin in the T2DM group, post 4hr, did not appear to ‘normalize’, which suggests the
cumulative exposure to endotoxin after a high SFA meal is disproportionately high compared
across any other group. This is in accordance with our previous data (Ceriello, Taboga et al.
2002;Ceriello, Assaloni et al. 2005) that high fat/SFA meal appears to lead to a significant
rise in inflammatory markers as well as deterioration in endothelial function.
Furthermore, in the T2DM subjects the rising endotoxin levels may be further compounded
by re-feeding. These data appear to indicate that a person eating 3 high SFA meals each day
may encounter endotoxin levels that remain perpetually high, as re-feeding may increase the
levels. As such, fasted endotoxin data, whilst important, may appear to miss the daily
variation, as feeding data appears to show. The type of meal is clearly important, as previous
studies highlight that dietary changes alter circulating endotoxin and influence inflammation,
even in healthy subjects (Cani, Amar et al. 2007; Ghanim, Abuaysheh et al. 2009;
Schedlowski, Engler et al. 2014). In addition, recent studies have reported that the
simultaneous ingestion of certain ‘healthy’food groups with saturated fat can negate an
increase in circulating endotoxin and the customary inflammatory response (Deopurkar,
Ghanim et al. 2010). As it is acknowledged that obese and T2DM subjects tend to eat high
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SFA without correspondingly high levels of fruit or healthy foods, this diet would clearly
impact on their endotoxin and inflammatory status (Arnold, Mann et al. 1997;Ghanim,
Abuaysheh et al. 2009;Vitolins, Anderson et al. 2009). Therefore, a high SFA intake could
represent a continual inflammatory insult for T2DM subjects, daily.
In the obese and IGT groups, the post-prandial 4hr endotoxin levels appear to plateau, whilst
still remaining high compared with NOC subjects. Subsequently, another SFA meal may
compound the circulating endotoxin levels further within the obese and IGT groups;therefore
the type and frequency of meals may significantly impact on the metabolic risk. In addition to
the type of meal, the food intake frequency is also relevant - although currently there are very
few studies examining the importance of this.
Previous studies indicate no difference between a diet based on 3 meals a day or a diet
comprising of smaller meals and snacks, with regard to the long-term effects on glucose,
lipid, or insulin responses - although the unknown acute post-prandial effects on the
inflammatory status may have a more profound long-term impact (Beebe, Van Cauter et al.
1990;Arnold, Mann et al. 1997). In addition, other studies have often stressed the division of
food intake should be based on individual preference, with no clear recommendations on
pattern of food intake. W ithin T2DM clinics, the recommendation for patients currently is to
consume 5 smaller meals per day. This may arise to reduce the potentially overwhelming
orexigenic effects patients might experience with only 3 meals a day, as well as the potential
spikes in insulin, although the data do not necessarily give clear insight into these benefits
(Beebe, Van Cauter et al. 1990;Arnold, Mann et al. 1997). In any of these studies,
compliance of subjects to advice and meal frequencies is difficult to verify.
Besides the role of endotoxin on inflammatory status, previous studies have shown that
increasing endotoxin levels appear to reduce the reactivity of retinal microvasculature, even
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in healthy subjects (Kolodjaschna, Berisha et al. 2008). Such studies have shown that Intra
venous administration of endotoxin leads to reduced measurements on the RVA similar to the
findings in this study (Kolodjaschna, Berisha et al. 2008);(Blum, Bachmann et al. 1997).
Similarly fat intake, even in healthy people, leads to a higher endotoxin level (Erridge, Attina
et al. 2007;Grunfeld and Feingold 2009).
In this current study, circulating endotoxin appears to have risen in line with expectations, as
a result of the high fat meal. Similarly, these high levels of endotoxin in the bloodstream
resulted in a depressive effect on both macrovascular and microvascular function, as noted in
previous studies. Subjects with T2DM, with the highest circulating endotoxin compared with
other groups, showed a depression in vascular reactivity for a prolonged period, both at the
macro and microvascular levels. Animal studies have already revealed that chronic
endotoxinaemia results in a metabolic syndrome ranging from obesity, IGT and T2DM
(Turnbaugh, Ley et al. 2006;Grunfeld and Feingold 2009). This chapter may support this
theory but has been unable to provide direct significant associations between either changes
in FMD or RVR data and endotoxin levels. Such a lack of correlation may have arisen due to
the size of the cohort, as well as the differential responses within each cohort, which may
have produced a wide variation in response to the fat meal.
However, from this study it was demonstrated that SFA meal leads to a statistically
significant increase in lipid levels, particularly triglycerides, which correlated with depressed
endothelial function at the macrovascular level. This study also demonstrated that rising
levels of lipids in all groups followed a similar pattern to that of increasing endotoxin levels.
Therefore, we might be able to deduce that increasing endotoxin levels, as part of a SFA
meal, appear to show a trend with a simultaneous fall in endothelial function at the
macrovascular level, in all groups. Further studies would be required, however, to assess
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these trends in a larger cohort in order to determine a significant effect, as previous studies
have noted (Kolodjaschna, Berisha et al. 2008)
Based on these current studies, more frequent saturated fat exposure may exacerbate
endotoxin, inflammation and depress vascular reactivity, further. Also, smaller more frequent
meals have the potential to allow endotoxin to spike several times a day, thus activating the
innate immune system within adipose tissue without desensitization (Creely, McTernan et al.
2007;Ghanim, Abuaysheh et al. 2009;Deopurkar, Ghanim et al. 2010;Youssef-Elabd,
McGee et al. 2011). As such, the resulting downstream production of diabetogenic cytokines
would be in continuous production, as previous in vivo and in vitro studies have demonstrated
(Creely, McTernan et al. 2007;Ghanim, Abuaysheh et al. 2009;Deopurkar, Ghanim et al.
2010;Youssef-Elabd, McGee et al. 2011).
The TG levels did not differ significantly across the 4groups of subjects at any of the time
points;however the TG levels did increase from baseline to 4hr within each group, in a
similar pattern to circulating endotoxin, but most significantly in the metabolic risk subjects
(obese, IGT and T2DM), whilst also demonstrating an association with endotoxin, over the
4hr period (Creely, McTernan et al. 2007;Miller, McTernan et al. 2009). The 3 different
metabolic states showed significantly higher fasting TG levels than NOC subjects, which
post-prandially became further exacerbated in the obese and T2DM subjects.
Unsurprisingly, post-prandial TG levels increased in a similar pattern to circulating
endotoxin, whilst also demonstrating an association, over the 4hr period (Creely, McTernan et
al. 2007;Miller, McTernan et al. 2009). The 3 different metabolic states showed no
significant differences in TG levels compared with levels in NOC subjects. However, the
significant correlation between fasting TG and endotoxin levels confirms previous studies in
which an association between these two metabolic parameters had been observed (Creely,
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McTernan et al. 2007;Miller, McTernan et al. 2009). Our data indicated that the association
between TGs and circulating endotoxin became stronger in the post-prandial state each hour
over the 4hr duration, substantiating previous evidence that lipids mediate the transfer of
endotoxin from the GI tract into the circulation (Brun, Castagliuolo et al. 2007;Youssef-
Elabd, McGee et al. 2011).
Concurrent with post-prandial changes in TGs the LDL/HDL ratio reduced compared with
baseline measurements. Specifically HDL was significantly reduced at time points post-
prandially within all except the NOC group;potentially due to parallel elevations in
chylomicrons and VLDL, as noted in other studies (Callow, Summers et al. 2002;Thomsen,
Storm et al. 2003;Hanwell, Kay et al. 2009). W hilst it is established that obese T2DM
patients suffer from a syndrome of high serum TG and low HDL(Laakso and Pyorala 1990),
low levels of HDL are also associated with low levels of sCD14(Eggesbo, Hjermann et al.
1994). This corresponds with the data that endotoxin has been demonstrated to bind to HDL
in the presence of sCD14and lipopolysaccharide binding protein (LBP) (Parker, Levine et al.
1995;W urfel, Hailman et al. 1995), an enzyme involved in presentation of endotoxin to
sCD14. This would support a role for HDL in immunological response to endotoxin.
Therefore a reduction in HDLwould reduce the removal of endotoxin further and exacerbate
the inflammatory status further, compounded by higher circulating levels of endotoxin in the
obese, IGT and T2DM subject groups.
W hilst our studies have highlighted the impact of metabolic disease status on circulating
endotoxin, it is important to recognize the limitations of the study. In all research, it is always
preferable to increase the subject numbers that comprise each cohort. In the present studies,
increased numbers might have noted different post-prandial responses to the high fat meal
within each cohort, if the groups were further sub-divided. However, in light of this being a
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cross-sectional study, in which intra and inter comparisons can be made, the numbers do not
detract from the findings. Consistent and significant trends were observed within the subjects
over the 4hr post-prandial duration and differences between the cohorts duly noted.
W e also recognize that the research subjects were given a very high-fat meal (75g), roughly
equivalent to their total daily intake of fat, which some observers might argue is an excessive
(non-physiological) amount of fat. However, despite the fat load which was based on
previous studies (Ceriello, Assaloni et al. 2005), there was no significant change in LDL,
HDL or total cholesterol levels (apart from Triglycerides) post-prandially in the NOC
subjects, in contrast to the other groups. Furthermore administration of 75g glucose could also
be considered high and would far exceed normal intake of glucose in one sitting, yet this is
standard clinical practice for assessment of insulin sensitivity, whereas the fat load is only
currently used as a research tool. No ill effects were noted in any of the patients during or
after the study.
In summary, our current data sheds new light on our understanding of metabolic
endotoxinaemia in the post-prandial state in metabolic disease. Our findings suggest that
circulating endotoxin levels change depending upon whether you are pre-diabetic, non-obese,
obese, have IGT or have T2DM. Further that the circulating endotoxin levels noted in
subjects with T2DM, at 4hr post-prandial high fat meal, far exceed our previous
understanding based on other feeding studies in healthy subjects or the fasted state in T2DM
subjects. Therefore, our 4hr data suggest a much higher inflammatory risk than previous
studies have indicated. These findings highlight the point that requesting patients to eat
smaller, more frequent meals may actually increase their inflammatory risk further, especially
in subjects with T2DM - the diet of which tend to favour high fat foods (Arnold, Mann et al.
1997). W hilst vascular reactivity was affected by the high fat meal, the acute effects were less
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pronounced than anticipated - which may suggest that continual feeding may yield more
visible effects than one meal in isolation.
Finally, whilst the most obvious solution to metabolic endotoxinaemia appears to be to reduce
saturated fat intake, the W estern diet is not conducive to this mode of action and it is difficult
for patients to comply with this request. Therefore we need to understand the complexity of
diet, meal frequency and its acute effects on inflammatory and vascular risk and provide
guidelines to particular subject groups, as leaving food intake to ‘individual preferences’
appears not to represent a beneficial solution to reduce the inflammatory state in metabolic at-
risk subjects. Further studies looking at types of SFA, plant or animal based oils, food
products having influence on endotoxin absorption and transport –would assist in providing
individual advice for particular risk groups.
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Chapter 4
Impact of endotoxaemia on sub-clinical inflammation
and endothelialdysfunction in obese children
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4.1 Introduction
Environmental, physical and nutritional factors appear critical in determining lifetime disease
risk profile for cardiovascular disease (CVD), which is a leading cause of mortality
worldwide (Bartha, Fernandez-Deudero et al. 2012; Jankovic, Geelen et al. 2015;
Reinikainen, Laatikainen et al. 2015). CVD development in later life shows an increased risk
when the condition is preceded by prior chronic inflammatory conditions (John and Kitas
2012;Banerjee, Biggs et al. 2013;Eguchi and Manabe 2014;Olza, Aguilera et al. 2014;
Kranendonk, van Herwaarden et al. 2015). Therefore the clinical value of determining the
factors that induce an inflammatory response in early life appear important to address is
compelling.
Clearly childhood obesity per se has a significant impact on disease risk, inflammation and
CVD, however, adipose tissue (AT) may be an early contributor to metabolic dysfunction
through prior systemic insults, which initiate an inflammatory response (Cook, W eitzman et
al. 2003;Invitti, Guzzaloni et al. 2003;Creely, McTernan et al. 2007;Eguchi and Manabe
2014;Esser, Legrand-Poels et al. 2014;Olza, Aguilera et al. 2014;Sypniewska 2015;Zhao,
Fu et al. 2015).
One cellular mechanism for an increased inflammatory response may arise through activation
of the innate immune system as observed in human AT (Creely, McTernan et al. 2007;Baker,
Harte et al. 2009). Previous studies have shown that increased activation of the innate
immune pathway may arise through excess circulating gut derived bacteria, known as
lipopolysaccharide (LPS) or endotoxin;which represents the outer cell wall membrane of
gram-negative bacteria (Creely, McTernan et al. 2007;Baker, Harte et al. 2009;Piya, Harte et
al. 2013). In human AT it appears endotoxin has an immediate impact on the innate immune
pathway, acting via key receptors known as the toll like receptors (TLRs), which recognise
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antigens such as the LPS component, to initiate an acute phase response to infection (Creely,
McTernan et al. 2007;Eguchi and Manabe 2014). Stimulation of the TLRs leads to
intracellular activation of NFkB, a key transcription factor in the inflammatory cascade that
regulates the transcription of numerous pro-inflammatory adipocytokines (Creely, McTernan
et al. 2007;Baker, Harte et al. 2009). Therefore whilst in vitro,endotoxin may act as a
mediator of inflammation through activation of NFkB, leading to a rapid response, in an in
vivo situation that may be further exacerbated by an increasing fat mass, such as in obesity
(Dixon, Valsamakis et al. 2008;Miller, McTernan et al. 2009;Harte, da Silva et al. 2010;
Harte, Varma et al. 2012;Li, Ma et al. 2015).
Clinical studies have also implicated gut derived endotoxin as a direct ‘primary mediator’to
activate the inflammatory state, contributing to metabolic disease, with current cross sectional
data showing elevated systemic endotoxin levels in conditions of obesity, coronary artery
disease, type 2 diabetes mellitus and fatty liver disease (Creely, McTernan et al. 2007;Piya,
Harte et al. 2013;Eguchi and Manabe 2014), which is reduced with weight change (Dixon,
Valsamakis et al. 2008;Harte, da Silva et al. 2010).
Studies in adults has also shown circulating endotoxin to be positively associated with waist,
waist-hip-ratio, insulin levels, inflammatory cytokines as well as lipids, including total
cholesterol, triglycerides, LDL-cholesterol and negatively associated with HDL-cholesterol
(Dixon, Valsamakis et al. 2008;Miller, McTernan et al. 2009;Harte, da Silva et al. 2010;
Harte, Varma et al. 2012;Eguchi and Manabe 2014;Li, Ma et al. 2015).
Recent studies in obese children and adolescents has demonstrated that systemic
inflammatory cytokines such as plasminogen activator inhibitor-1 (PAI-1) and C-reactive
protein (CRP) are elevated, along with vascular injury and atherogenesis markers, such as
vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule type-1
117
(ICAM-1) (Koning 2015;Lovren, Teoh et al. 2015). W hether such pathogenic biomarkers
directly correlate with systemic endotoxin concentrations in obese children and adolescents is
undetermined. Therefore the aim of this study was to examine bacterial endotoxin as a
potential biomarker of sub-clinical inflammation and early CVD risk in childhood obesity.
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4.2 Methods and Materials
4.2.1 Study subjects
A total of 60 (unless stated otherwise in the figure legend) obese children and adolescents
with varying degrees of obesity (Body Mass Index) (BMI: mean±(SD) 35.1±5.2kg/m2;age:
13.9±2.3 years) were recruited among those referred for weight loss intervention to the
obesity centre of the Istituto Auxologico Italiano. All subjects were above the age and sex
adjusted 97th BMI percentile, which defines obesity according to the Italian BMI charts
(Cacciari, Milani et al. 2002) and had an age range of 8-18yrs. The Ethics Committee of the
Italian Institute approved this study and informed consent was obtained from all subjects and
their parents. All subjects underwent an oral glucose tolerance test (1.75 g/Kg, up to a
maximum of 75 g glucose in 250 ml of water) following an overnight fast. Plasma samples
were drawn at baseline, after 30 min and 120 min, for determination of plasma glucose and
insulin concentration. Categorisation of glucose tolerance status was made using the W orld
Health Organisation criteria (Li, Ma et al. 2015). The impaired fasting glucose was defined by
fasting glucose levels 5.6mmol/l (M.Nathan 2007;Nathan, Davidson et al. 2007). Blood
samples were drawn for measurement of endotoxin, adiponectin and, markers of
inflammation and CVD. Blood pressure measurements were taken as previously described
(Invitti, Guzzaloni et al. 2003). Insulin resistance was measured by HOMA-IR (Homeostatic
Model Assessment of Insulin Resistance) (fasting insulin xfasting glucose/22.5) (Matthews,
Hosker et al. 1985).
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4.2.2 Biochemical Measurements
Serum endotoxin was assayed using a Chromogenic Limulus Amebocyte Lysate (LAL) test,
which is a quantitative test for gram-negative bacterial endotoxin (Cambrex, New Jersey,
USA) endotoxin-free vials were utilised throughout. Gram-negative bacterial endotoxin
catalyzes the activation of a pro-enzyme in the Limulus Amebocyte Lysate (LAL). The initial
rate of activation is directly determined by the concentration of endotoxin. The activated
enzyme catalyzes the splitting of p-nitroaniline (pNA) from the colourless substrate Ac-lle-
Glu-Ala-Arg-pNA. The pNA released was measured photometrically at 405-410 nm
following termination of the reaction. The correlation between the absorbance and the
endotoxin concentration is linear in the 0.1-1.0 EU/mL range. Intra-assay CV 3·9±0·46,
inter-assay CV 9·6±0·75. For the purposes of these studies all samples were run in duplicate
within the same plate, therefore no inter-assay variability was observed in this study. To
assess recovery of endotoxin within the assay, previous studies have utilised known
concentrations of recombinant endotoxin (0.25 and 1.00 EU/mL) were added to diluted,
pooled plasma to determine whether the expected concentration correlated closely with the
actual observed value and whether there were any variations due to reaction with plasma
contents [16]. Lyophilized endotoxin (E. coli origin) was used to generate a standard curve
with the Chromogenic LAL test kit from Cambrexand produced a corresponding curve in
accordance with the manufacturer’s instructions. In plasma, the recovery of spiked endotoxin
was 82.0 ± 3.3% efficient, similar recovery data were noted for serum. Plate to plate
variability within the same experiment was 7.4±0.9%, these findings were similar to those
observed from assessment by Cambrex(Creely, McTernan et al. 2007).
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A multiplexed CVD Panel 1 immunoassay (Linco Research, Missouri, USA) was utilised to
examine the circulating concentrations of the following inflammatory and CVD risk
biomarkers: (Tumour Necrosis factor-α) TNF-α, PAI-1 (tPAI-1, total) CRP, soluble 
intercellular adhesion molecule type-1 (sICAM-1), soluble vascular cell adhesion molecule-1
(sVCAM-1), MMP-9, MPO (Myeloperoxidase), VEGF (Vascular Endothelial Growth Factor)
and soluble endothelial selectin (sE-Selectin). The CVD Panel 1 immunoassay had a
sensitivity of 16-50,000 pg/ml for (Matrix MetalloProteinase-9) MMP-9, MPO and PAI-1
(Plasminogen Activator Inhibitor – 1) and further, a sensitivity of 80-250,000 pg/ml for
sICAM-1 (Soluble Intercellular Adhesion Molecule Type-1), sVCAM-1 and sE-Selectin;
with an intra- and interassay CV (co-efficient of variation) of 4.5-12.3% and 8.5-16.3%,
respectively. Plasma glucose was measured using an automated glucose analyser (Roche
Diagnostics, Mannheim, Germany). Serum insulin levels were measured by a
chemiluminescent assay (DPC, Los Angeles, USA) with a sensitivity of 14.3 pmol/l and
intra- and interassay CV of 3.7% and 6.7%, respectively.
4.2.3 Statistical Analysis
All analyses were performed using statistical software (SPSS, version 14;W oking, UK).
Variables that were not normally distributed were log transformed. Differences between
groups were calculated using a unpaired t-test for independent samples. A Pearsons’
correlation analysis was used to analyse bivariate relationships between endotoxin and the
various markers of inflammation and vascular injury. Data were expressed as mean  SD. A
p-value <0.05 was considered statistically significant.
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4.3 Results
4.3.1 Effect of gender on Biomarkers of Inflammation
From this cohort, biochemical analysis was performed on 24male subjects and 36female
subjects with matching BMI and age. Clinical and biochemical characteristics of male and
female obese subjects are provided in Table 4.3.1.
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Clinical and Biochemical
Characteristics
Male
Subjects
(±SD)
Female
Subjects
(±SD)
p value
Age (yrs) 14±3 14±2 -
BMI (kg/m2) 34.0±5.1 35.6±5.3 -
Fasting Glucose (mmol/l) 4.4±0.3 4.5±0.5 N/S
2 h glucose, mmol/l 6.0±1.0 5.7±1.0 N/S
HOMA-IR 2.6±1.2 3.3±2.1 N/S
Endotoxin (EU/ml) 10.1±5.4 5.3±3.7 p<0.01**
CRP (µg/ml) 7.5±8.3 9.0±7.5 N/S
TNF-α (pg/ml) 5.0±2.5 5.9±5.8 N/S
PAI-1 (ng/ml) 27.0±10.7 26.0±15.7 N/S
sICAM-1 (ng/ml) 110.4±37.4 103.1±47.9 N/S
Systolic BP (mmHg) 121.0±10.8 119.1±8.5 N/S
Diastolic BP (mmHg) 74.0±11.2 72.7±8.5 N/S
Table 4.3.1 Clinical and biochemical characteristics for obese, BMI and age-matched male
(n=24) and female (n=36) subjects. Data are expressed as mean±SD. Significant differences
in data between male and female subjects are highlighted (P-Values: *, p<0.05, **, p<0.001).
No significant gender differences were observed in HOMA-IR, blood pressure or several
markers of inflammation and CV (cardiovascular) injury.
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4.3.2 Correlation of Endotoxin with Biomarkers of Inflammation and CVD in Childhood &
Adolescent Obesity
In this study circulating endotoxin concentrations significantly and positively correlated with
TNF-α (p<0.05, r2=0.077) and MCP-1 (Monocyte Chemoattractant Protein-1) (p<0.01,
r2=0.178) (Figure 1A and 1B). However, no significant correlation was noted between
circulating endotoxin levels and CRP (p=N.S, r2=-0.069).
Figure 1A
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Figure 1A and 1B. Correlation between log endotoxin (EU/ml) levels and the inflammatory
markers: (A) log TNF-α pg/ml (p<0.05) (B) log MCP-1 ng/ml (p<0.01), in BMI and age-
matched children and adolescents.
W ith regards to CVD risk markers, circulating endotoxin concentrations further correlated
with several parameters of atherogenesis and vascular injury;these included PAI-1 (p<0.01,
r2=0.215), sICAM-1 (p<0.01, r2=0.159), MMP-9(p<0.01, r2=0.159), MPO (p<0.05, r2=0.07)
and VEGF (p<0.01, r2=0.161) (Figure 2A-F).
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Figure 2E
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Figure 2A-F. Correlation between log endotoxin (EU/ml) levels and the following markers of
CVD: (A) log PAI-1 (ng/ml) (p<0.05), (B) log sICAM-1 (ng/ml) (p<0.05), (C) log MMP-9
(pg/ml) (p<0.05), (D) log MPO (pg/ml) (p<0.05), (E) log VEGF (pg/ml) (p<0.05) and (F) log
eSelectin (X/ml) (p<0.05) in BMI and age-matched children and adolescents.
No significant correlation was observed between endotoxin and eS-Selectin levels (p=0.055,
r2=0.067) or sVCAM-1 levels (p=N.S, r2=0.054).
Additional analysis of serum concentration data revealed that circulating endotoxin levels
positively correlated with systolic blood pressure (p<0.05;r2=0.155;n=37) (Figure 3A) and
diastolic blood pressure (p<0.05;r2=0.083;n=51) (Figure3B).
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Figure 3A and 3B. Correlation between log endotoxin (EU/ml) levels and (A) systolic blood
pressure (mm Hg) (n=37) and (B) diastolic blood pressure (mm Hg) (n=51) in BMI and age-
matched children and adolescents.
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Figure 4. Comparison of the mean relative endotoxin serum concentrations (EU/ml) ±SEM
in male and female BMI and age-matched children and adolescents.
Endotoxin was higher in males than females as a direct comparison (Figure 4).
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4.4 Discussion
These current studies highlight that in childhood obesity circulating endotoxin is significantly
correlated with pro-inflammatory markers, TNF-α, MCP-1, as well as biomarkers of 
atherogenesis and vascular injury including PAI-1, sICAM-1, MMP-9 and MPO, VEGF.
Furthermore, data analysis also determined that circulating endotoxin levels are positively
correlated with both systolic and diastolic blood pressure in children with obesity. Taken
together these findings also indicate that the presence of metabolic endotoxinaemia, which
appears to occur in childhood, correlates with pathogenic pro-inflammatory factors in a
similar manner to that noted in adults with metabolic disease (Creely, McTernan et al. 2007;
Dixon, Valsamakis et al. 2008;Baker, Harte et al. 2009;Harte, da Silva et al. 2010). These
studies also appear to suggest that the raised endotoxin levels in childhood are coupled to a
noted high disease risk profile and blood pressure, which together ultimately could lead to an
earlier life progression of CVD. Endotoxin may also account for, in part, the continual pro-
inflammatory state experienced in obese children (Gilardini, McTernan et al. 2006;Al-Attas,
Al-Daghri et al. 2010;Kheirandish-Gozal, Peris et al. 2014;Chang, Jian et al. 2015).
These studies also observed for the first time a noted significant rise in circulating endotoxin
in boys compared with girls. W hilst this was not the aim of the study these findings appear
consistent with gender-specific effects noted in adults;maintained across several ethnicities
(Miller, McTernan et al. 2009). Prior studies in adults suggest a higher endotoxin-induced
pro-inflammatory cytokine release in men than women, although this study in children did
not identify this gender specific aspect (W illerson and Ridker 2004;Dandona, Aljada et al.
2005). Such a disparity in endotoxin-induced pro-inflammatory cytokine release between the
children and adults with obesity may arise, in part, due to the difference in exposure time to
endotoxin;which in obese adults may give rise to long-term damaging inflammatory change
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leading to T2DM (Matthews, Hosker et al. 1985;Gilardini, McTernan et al. 2006;Nathan,
Davidson et al. 2007;Temple, Pham et al. 2008;Smit, Heederik et al. 2009;Al-Attas, Al-
Daghri et al. 2010;Bhatia, Sekhon et al. 2014;Kheirandish-Gozal, Peris et al. 2014;Chang,
Jian et al. 2015).
These studies also suggest that changes in inflammation, vascular dysfunction, and blood
pressure in childhood obesity may arise beyond the known impact of the cardiometabolic
lipid profile (Dandona, Aljada et al. 2005;Gilardini, McTernan et al. 2006;Nadeau, Maahs et
al. 2011;Chang, Jian et al. 2015). A key mediator to increase disease risk arise from
circulating commensal bacterial endotoxin, derived from the gastrointestinal-tract eliciting a
pro-inflammatory response in prior childhood and adolescent obesity studies (Pussinen,
Havulinna et al. 2011;Assimakopoulos, Tsamandas et al. 2013). Additionally, adult studies
highlight that diets high in fat and or processed meat appear to raise endotoxin levels further,
whilst dairy products and other food combinations may reduce endotoxin levels and
inflammation (Deopurkar, Ghanim et al. 2010;Harte, Varma et al. 2012;Schwander, Kopf-
Bolanzet al. 2014;Schmid, Petry et al. 2015). As such further future insight into examining
the impact of diet on endotoxin levels in children with obesity may highlight important
interventions to reduce the long-term health risk (Creely, McTernan et al. 2007;Lira, Rosa et
al. 2010;Assimakopoulos, Tsamandas et al. 2013;Mischke and Plosch 2013;Kellow,
Coughlan et al. 2014).
Several risk factors in childhood have been proposed to predict the later development of CVD
including obesity, hypertension and endothelial dysfunction promoting atherogenesis and
thrombosis (Skurk and Hauner 2004;Cote, Harris et al. 2013;de Koning, Denhoff et al. 2015;
Ramji and Davies 2015). In our cohort of obese children and adolescents, several biomarkers
of vascular injury and endothelial dysfunction, including PAI-1, sICAM-1, MMP-9, MPO
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and VEGF, were significantly and positively correlated with circulating endotoxin
concentrations. The observed pro-inflammatory biomarker risk profile in the obese children
appears to be similar to both what has been identified in adults with CVD as well as studies
comparing obese and lean children (de Koning, Denhoff et al. 2015).
Hypertension has been identified as a key risk factor for atherogenesis and vascular injury,
and this study noted a positive association between endotoxin with systolic and diastolic
blood pressure. As such a diet that raises endotoxin levels would appear to also increase
blood pressure. W hilst this is a cross-sectional study , which therefore cannot determine a
causal relationship, in previous studies have demonstrated that mice fed a continuous
endotoxin bolus, exhibited a subsequent increase in vascular dysfunction (Hao, Zhang et al.
2010;Sordi, Chiazza et al. 2015). This is consistent with the concept that an endotoxin-
induced inflammatory response in childhood obesity, may consequently contribute to an
accelerated risk of CVD in later life. Furthermore the noted correlations between circulating
endotoxin and biomarkers of endothelial dysfunction, in this childhood obesity study, could
also promote a cluster of these pro-atherogenic factors contributing to accelerated
atherosclerosis, arterial stiffness and CVD in later life (Thompson, Obarzanek et al. 2007;
Nadeau, Maahs et al. 2011;Prasad, Kabir et al. 2011;Armstrong, Cote et al. 2014;Cote,
Phillips et al. 2015).
This study had some limitations, namely: the cross-sectional design which did not allow
causal determinations and a limited sample size indicating modest correlations. Further, the
lack of gender-effects on the correlations between endotoxin and the pro-inflammatory
factors may also be considered a reflection of the limited cohort size. Thus, future studies
exploring further aspects of these observations in larger cohorts are warranted.
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In summary, this study highlights the relationship between endotoxin and several
inflammatory and CVD risk biomarkers, particularly as an early player in obesity-related
inflammatory disorders during childhood and adolescence even though we did not correlate
endotoxin with age.
Furthermore, even at an early age in the obese state, female subjects exhibited lower
endotoxin levels than their male counterparts, suggesting a more favourable metabolic profile.
This may manifest in later life as delayed CVD mortality and morbidity for females in
contrast to males. The reason for such a difference is not clearly known even though dietary
and hormonal differences could be speculated. Finally, among the inflammatory markers
evaluated in this study, endotoxin may serve as a potential mediator of sub-clinical
inflammation in childhood and adolescent obesity as noted in adult studies.
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Chapter 5
Assessment ofEDusingNon invasive vascular function in
Healthy subjects
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5.1 Introduction
This chapter is intended to validate 2 newer technologies of FMD brachial artery
measurement and RVA retinal artery measurements in healthy subjects using Glucose
ingestion as physiologic stress. The next chapter uses the same healthy cohort when
comparing T2DM subjects for some parameters.
5.1.1 Endothelium
The endothelium is a specialized layer of thin mononuclear cells that covers the inner
surfaces of all blood vessels. It forms a barrier across the circulating blood from the vascular
smooth muscle and tissues. In healthy subjects, unperturbed vascular endothelium functions
as an athero-protective organ through vasoactive mediators such as nitric oxide (NO),
prostacyclin, and endothelium derived relaxation factor (EDRF). It senses mechanical stimuli,
such as pressure and sheer stress and responds to both exocrine and paracrine hormonal
stimuli. In response, it releases agents that regulate vasomotor function, trigger inflammatory
processes, and affect homeostasis (Drexler 1998;Esper, Nordaby et al. 2006;Deanfield,
Halcoxet al. 2007;Shimokawa and Godo 2015). However, in subjects with cardiovascular
disease (CVD) or indeed any vascular disease, homeostasis of the functional endothelium is
compromised resulting in endothelial dysfunction.
5.1.2 Endothelial dysfunction
Normal endothelial function is crucial in maintaining cardiovascular health. Impairment
causes physiological derangement of the vascular tone, inflammation and thrombosis. Thus,
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dysfunctional endothelium loses its protective effect on the vasculature. It is now accepted as
one of the first quantifiable steps in the process of progressive atherosclerosis (Drexler and
Hornig 1999;Endemann and Schiffrin 2004;Esper, Nordaby et al. 2006;Deanfield, Halcox
et al. 2007) and it can predate clinically obvious vascular pathology by many years (Benzuly,
Padgett et al. 1994;Vlahos, Naka et al. 2014). Assessment of endothelial dysfunction has also
been shown to be of prognostic significance in predicting vascular events (Brevetti, Silvestro
et al. 2003), including heart attacks and stroke (Celermajer, Sorensen et al. 1994;Neunteufl,
Heher et al. 2000;Schächinger, Britten et al. 2000;Chan, Mancini et al. 2003;Quyyumi
2003;Fichtlscherer, Breuer et al. 2004;Frick, Suessenbacher et al. 2005;Yoshida, Kawano et
al. 2006;Yeboah, Crouse et al. 2007). A key feature of this phenomenon is the inability of
vasculature to react appropriately, thereby inducing a pro-inflammatory, pro-thrombotic state
and reduced vasodilatation in response to appropriate stimulus (Sukhovershin, Yepuri et al.
2015). Dysfunctional endothelial cells are unable to produce NO to the same extent as healthy
endothelial cells and therefore their ability to react and dilate to stress is reduced (Vallance
and Chan 2001;Anderson 2003). This imbalance of homeostasis in endothelial function
creates a detectable difference in subjects with endothelial dysfunction verses individuals
with normal healthy endothelium.
The study therefore assessed the vascular endothelial function of healthy non diabetic (ND)
subjects using post-prandial glucose test as stress. The focus of this chapter was to assess the
macrovascular endothelial function initially and its response to glucose challenge/stress in
ND subjects. Secondly, this study examined similar effects of glucose challenge on
microvascular function in the same cohort of subjects. Macrovascular dysfunction, as elicited
by (flow mediated dilatation) FMD, has already been shown to be an important predictive
factor not only for atherosclerosis (Ross 1993), but also for future CVD (Celermajer,
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Sorensen et al. 1992;Gokce, Keaney et al. 2002;Vita and Keaney 2002;Gokce, Keaney et al.
2003;Yeboah, Crouse et al. 2007).
This study would attempt to re-affirm previous data using a more advanced, validated and
accurate software to measure endothelial function. The study would then investigate the
effects of physiologic stress on the endothelial function at both macrovascular and
microvascular levels in ND subjects. Microvascular function would be evaluated utilizing a
newer system of Dynamic vessel analysis (DVA) of retinal vessels. Finally, an attempt would
be made to compare and contrast both systems in the same groups.
5.2 Materials and methods
5.2.1 Demographics
The study was performed at UHCW NHS Trust on a group of ND subjects following initial
recruitment from their primary care practices. A total of 10 ND subjects were recruited into
the study. All ND subjects were of South Asian Origin except one who was Afro- Caribbean
descent. The diagnosis of ND status was made according to the 2006 W HO criteria with
fasting glucose level of ≤ 7.0 mmol/l. The clinical characteristics of the group are reported 
below in (table 5.2.1).
The subjects were drug naïve and therefore not under the influence of any exogenous
substances which could potentially influence endothelial function.
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ND /Healthy subjects Mean Std. Error (SEM)
Age 39.8 3.6
Sex male/female n 7/3 -
BMI, Kg/m² 25.4 1.0
Fasting glucose, mmol/l 5.2 0.2
Glycated Heamoglobin % 5.8 0.1
Diastolic blood pressure 71.6 2.4
Total cholesterol, mmol/litre 5.1 0.3
HDL, mmol/litre 1.4 0.1
LDL, mmol/litre 3.1 0.2
TG, mmol/litre 1.3 0.2
Mean FMD % 3.7 1.6
Mean RVR % 3.2 0.5
Table 5.2.1 ND subjects’demographic profile and baseline characteristics
Data are expressed as means± SEM (standard error of mean). As noted in table 5.2.1, the
mean BMI for the group is favourable at 25. Similarly, the mean resting diastolic blood
pressures and fasting glucose were all within acceptable normal limits.
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5.2.2 Patient Recruitment and selection
Only non-smoking subjects with a normal resting ECG and blood pressure were selected for
the study. The full list of inclusion and exclusion criteria is covered in detail in chapter 2.
Subjects on aspirin, statins, or supplemental vitamins were excluded - as they have been
shown to influence endothelial function (Drexler and Hornig 1999;Ceriello, Taboga et al.
2002). All subjects were recommended to consume their habitual diet during the entire period
of the study. A validated dietary questionnaire was utilised to obtain dietary habits. Subjects
were recruited once they fulfilled all the inclusion and exclusion criteria for the study. None
of the subjects had any history of retinopathy or renal dysfunction.
5.2.3 Clinic Visit
The initial clinic visit was undertaken in the mornings to facilitate fasting blood tests. Full
Ethical approval was obtained for the conduct of the study from the local Research Ethics
committee. Specific details regarding organization and conductance of the clinic visits were
covered in detail in chapter 2. Once at the clinic, all efforts were made to explain the study
protocol in the subjects’own language. After informed consent and enrolling into the study,
fasting blood and urine samples were obtained. Screening blood tests were also performed for
both baseline measurements to qualify for the study, as well as to assess their glucose control.
Routine blood tests included renal functions, glucose, HbA1C and full cholesterol profile,
which were subsequently sent to the UHCW biochemistry laboratory for analysis. All
subjects then had their height, weight, abdominal circumference and BMI measurements
taken using the same standard equipment. Blood samples were taken using standard technique
either from the right or left ante- cubital vein in a sitting position. Blood pressure was
measured using an automated sphygmomanometer on the left arm and rechecked after 2 min.
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Finally a 12 Lead ECG was performed using the same machine for the duration of the study.
Female chaperones were utilized during the clinics as deemed appropriate.
5.2.4 Study protocol
Vascular function tests (as detailed below) were performed and blood samples were drawn at
0 (fasting state), 1 (1 hr post stress), 2 (2 hr post stress), 3 and 4hr post glucose stress. The
glucose stress was a standard oral glucose tolerance test which involved taking seventy five
(75) grams of glucose as a drink. The quantity of glucose utilized is standard and according to
existing published literature (Ceriello, Assaloni et al. 2005). Serum glucose, full lipid profile,
insulin and endothelial markers were also assayed along with the vascular function tests at
each time point, as described above. Vascular function tests involved testing endothelial
function at the level of the arm and retina. These tests utilized ultrasound techniques to
measure flow-mediated vasodilatation (FMD) of the brachial artery and, similarly, retinal
vessel reactivity (RVR) using a Retinal vessel analyzer (RVA).
5.2.5 Serum and plasma isolation
Using the standard procedure serum and plasma was isolated during the clinic visit. Once
blood was drawn and into separate tubes, the tubes collecting serum and plasma were
independently stored on ice and transported to the research laboratory, for storage, based at
the Clinical Sciences Research Institute Laboratories (CSRI) at UHCW NHS Trust, Coventry.
The detailed procedure is described in chapter 2.
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5.3 Vascular Function Tests
The following details describe the status of vascular inner lining membrane, the endothelium.
5.3.1 Endothelial Function at macrovascular level
Endothelial function at macrovascular level was evaluated by measuring flow-mediated
vasodilatation (FMD) of the brachial artery. FMD is a non-invasive method of assessing the
endothelial function. The specific details of the test are explained in chapter 2. The
examination was carried out in a temperature and light controlled room on subjects, who were
lying comfortably flat on a couch (AppendixI, Figure 1 f). The temperature was constantly
maintained at 21ºC using an efficient central air conditioner. A BP cuff was placed on the left
arm, which was connected to a quality checked and NHS (National Health Service) approved
automated BP machine, that was used to check systolic and diastolic BP at various times
during the study protocol. The same machine was used in all study subjects during the entire
duration to reduce any possible variations between machines. ECG tracing was obtained by 3
leads connected to the VIVID 7 ECHO machine (GE Vingmed System V) (Appendix I,
picture 1 g). The details of endothelial function testing are covered in chapter 2.
5.3.2 Flow mediated dilatation (FMD) Measurements
In this study, brachial arteries were imaged with a standard ultrasound system (VIVID 7
ECHO machine (GE Vingmed System V) connected with a 12 MHzflat linear transducer
probe. The ultrasound system was connected to a personal computer equipped with a frame
grabber and artificial neural network wall detection software (vessel image analysis) (VIA)
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(Sidhu, Newey et al. 2002), as described in chapter 2. The VIA software automatically detects
and tracks the anterior and posterior walls within a user defined region of interest (Sidhu,
Newey et al. 2002). The details of the procedure and the protocol used are described in
chapter 2.
The endothelium independent dilatation of the brachial artery was calculated similarly to the
percentage increase in mean diameter 5 min after glyceryl trinitrate administration. The FMD
was calculated and displayed within seconds of completing the study, using VIA software, as
previously described. This new technique has previously been shown to minimise the
variability of measurement (Sidhu, Newey et al. 2002). Using a reference two dimensional
image of the artery for comparison in repeat studies also ensured that the same section of
artery was scanned every time and on subsequent days. Similar measurements to detect
endothelial function were undertaken in the retinal vasculature in order to study
microvascular function. For this part of the study, the following procedure was used.
5.3.3 Retinal Vessels Reactivity Measurements
Observations and measurements in retinal vessels detect microvascular changes in a direct
and non-invasive method. This method is used by clinicians using an ophthalmoscope to
identify changes in the vascular bed relating to diabetes, hypertension and other
cardiovascular risk parameters. However, early functional vascular changes due to diabetes
and hypertension could occur without any identifiable or obvious lesions on traditional
ophthalmoscope examination (HICKAM and SIEKER 1960). Similarly, early functional
changes in the retinal vascular bed may not be identifiable on current retinal screening
programmes based on identifying structural abnormalities. Therefore, in order to identify
these early functional vascular changes of vasosclerosis (when there is little or no change on
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ophthalmoscope examination (HICKAM and SIEKER 1960) or retinal screening fundal
photographs), the RVA, with the ability to objectively measure vascular function, was utilized
to measure microvascular function in this study.
RVR was measured using the RVA (Imedos, GmbH). The fundamental components of this
system consisted of a fundus camera (field of 50°;model FF 450;Zeiss, Jena, Germany), a
video camera, a real-time monitor, and a computer with image-analysis software for the
accurate determination of retinal arterial and venous diameter. The details of the system were
explained in chapter 2.
5.3.4 Mechanism of wall motion detection-Retinal Vessel Analyser
The RVA system, as a method suitable for quantitative examination of retinal vascular
function, has been previously validated in a clinical methodological study by Nagel (Nagel
and Vilser 2004). The RVA methodology and system information is described in detail in
chapter 2.
5.3.5 Retinal Vessel Analyser (RVA) Protocol
In brief, all subjects had 1 % Tropicamide applied, usually to the right eye, 15-30 min before
the actual scanning for pupillary dilatation. The subjects were seated before the fundal camera
and the stool height was adjusted so that the subject was comfortable for the duration of the
study. The image of the retina was adjusted on the screen of the real-time monitor. A suitable
area in the retina was picked for scanning after adjusting the camera to the dilated pupil. Once
a clear fundus image with good contrast was obtained, the scanning commenced according to
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a fixed protocol. The fundus of the eye was examined under green light. (The details of this
protocol are discussed in detail in chapter 2). A graph, similar to the one in the example noted
in (AppendixII, Figure 2 c and Figure 2 d) , was obtained at the end of scanning. This
figure reveals the vascular reactivity result on-line, instantly. The results are shown below.
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5.4 Results
5.4.1 Physiological stress response
Baseline plasma glucose levels increased significantly over time following ingestion of 75
grams glucose, as part of OGTT. The increased glucose levels reverted back to baseline levels
by 3 to 4hrs. The table below indicates that mean baseline values increased only modestly
following the OGTT, in keeping with efficient glucose metabolism in healthy individuals.
Glucose stress ND Mean serum glucose Std. Deviation
Fasting 5.2 0.6
1 hr. post 6.8 2.3
2 hr. post 6.0 * 2.5
3 hr. post 4.2 * 0.6
4hr. post 4.0 * 0.4
Table 5.4.1.1 Serum glucose levels following OGTT on ND subjects *P <0.05
The results shown in table 5.4.1.1 demonstrate significant changes to glucose levels at
baseline compared with the post-glucose stress time points (1-4hr) following OGTT in ND
subjects. During this time, the plasma triglyceride (TG) levels revealed a stable trend (table
5.4.1.2).
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Glucose stress ND Mean serum TG Std. Deviation
Fasting 1.3 0.6
1 hr. post 1.1 0.6
2 hr. post 1.4 1.6
3 hr. post 1.1 0.8
4hr. post 1.2 0.9
Table 5.4.1.2 Serum TG levels following OGTT in ND subjects
These findings confirm that, following OGTT, there is no significant change to TG levels
compared with baseline in ND /healthy subjects.
The levels remained consistent throughout the 5 hours of testing, including the fasting phase
and during an extended OGTT phase. This finding demonstrates that TG levels are not
influenced by glucose ingestion, which could also be interpreted as a validation of the glucose
challenge test, as expected.
5.4.2 Macrovascular response to OGTT
Flow mediated dilatation response (macrovascular response) of the brachial artery to
physiologic stress is detailed below (table 5.4.2).
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Glucose stress ND Mean FMD % Std. Error
Fasting 3.7 1.1
1 hr. post 1.6 0.8
2 hr. post 0.8* 0.9
3 hr. post 2.5 0.5
4hr. post 2.1 1.0
Nitroglycerine spray 14.6** 2.5
Table 5.4.2 FMD of brachial artery response to OGTT in ND subjects
*P <0.05 **P <0.01
As noted in Table 5.4.2, mean baseline flow mediated dilatation (FMD) of the brachial artery
in ND subjects was 9.8%. This value is significantly higher than the mean baseline levels
noted in T2DM subjects (as revealed in detailed in chapter 6).
At 1 hour post OGTT, the mean FMD significantly and profoundly reduced to 1.6 %. At
hours 2 and 3 after the OGTT, the FMD started to recover very slowly, thus revealing the
acute effects of post-prandial glucose stress on the healthy endothelium.
In contrast to the above endothelial dependant depressive effect noted with acute
hyperglycaemia, FMD response levels of 14.6 % were seen upon administration of
Sublingual nitroglycerin (GTN, 250 µgrams). This level of dilatation (response) noted after
GTN spray is statistically significant and is indicative of non-endothelial dependant dilatation
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secondary to smooth muscle relaxation. This effect appears to be independent of endothelial
influence on the vascular reactivity.
5.4.3 Microvascular response to OGTT
Retinal vessel diameter measurements were represented as percentages similar to FMD
brachial artery measurements. Microvascular (retinal vessel reactivity-RVR) response to
OGTT is shown below (5.4.3).
Glucose stress ND Mean RVR % Std. Error
Fasting 3.2 0.5
1 hr. post 3.3 0.5
2 hr. post 2.7 0.2
3 hr. post 2.6 0.3
4hr. post 3.3 0.5
Table 5.4.3 RVA of retinal artery in response to OGTT in ND subjects
As noted in Table 5.4.3, the mean baseline retinal vessel reactivity (RVR) in ND subjects
during the fasting state was 3.2 %. It is significantly high compared with T2DM subjects (as
shown in chapter 6). At 1 hr post glucose ingestion, the mean RVR increased to 3.3 %. This
trend of increasing reactivity measurements to stress was quite different from the reducing
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reactivity measurements of the macrovasculature, as represented by brachial artery reactivity.
At 2 and 3 hr post-glucose stress, the reactivity measurements started to reduce to even below
the baseline value. This dynamic trend of an initial increase before a gradual depression, in
terms of arterial reactivity in the microvasculature, seemed to follow a similar pattern to that
of blood glucose levels - which reached a peak at hour 1 before regressing. It is therefore,
likely that this initial high reactivity could be related to high glucose levels acting as a
stimulus.
5.4.4 Summary
In summary, following the OGTT in healthy ND subjects, serum glucose levels increased to a
peak at 1 hr before gradually reducing back to pre-prandial levels. The levels reached
statistical significance at hr 2, 3 and 4. At the same time, serum TG levels did not change
significantly, which supports the validity of the OGTT for this group of subjects. In a recent
study, it is quite clear that FMD does not significantly change to usual physiologic changes
during the morning in healthy people (Thosar, W iggins et al. 2015). Therefore this study
reveals that glucose stress implications on FMD are real and significant. W hilst the serum
glucose levels changed significantly during the OGTT, the macrovascular response, as
represented by brachial artery FMD % levels, depressed to significantly low levels by hour 2
before recovering. The interesting finding in this study was the response of microvascular
reactivity to OGTT, as represented by RVR %. These levels revealed that instead of
immediate depressed reactivity to glucose load, as observed at the FMD% of macrovascular
response, the values increased - albeit slightly - before showing a similar trend in reduced
reactivity at the microvascular level. This unique response at the microvascular level needs to
be explored.
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5.5 Discussion
This study utilized two new validated software programmes to measure endothelial function
at both microvascular and macrovascular levels. These newer systems are more reliable and
measure changes instantly in an “online” fashion. Seldom have both these systems been
utilized together in a simultaneous fashion. Therefore, the data obtained from this study is
interesting and worth exploring further.
In the first stage, this study indicated that post-prandial hyperglycaemia manages to induce
endothelial dysfunction, which could be measured both at macrovascular and microvascular
levels. In addition, it was observed for the first time, that acute hyperglycaemia had an
immediate but potentially divergent physiological effect at micro- and macrovascular levels
of endothelial function. Macrovascular reactivity appears to be immediately and profoundly
depressed with increasing glucose levels, within 1 hr of glucose intake. At the same time,
microvascular reactivity and function does not appear to be depressed immediately after
glucose intake. Instead, microvascular reactivity measurements appear possibly to increase in
line with increasing glucose before declining function. This is an interesting finding.
In a group of fasted normo-glycaemic, normotensive ND subjects, baseline measurements of
arterial reactivity in response to physiological stimulus was between 3 to 4% at both the
macrovascular and microvascular levels. At the level of the brachial artery, macrovascular
response, was in line with expected FMD % for a healthy population (W itte, W esterink et al.
2005). In a meta-analysis, examining normal healthy populations with low risk, very similar
to this study, the mean baseline FMD parameters were around 3.5 % in the lower quartile for
the total study population (W itte, W esterink et al. 2005), a level significantly higher
compared with T2DM subjects (Mean 1.52%). Similar results were obtained in other studies
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(Ceriello 1998;Kawagishi, Matsuyoshi et al. 1999;Ceriello, Quagliaro et al. 2004;Abd El
Dayem, El Magd El Bohy et al. 2015).
This current study revealed that OGTT in healthy ND subjects broadly resulted in decreased
reactivity measurements, both at the macrovascular and microvascular levels, by 2 to 3 hrs - a
finding in line with previous published data (Ceriello, Taboga et al. 2002;Dorner, Garhöfer et
al. 2003;Ceriello, Quagliaro et al. 2004). However, the novel finding of an acute increase in
reactivity, before the reduction in the microvascular reactivity, to OGTT needs to be
explored. This finding of an initial increase in the microvascular reactivity not only differs
from the reactivity response at the macrovascular level, but is also at odds with another
microvascular function study performed previously (Dorner, Garhöfer et al. 2003). One
simple explanation for this transient increase in reactivity could be an initial increase in blood
flow, secondary to acute hyperglycaemia which could, in turn, lead to increased reactivity
measurements. However, at the macrovascular level, a similar increase in flow did not
translate into an immediate increase in reactivity. The mechanisms for initial difference in
reactivity measurements between micro- and macrovasculature functions could potentially be
explained by a number of factors.
Firstly, sympathetic innervations are absent in the retinal vessels, unlike the macrovasculature
(Konno, Feke et al. 1996). Therefore, the RVR could be dependent on the local
autoregulatory mechanisms involving local factors including pH, pCO2, pO2 and glucose
(Konno, Feke et al. 1996). The local factors appear to be much more influential in the small
distal vascular beds, as noticed in the microvasculature of the retina. Therefore, the initial
increase in the response of the retinal vessels could well be influenced by immediate local
factors. The ‘local factors’theory, thus, appears to explain the initial difference in reactivity
measurements of retinal vessels post-glucose load compared with the macro vascular
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response. Other studies have highlighted similar findings. Luksch and colleagues (Luksch,
Polak et al. 2001) have identified that, glucose exerts an additive vasodilator effect on the
ocular circulation resulting in initial increased reactivity or flow. Therefore the distinctions in
the structure, function and dynamics of both micro and macrovascular beds appear to be
important considerations in explaining the notable differences between them with regard to
vascular reactivity.
The second potential “theory”to explain the apparent differences involves the divergence in
the endothelial cells lining the vasculature. Retinal endothelium is serving an end artery when
Brachial artery endothelium serves a conductance vessel. Retinal endothelial membrane is
also uniquely different from endothelial lining of macrovasculature. It is part of the retinal
blood/ocular barrier, which is involved in the specialized function of homeostasis of the
neuro-retina (Cunha-Vaz1979). As part of the barrier function, a layer of pericytes, which are
closely related to the endothelial surface, express aldose reductase. Aldose reductase, as part
of the polyol pathway of glucose metabolism, leads to endothelial dysfunction by inducing
cellular damage. This ultimately leads to changes in retinopathy (Oishi, Kubo et al. 2002).
The permeability of this endothelial membrane to solutes and electrolytes is also different
from any other endothelial surface (Cunha-Vaz 1979). Glucose uptake at the retinal
endothelium is not dependant on insulin levels and glucose appears to move freely into the
cells. Glucose uptake into the retinal endothelial cells also occurs through carrier mediated
facilitated diffusion using specific plasma membrane glycol proteins, the glucose transporters
(GLUT 1 and 3). These transporters are distinctive in their kinetic properties, tissue
distribution and response to stimuli (Rajah, Olson et al. 2001) and regulate glucose uptake in
a significantly different way to other endothelial surfaces. High glucose levels in the plasma
do not down-regulate the expression of GLUT 1, as seen in other regions. Conversely, in the
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retinal endothelial surface, these levels increase (Rajah, Olson et al. 2001). An acute increase
in glucose levels in the retina quickly builds up sorbitol and fructose through the polyol
pathway, which ultimately results in high retinal lactate levels (Kohner, Hamilton et al. 1975;
Van den Enden, Nyengaard et al. 1995). The resultant acidic environment, and fall in pH
accompanying hypoxia, leads to an increase in blood flow and therefore reactivity. This might
explain the transient increase in reactivity seen here in the microvascular response to glucose.
The third explanation for the difference in reactivity could be based around blood flow and
effect of Neuro-vascular network. Blood flow tends to increase following the release of cuff
compression at the macrovascular level. Similarly, at the microvascular level, after flicker
stimulation, blood flow in the retina increases (Bill and Sperber 1990;Harris, Ciulla et al.
1998). The increased blood flow in the distal micro-circulation could be leading to increased
RVR before changes of acute hyperglycaemia lead to profound depression. It is unclear, at
this stage, the effect of the dynamics of blood flow in two dissimilarly sized vessels with
distinct haemodynamic influences and properties on the difference in reactivity between
micro and macro-circulation.
After the initial difference in reactivity, both vessels revealed profound depression of
reactivity and function in response to the OGTT. These findings were supported by previous
studies (Kawano, Motoyama et al. 1999;Ceriello, Assaloni et al. 2005), whilst other studies
(Ceriello 1998) have described other mechanism via which acute hyperglycaemia may exert
its depressive effect on the endothelium. Hyperglycaemia resulted in labile non-enzymatic
glycation, inducing free radical formation and oxidative stress (Ceriello, Quatraro et al.
1992). The production of free radicals during an acute rise of blood glucose concentration
may occur, not only by the process of labile glycation (Ceriello, Quatraro et al. 1992), but
also directly through a mechanism of auto-oxidation (W olff and Dean 1987). Oxidative stress
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is considered to represent a prime force for endothelial dysfunction. All these changes,
paradoxically, appear to amplify the deleterious effects of hyperglycaemia on the retinal
endothelial surface more so than the other endothelial surfaces.
In summary, for the first time, the present study describes a simultaneous but varying effect
of acute glucose uptake on micro- and macrovascular endothelial function in ND subjects. It
reaffirms the previously known view of acute endothelial depression on macrovascular
function as a result of glucose challenge, but revealed that the blood flow dynamics of the
micro-circulation responds differently. Microvascular reactivity appeared, initially, to
increase secondary to flow dynamics before revealing a depressive effect of acute
hyperglycaemia. This study, therefore, proposes that an acute increase in serum glucose is
deleterious to both vascular beds and that this effect can be reliably detected at both sites by
the newer vascular software and “online”analysis.
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Chapter 6
Assessment ofED usingNon invasive vascular function in high
risksubjects (T2DM)compared withHealthy subjects
154
6.1 Introduction
Current evidence supports the concept that hyperglycemia significantly contributes to the
development of both cardiovascular and microvascular complications of Type 2 diabetes
mellitus (T2DM) (Holman, Paul et al. 2008). Diabetic retinopathy is a highly specific
microvascular complication of diabetes and the leading cause of blindness in industrialized
countries (Simo and Hernandez2009). Endothelial dysfunction is considered a key factor in
the development of both cardiovascular disease (CVD) and retinopathy (Pemp and
Schmetterer 2008;Xu and Zou 2009). However, whilst it is widely accepted that this
condition produces a reduced circulation at the level of large arteries (Xu and Zou 2009), the
data, regarding the retinal circulation, are still controversial. In patients with T2DM with
absent or mild diabetic retinopathy, increased retinal blood flow has been reported (Pemp and
Schmetterer 2008). Grunwald and colleagues (Grunwald, Riva et al. 1995) investigated
retinal haemodynamics in the macular microcirculation, using the blue field simulation
technique, and in the major retinal veins, by a combination of bi-directional laser doppler
velocimetry and monochromatic fundus photography. Progression of diabetic retinopathy was
assessed from fundus photographs taken at baseline and at the end of the study. The results
suggested that increased flow in the macular microcirculation may be associated with
progression of retinopathy, thus supporting the hypothesis that increased blood flow may play
a role in the development of diabetic microangiopathy. It has been widely reported that an
acute increase of glycaemia produces endothelial dysfunction at the macrovascular level in
both normal subjects and patients with T2DM (Ceriello 2008). The data on the effect of acute
hyperglycaemia on retinal blood flow are still controversial. It has been reported that acute
hyperglycaemia does not affect retinal circulation (Gilmore, Hudson et al. 2007) or reduce it
(Dorner, Garhöfer et al. 2003), and that postprandial hyperglycaemia reduces oscillatory
potentials in subjects with T2DM (Arlotte, Perrott et al. 2004). Retinal function can be
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measured by electro-retinogram. W ith this methodology, the retinal oscillatory potential is
evaluated by two waves: the a-wave, used as an indexof outer retinal function;and the b-
wave, as an index of inner retinal function. The abnormalities in the oscillatory potentials
seem to reflect severe disturbances in the retinal circulation. A correlation appears to exist
between severely reduced oscillatory potentials and a circulatory deficiency in the retina
(Arlotte, Perrott et al. 2004). The aim of this study was to explore the effect of acute
hyperglycaemia during an oral glucose tolerance test, simultaneously at the level of
macrocirculation (FMD- Flow mediated dilatation of brachial artery ) and micro-circulation
(RVR- Retinal vessel reactivity of retinal artery) in subjects with T2DM.
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6.2 Subjects and methods
Twenty-one subjects with T2DM (duration of disease less than 7 years, 17 patients on oral
agents and diet and four on diet only) and 10 healthy control subjects ( previous chapter),
matched for age and BMI, were recruited into the study. The clinical characteristics of the
group with diabetes are reported in Table 1. All subjects were non-smokers. They had a
normal resting electrocardiogram, renal function tests and blood pressure (BP). They had no
history of any vascular disease or retinopathy and were not taking aspirin, statins or
supplemental vitamins at the time of recruitment into the study, as these drugs can influence
endothelial function (Drexler and Hornig 1999;Ceriello, Taboga et al. 2002). All subjects
then had their height, weight, abdominal circumference and BMI measurements taken using
the same standard equipment. Blood samples were taken either from the right or left
antecubital vein in a sitting position. BP was checked with a BP monitor on the left arm and
rechecked after 2 min. Finally a 12-lead electrocardiogram was performed, using the same
machine for the duration of the study. Ethical approval was obtained for the conduct of the
study from the Coventry Research Ethics committee, UK.
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T2DM subjects
Sex male/female 12 /9
Age (years) 46.4±2.1
BMI (Kg/m²) 30.1 ±1.1
Fasting plasma glucose (mmol/l) 7.8±0.4
Glycated Heamoglobin HbA1C ( %) 7.8±0.3
Diastolic blood pressure-resting (mmHg) 76.1 ±1.7
Total cholesterol (mmol/litre) 4.5 ±0.2
HDLcholesterol (mmol/litre) 1.2 ±0.1
LDLcholesterol (mmol/litre) 2.5 ±0.2
TG (mmol/litre) 1.6±0.1
FMD (%) 2.5 ±0.4
RVR (%) 1.4±0.4
Table 6.2 Baseline characteristics of patients with T2DM
Data are expressed as means ±SEM (standard error of mean).
FMD, flow-mediated dilatation; RVR- retinal vessel reactivity.
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6.2.1 Study protocol
In patients with T2DM, vascular function tests, including flow-mediated dilatation (FMD) at
the level of the brachial artery and retinal vessel reactivity (RVR), were performed under
basal fasting conditions. At timed intervals before and after a standard oral glucose tolerance
test (OGTT), both FMD and RVR were evaluated. Blood samples for assessing glycaemia
were drawn at 0 (fasting state), 1, 2, 3 and 4hr post-OGTT (75 g glucose).
6.2.2 Flow-mediated dilatation (FMD)
In brief, endothelial function at the macrovascular level was evaluated by measuring FMD of
the brachial artery as described before. Brachial artery FMD (LOGIQ e_ system;GE
Vingmed Horten, NO, USA) was determined using a protocol similar to published studies
(Sidhu, Newey et al. 2002). At the end of the study each day, 250 µg of sublingual glyceryl
trinitrate (GTN) was administered in order to asses endothelium independent vasodilatation
(Ceriello, Taboga et al. 2002). The intra-observer variability for repeated measurements of
resting arterial diameter was 0.02 ±0.02 mm.
6.2.3 Retinal vessel reactivity (RVR) measurements
In brief, RVR (Nagel and Vilser 2004) was measured using a retinal vessel analyser (RVA;
Imedos GmbH, Jena, Germany) (Seifertl and Vilser 2002) as described previously. After
obtaining a clear fundus image with good contrast and no reflections, the scanning was
started, according to a fixed protocol (Gugleta, Zawinka et al. 2006), as described in detail in
chapter 2. The maximum vasomotion in response to flicker stimulation was measured in two
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chosen segments of the major temporal inferior branch of the arteriole and venule. Three
points of maximum dilation were obtained in all measuring sites (proximal and distal in
arterioles and venules) and expressed as a percentage of the corresponding first baseline
value.
6.2.4 Biochemical and physical parameters
Blood samples were drawn at 0 (fasting state), 1, 2, 3 and 4hr for the glucose assay, using the
glucose oxidase method.
6.2.5 Power calculations
To ensure that the study design had a reasonably high statistical power to detect the smallest
difference in group means for FMD, the power calculation was performed in G*Power 3.0.5
(http://download.cnet.com/G-Power/3000-2054_4-10647044.html). The acceptable power
was set conventionally to 0.80 (P =0.20) and statistical significance level (P) was 0.05 (two-
tailed). As no dynamic data were available for RVR, the sample size was calculated for FMD
based on our previous study (Ceriello, Taboga et al. 2002). The estimated power was 0.92,
revealing that the sample size of 20 subjects was adequate to determine whether the response
of endothelium to glucose, during an OGTT, is significant or not.
6.2.6 Validity measurements of vascular tests
All the above values were confirmed by the high levels of validity measurements recorded for
each scan. Using the FMD software, the obtained values were corroborated by the low levels
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of noise recorded for each scan. According to the manufacturer of the software program, a
noise level of less than 40% is considered as valid for the results obtained (Sidhu, Newey et
al. 2002). This confirms the validity of the values obtained at each time point for the study.
Similarly, according to the manufacturer of the RVA software program, a validity
measurement of more than 40% (valid cycles) was considered to be a reliable indicator of the
accuracy of the results obtained (Seifertl and Vilser 2002). They were explained in detail in
chapter 2.
6.2.7 Statistical analysis
Statistical analysis for this study was performed using SPSS version 17 (SPSS Inc., Chicago,
IL, USA). Initially, the Kolmogorov–Smirnov test was used to determine whether the
variables had a normal distribution. Baseline data comparisons between subjects with T2DM
and ND subjects were performed using an unpaired Student’s t-test or the W ilcoxon signed
rank test, where appropriate. In addition, for both FMD and RVR evaluation during the
OGTT, non-parametric tests, Kruskal–W allis one-way ANOVA and W ilcoxon signed ranks
test, were used (Appendix III- 6.2.7.1-6.2.7.8). Statistical significance was defined as P <
0.05. Data are expressed as mean ±SEM.
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6.3 Results
As reported in Table 6.2, seven male and three female control subjects were recruited, while
12 male and nine female subjects with T2DM participated. The ages of the ND subjects and
subjects with T2DM were 39.8 ± 3.6 and 46.4 ± 2.1 years, respectively, and the BMI
measurements for the ND subjects and the subjects with T2DM were 25.4±1.0 and 30.1 ±
1.1 kg ⁄m2, respectively. Mean age for T2DM subjects was slightly older compared to ND
subjects. Baseline FMD and RVR were significantly lower in subjects with T2DM compared
with the ND subjects (Table 6.2).
6.3.1 Serum Triglycerides (TG)
The findings below in Table 6.3.1 indicate that, with an OGTT, there is no statistically
significant change to TG levels compared with baseline on subjects with T2DM subjects.
Glucose stress ND Mean serum TG Std. Deviation
Fasting 1.56 0.73
1 hr. post 1.57 0.71
2 hr. post 1.60 0.71
3 hr. post 1.71 0.75
4hr. post 1.69 0.76
Table 6.3.1 Serum triglyceride (TG) levels on OGTT on subjects with T2DM
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It indicates that, in subjects with T2DM, pure glucose ingestion had no significant effect on
plasma TG levels. The levels remained consistent during 5 hours of testing, including the
fasting phase and during an extended OGTT phase. This confirmed TG levels are not
influenced by glucose ingestion, which could also be interpreted as validating the glucose
challenge test, in line with expectations.
6.3.2 Serum Glucose
As expected, during the OGTT, glycaemia in patients with diabetes rose rapidly by 3 hr and
returned to basal values at the end of the study (Figure 6.3.2.1).
Figure 6.3.2.1 Serum Glucose levels on OGTT in T2DM subjects compared with ND
(Healthy controls) from chapter 5.
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6.3.3 Mean Flow mediated dilatation (FMD)
At 1 and 2 hr post-OGTT, the mean FMD was significantly reduced (P <0.05). However, at
3 hr after the OGTT, the FMD slowly started to recover and, by 4hr post-OGTT, the FMD
showed recovery. This level was comparable with the baseline level. The FMD dynamic
change to the OGTT is shown in Figure 6.3.3.1 and 6.3.3.2. Endothelial independent
vasodilatation was not affected in this experiment (baseline 12.3 ±4.4vs. 12.2 ±4.0%).
Figure 6.3.3.1 FMD % dynamic chsnge to OGTT comparing T2DM with ND (Healthy
control) subjects from chapter 5.
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Figure 6.3.3.2 Vascular reactivity on OGTT in T2DM subjects
Glycaemia, flow-mediated dilatation (FMD) and retinal vessel reactivity (RVR) during the
OGTT in subjects with T2DM. *P <0.05 vs. baseline.
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6.3.4 Mean Retinal vessel reactivity (RVR)
RVR was represented as percentages similar to FMD brachial artery measurements. Baseline
values are calculated using the RVA software during the time when no flicker was given but
the vessels were being monitored. Similarly, but in contrast to FMD, at 1 and 2 hr, and also at
the 3-hr post-glucose ingestion, the mean RVR significantly increased (P < 0.05) and was
back to baseline levels at the 4hr time point as noted in figure 6.3.3.1 and 6.3.4.1.
Figure 6.3.4.1 RVA % dynamic reactivity to glucose stress comparing T2DM with ND
(Healthy control) subjects from chapter 5.
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6.4 Discussion
In this study, it is reported for the first time, that an acute increase in glycaemia
simultaneously induces an alteration at the level of macro-circulation of the forearm and in
the retina of subjects with well-controlled T2DM as evidenced by HbA1C levels. This study
further revealed that, in basal, fasting conditions, both FMD and RVR are relatively low in
patients with T2DM compared with ND control subjects (from previous chapter) as noted in
previous studies (Nguyen, Kawasaki et al. 2009;Pemp, W eigert et al. 2009). W hilst there is
general agreement that acute hyperglycaemia induces an endothelial dysfunction at the level
of the macro-circulation (Xu and Zou 2009), data on the retinal circulation are controversial.
No effect or worsening action of hyperglycaemia on retinal circulation has been reported
(Dorner, Garhöfer et al. 2003;Gilmore, Hudson et al. 2007).
Baseline fasting levels of endothelial function of ND subjects at both the macro and micro-
vascular level, as represented by reactivity measurements, appeared to be higher compared
with T2DM subjects. This phenomenon has, again, been noted in recent papers (Pemp,
Garhofer et al. 2009;Abd El Dayem, Battah et al. 2014). It was clear that post-prandial
hyperglycemia had a depressive effect on the endothelial function (Ceriello, Taboga et al.
2002), which could be caused via oxidative stress (Nappo, Esposito et al. 2002).
Moreover, hyperglycaemia, in the post-prandial state, appears to reduce oscillatory potentials
(Arlotte, Perrott et al. 2004). It has been suggested that nitric oxide (NO) production is
involved in the effect of hyperglycaemia, not only at the level of forearm circulation but also
at the level of the retinal circulation (Pemp, W eigert et al. 2009). Several compounds largely
used in patients with diabetes, such as ACE inhibitors, AT-1 blockers and statins, can
interfere with NO action (Ceriello 2008). In other previous studies, for the most part, these
factors may have not been taken into account. This study had exclusion and inclusion criteria
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clearly defined to prevent any of the subjects or patients on those agents to be able to
participate in the study.
Diabetic retinopathy is a highly specific microvascular complication that is a result of
microvascular retinal changes ultimately leading to parenchymal changes. The two most
important features of retinopathy include microvascular caliber changes and microvascular
dynamic reactivity to stress, particular to physiological states such as hyperglycaemia, and
people with diabetes. Apart from obvious parenchymal changes, these markers are highly
significant. In a population-based prospective study, it was noted that retinal vascular caliber
predicted cardiovascular death, independent of traditional cardiovascular risk factors in men
and women aged 49–75 years (W ang, Liew et al. 2006). Furthermore, generalized narrowing
of the retinal arterioles has now been associated with incident stroke, coronary artery disease
(CAD) and hypertension, independent of other risk factors (W ang, W ong et al. 2008). The
evidence that acute hyperglycaemia, during an OGTT, induces simultaneously an endothelial
dysfunction in the forearm and vasodilatation in the retina is a novel finding. Endothelial
dysfunction is considered an independent risk factor for a future cardiovascular events (Xu
and Zou 2009), while increased blood flow in the retina is considered a risk factor for the
development of retinopathy (Pemp and Schmetterer 2008). Post-prandial hyperglycaemia is
an important contributing factor in the development of CVD in people with T2DM. There is
now a strong clinical association between retinopathy and CVD in diabetes, with retinopathy
associated with an approximate two fold increased risk for CVD and all-cause mortality in
individuals with T2DM (Juutilainen, Lehto et al. 2007).
Post-prandial hyperglycaemia is now being considered an independent risk factor for the
development of retinopathy in diabetes (Shiraiwa, Kaneto et al. 2005). Similarly, it was
recently demonstrated that ‘post-challenge’glucose levels measured during an OGTT might
168
be used as a predictor of ‘postprandial hyperglycaemia’(Meier, Baller et al. 2009). W ith this
backdrop, this study points to the finding that the macro-circulation and the retinal circulation
simultaneously respond to an acute increase in glycaemia. It should also be noted that, during
an OGTT, apart from glucose, changes in the levels of other hormones and insulin could be
involved in endothelial influence. However, these effects should be similar in both groups and
therefore unlikely to explain the disparity. This finding, therefore, has the potential to
advance current opinion and help to better explain the relationship between increased CVD
risk and changes of retinopathy.
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Chapter 7
Effect ofMetformin in reducing the Cardiovascular risk in
subjects withT2DM
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7.1 Introduction
Cardiovascular disease (CVD) is the major cause of premature death in T2DM. T2DM is
associated with a two-fold to three-fold increased risk of coronary heart disease (CHD) in
men and a three-fold to five-fold increased risk in women in comparison to the non-diabetic
(ND) population (Grant 2003). T2DM along with metabolic syndrome further increases the
CVD risk (Athyros and Mikhailidis 2015). In diabetic CVD population, dyslipidaemia is a
key feature (Ali, Jamil et al. 2015), where small dense LDL particles propagate major
atherogenic events. The underlying mechanism producing small, dense LDL particles is
related to hepatic oversecretion of apolipoprotein B100 (apoB100) and impaired clearance of
LDL by the high-affinity LDL receptor (Taskinen 2003). The normal circulation/residence
time of LDL in plasma is 3 days but this is increased up to 5 days for small, dense, highly
atherogenic LDL (Packard 2003). Atherogenicity and plasma residence time of LDL may be
influenced by damage to apoB100 by glycation, oxidation and nitration reactions. The
quantitative amounts of such damage in healthy human subjects and diabetic patients remain
unclear.
Glycation of proteins is a complex series of parallel and sequential reactions, collectively
called the Maillard reaction. In the early stage, reactions of the amino acid residues are
directed at the lysine and amino-terminal residues leading to the formation of early glycation
adducts - fructosyl-lysine (FL), and other fructosamine derivatives. Later stage reactions lead
to advanced glycation end products (AGEs). FL slowly degrades to form AGEs. Glyoxal,
methylglyoxal and 3-deoxyglucosone (3-DG) are physiological dicarbonyl metabolites and
potent glycating agents, formed by the degradation of glycolytic intermediates, glycated
proteins and lipid peroxidation. They react with proteins to form AGEs, directed mainly at
arginine residues. The most important AGEs quantitatively are hydroimidazolones derived
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from arginine residues. These are modified by glyoxal, methylglyoxal and 3-DG to G-H1
(glyoxal derivative), MG-H1(methylglyoxal derivative), and 3DG-H(deoxyglucosone
derivative), respectively.
N-carboxymethyl-arginine (CMA) is a further arginine-derived adduct formed by glyoxal.
Other important and widely studied AGEs are carboxymethyl-lysine (CML), carboxyethyl-
lysine (CEL), and pentosidine. In addition to this, one of the markers of oxidative damage to
proteins is methionine sulfoxide (MetSO), formed by the oxidation of methionine, and
dityrosine.. A widely studied marker of nitration damage to proteins is 3-nitrotyrosine (3-NT)
(Gaut, Byun et al. 2002).
In current clinical practice, metformin is the most widely prescribed oral glucose-lowering
agent for the treatment of T2DM. It improves glycaemic control and decreases the risk of
CVD (Bailey 2008;Fung, W an et al. 2015). Ohira and colleagues have shown that
metformin therapy in patients with T2DM increased the LDL particle size (Ohira, Miyashita
et al. 2007) and decreased plasma concentrations of remnant lipoprotein cholesterol. Remnant
lipoprotein cholesterol is a predictor of myocardial infarction (MI) and thought to reflect
increased residence time and atherogenicity of cholesterol ester–rich chylomicrons and
VLDL (Jialal and Devaraj2002). Metformin also decreased the plasma concentrations of
methylglyoxal in T2DM patients (Beisswenger, Howell et al. 1999) and may decrease
oxidative stress (Cahova, Palenickova et al. 2015) and related oxidation of LDL (Formoso,
De Filippis et al. 2008).
Therefore the aim of this chapter was to assess and quantify the lipoprotein damage in T2DM
patients compared with healthy controls. The effect of metformin will then be investigated
with regard to its effects on lipoprotein damage. The study would utilise the gold standard
method of stable isotopic dilution analysis, “liquid chromatography– tandem mass
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spectrometry”(LC-MS/MS) to measure protein glycation, oxidation and nitration adducts in
apoB100 of LDL. This would help to assess the potential increased lipoprotein damage in
patients with T2DM with respect to normal healthy subjects (ND) and to investigate the effect
of metformin therapy.
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7.2 Subjects and Methods
7.2.1 Study population
Patients with T2DM and healthy ND) subjects were recruited to the study from patients
attending the Foleshill Medical centre, Coventry and from the Diabetes Clinics at Colchester
General Hospital, Colchester, U.K. Healthy volunteers, as controls, were recruited from
partners and friends of the patients with diabetes and those of investigators. Ethical approval
for the study was given by the local ethics committees (Coventry Research Ethics Committee,
Coventry, U.K and North and Mid-Essex Local Research Ethics Committee, Chelmsford,
U.K.). Inclusion criteria were T2DM with normoalbuminuria (albumin excretion rate
30mg/24hr), age 40–80 years, and stable HbA1C. Exclusion criteria were individuals with
significant co-morbidities who participated in any interventional study within 30 days,
recipients of renal and/or pancreatic transplants and women who were pregnant or
breastfeeding or of child-bearing potential not using adequate contraceptive precautions.
Metformin therapy was given in the dose range 0.85–3g/day;median 1.50 g/day. The
duration of metformin therapy was in the range 1–20 years;median 4 years. Participant
characteristics are shown in table 7.2.1. Venous blood samples (fasting) were taken after
informed consent. Plasma was separated immediately and stored at -80°C until analysis.
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Table 7.2.1 Characteristics of T2DM patients and healthy control subjects
Data are mean ± SD or median (minimum - maximum). Significance: *P< 0.05, §P <0.01,
and ‡P <0.001, with respect to normal healthy control subjects;and †P <0.05, with respect to
T2DM patients receiving conventional therapy. Glomerular filtration rate (GFR).
Study Group
Healthy
subjects T2DM subjects
T2DM subjects not
receiving Metformin
therapy
T2DM subjects
receiving Metformin
therapy
n 21 32 19 13
Age (years) 56.5 ±9.7 60.5 ±12.2 64.1 ±12.8* 55.2 ±9.5
Sex male/female 10 /11 14/18 11 /8 3 /10
BMI ( Kg/m²) 28.6±3.6 33.7 ±6.3‡ 31.5 ±6.3 37.1 ±4.8‡†
Duration of T2DM (years) -- 11 ( 1-35) 13 ( 1-35) 8( 1-25)
Fasting plasma glucose (mmol/l) 5.14±0.74 8.75 ±2.51‡ 9.15 ±2.41‡ 8.17 ±2.62§
HbA1C ( %) 5.48±0.57 8.20 ±1.94 8.25 ±2.04‡ 8.13 ±1.85‡
Total cholesterol (mmol/litre) 5.11 ±1.43 4.90 ±1.02 4.71 ±1.00 5.18±1.01
LDLcholesterol (mmol/litre) 3.18 ± 1.41 3.01 ± 1.01 2.89 ± 1.04 3.17 ± 0.98
HDLcholesterol (mmol/litre) 1.55 ±0.81 1.24±0.30 1.18±0.23 1.34±0.36
Triglycerides (mmol/litre) 1.16±0.31 2.23 ±1.02‡ 2.13 ±1.09§ 2.37 ±0.94‡
Systolic blood pressure (mmHg) 130 ±20 141 ±22 140 ±24 142 ±21
Diastolic blood pressure (mmHg) 77 ±8 78±8 77 ±10 78±10
GFR (Glomerular filtration rate) (ml/min) 99±20 100 ±42 89±30 116±52
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7.2.2 Isolation of LDL
For rapid and same-day preparation of LDL, a self-generating gradient of iodixanol in a
vertical rotor (S120VT) was used in a Sorvall MTX 150 micro ultra centrifuge (Hitachi). The
density of plasma was increased to 12% using 60% iodixanol solution (OptiPrep;Axis-
Shield). The Plasma (0.9ml) was layered under 0.9 ml of 9% iodixanol in a 2-ml ultra
centrifuge tube (polyallomer, no. S302897A;Hitachi) and further void filled with 0.2ml
nitrogen-purged phosphate buffered saline (PBS). The sample was centrifuged (501,000g,
16°C, 2.5 hr) with low acceleration and deceleration technique. LDL was washed with
nitrogen-purged water (4ml x3) over 100-kDa microspin filters (Amicon) to remove
iodixanol. The LDL was stored at -20°C until further analysis. Sample handling was
performed under subdued light. Protein concentration was measured by Bradford assay. Lipid
peroxidation of LDL was assessed by measuring thiobarbituric acid reactive substances
(TBARS). TBARS were quantified by reference of the chromophoric response to a standard
curve constructed from malondialdehyde tetramethyl acetal and expressed as
malondialdehyde equivalents. The purity of LDL was assessed by “sodium dodecy
sulfate polyacrylamide gel electrophoresis” (SDS-PAGE) denaturing and agarose non-
denaturing electrophoresis.
7.2.3 In vitro modification of LDL
LDL was glycated minimally by methylglyoxal and glucose in vitro to assess the major
glycation adducts formed. LDL glycated minimally by methylglyoxal (MGmin-LDL) was
prepared by incubation of methylglyoxal (200mol/l) with LDL (4.2mg/ml) in PBS (0.4
mmol/l diethylenetriamine-pentaacetic acid [DETAPAC], pH 7.4) at 37°C for 6 hr. The
glycated and control LDL was washed extensively with argon-purged ice-cold water using
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ultra-spin filters (Amicon 100-kDa cutoff membrane from Millipore) at 4°C, and stored at
4°C under argon and used within 2 weeks. LDL glycated minimally by glucose (AGEmin-
LDL) was prepared by incubation of glucose (25mmol/l) with LDL (3mg/ml) in PBS
(0.4mmol/l DETAPAC, pH 7.4) under argon (0.5ml) at 37°C for 7 days under sterile
conditions. Control LDLwas incubated without glucose. The glycated and control LDLwere
washed with argon-purged water ultrafiltration at 4°C, and stored at 4°C under argon until
further analysis. Electrophoretic mobility of native and modified LDL on agarose gel
electrophoresis was performed using a gel lipoprotein electrophoresis kit with barbital buffer,
pH 8.6(Helena).
7.2.4 Delipidation of LDL
An aliquot of LDL solution (20µl, 100µg) was transferred into a glass tube (50 x7.5 mm)
containing butylated hydroxytoluene in methanol (5µl, 2mg/ml), 20% trichloroacetic acid
(100µl), and water (75µl). The solution was mixed well, left on ice for 10 min and then
centrifuged (10,000g, 15 min, 4°C). The supernatant was removed and the pellet washed with
acetone (200µl) and diethyl ether (200µl) and dried under argon.
7.2.5 Enzymatic digestion of apoB100
Delipidated protein was hydrolysed exhaustively by modification of a published procedure
(Ahmed, Argirov et al. 2002). Protein was suspended in 100 mmol/l potassium phosphate
buffer, pH 7.4(50µl). Pronase E (20µl, 2mg/ml in 10 mmol/l KH2PO4buffer, pH 7.4) and
10µl penicillin (50 units/ml) and streptomycin (50µg/ml) were added and the samples
incubated at 37°C for 24hr. Thereafter, 10µl each of prolidase and aminopeptidase solutions
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(2mg/ml in 10mmol/l of potassium dihydrogen phosphate-KH2PO4 buffer, pH 7.4) was
added, and samples were incubated for a further 48hr. All steps were performed under argon.
A similar method was used previously to quantify the oxidative marker, 5-hydroxy-2-
aminovaleric acid in apoB100 (Pietzsch, Lattke et al. 2000).
7.2.6 Protein biomarker determination by LC-MS/MS
FL, AGE, oxidation and nitration markers were determined in enzymatic hydrolysates of
delipidated lipoproteins by stable isotopic dilution analysis LC-MS/MS (Ahmed and
Thornalley 2003).
7.2.7 Statistical Analysis
Data are mean ± SD for parametric data and median (minimum –maximum) or (lower –
upper quartile) for non-parametric data. Significance of difference between means was
assessed by Student t test and significance of difference between medians, by the Mann-
W hitney U test. Difference of proportions was assessed using Finney contingency tables.
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7.3 Results
7.3.1 Isolation of LDLand glycation by methylglyoxal and glucose in vitro
A new rapid method for isolation of LDLwas developed and used in this study. This method
used a single ultracentrifugation step for 2.5 hr only with samples at 16°C. High purity was
confirmed by a single protein band in denaturing SDS-PAGE and agarose non-denaturing
electrophoresis. Lipid peroxidation of isolated LDL from normal healthy control subjects, as
judged by TBARS content, was low: 0.81±0.45 nmol/mg protein (n=12). However, LDL
glycated minimally by methylglyoxal and glucose showed increased levels of AGE residues.
For glycation by methylglyoxal, MGmin-LDL showed increased content of MG-H1, CEL,
and Methylglyoxal-derived lysine dimer (MOLD) residues. The major AGE formed by
glycation with methylglyoxal was MG-H1 (98.4%), with minor formation of CEL(1.4%) and
MOLD (0.2%). In comparison, glycation of LDL by glucose, the major increase in glycation
adducts was that of FLresidues with a minor increase in CMLresidues (Table 7.3.1).
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Table 7.3.1 Changes in protein glycation adduct residues in human LDLminimally modified
by methylglyoxal and glucose in vitro
Data are mol adduct/mol apoB100;mean ±SD (n .3). Control 1 and control 2 are incubations
of LDLfor 6hr and 7 days without methylglyoxal and glucose, respectively. Significance: *P
<0.001. †P <0.01. Other adduct residues, G-H1, 3DG-H, CMA, pentosidine, MetSO,
dityrosine, and 3-NT, were not changed significantly during the incubation with glycating
agents.
7.3.2 Protein damage markers in apolipoprotein B100 of LDL in healthy human subjects
and patients with T2DM
In healthy human subject’s apolipoprotein B100 of LDL, the mean FL residue content was
2,900pmol/mg apoB100, equivalent to 1.49mol/mol apoB100 or 4.17mmol/mol Lys. W hilst
major AGE residues quantitatively were MG-H1, median content of 46.8pmol/mg apoB100,
equivalent to 0.024mol/mol apoB100 or 0.16mmol/mol Arg;and CML, median content
24.0pmol/mg apoB100, equivalent to 0.012mol/mol apoB100 or 0.035mmol/mol Lys.
Median total arginine-derived AGE residue content (G-H1+MG-H1+3DG-H+CMA+
Glycation adduct Control 1 MGmin-LDL Control 2 AGEmin-LDL
FL 2.21±0.21 1.99±0.36 3.10±0.67 6.08±0.37*
CML 0.031±0.004 0.032 ±0.007 0.056±0.009 0.070 ±0.003†
CEL 0.004±0.001 0.024± 0.003* 0.011 ± 0.003 0.013±0.003
MG-H1 0.15±0.02 1.57 ±0.37* 0.23 ±0.03 0.21 ±0.01
MOLD 0.0002±0.0001 0.0025±0.0009* 0.0057±0.001 0.0092±0.002
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pentosidine) was 103pmol/mg apoB100, equivalent to 0.062mol/mol or 0.42mmol/mol Arg.
Median total lysine-derived AGE residue content (CML+ CEL+ MOLD+ pentosidine) was
33pmol/mg apoB100, equivalent to 0.017mol/mol or 0.047mmol/mol Lys. The major
oxidative marker was MetSO residues with mean content of 2084pmol/mg apoB100,
equivalent to 1.07mol/mol apoB100 or 13.7mmol/mol Met. The nitration marker 3-NT had a
median residue content of 2.3pmol/mg apoB100, equivalent to 0.0012mol/mol apoB100 or
0.0078mmol/mol Tyr (Table 7.3.2).
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Table 7.3.2 Markers of protein damage in apolipoprotein B100 of LDL
Data are pmol/mg apoB100;mean ±SD or median (minimum- maximum). Significance: †P <
0.05, ∞ P <0.01, and *P <0.001, with respect to healthy control subjects;and ‡P <0.05 and
§P <0.01, with respect to T2DM patients not receiving metformin therapy.
Type of Analyte Healthy
subjects
T2DM
subjects
T2DM subjects not receiving
Metformin therapy
T2DM subjects receiving
Metformin therapy
n 21 32 19 13
Fructosamine
FL 2900 ±1402 3347±1914 3789±1971 2682 ±1688
AGE
CML 24.0 ( 0.7-143.7) 20.6(1.7-58.9) 20.5 (3.9-58.9) 24.1(1.7-56.4)
CEL 3.5 ( 0.2-38.9) 17.3 (3.5-59.6)* 21.9(3.5-59.6)* 14.6(4.6-33.4) †
G-H1 3.6( 0.1-50.4) 31.5 (1.2-59.6) 44.0 (1.8-188.3)* 25.0 ( 1.2-59.0)†‡
MG-H1‡ 46.8(15.9-219.4) 197.0(3.0-474.4)* 235.8(45.5-474.4)* 91.3 (3.0-309.4)§
3 DG-H1 19.4(2.2-138.9) 60.0 (4.8-163.8)* 82.3 (4.8-163.8)* 39.4 (6.3-86.2)‡∞ 
CMA 20.3 (0.4-47.9) 26.8 (0.7-112.8) 38.3 (0.7-112.8)† 8.9(1.6-74.6)‡
MOLD 1.8( 0.3-51.5) 9.0 (0.2-
31.8)∞ 
12.2 (0.2-31.8)∞ 7.6(1.5-27.3) †
Pentosidine 0.26(0.03-0.84) 0.76 (0.08-2.13)* 0.75 (0.18-2.13)* 0.76 (0.08-1.61)∞ 
Oxidation
MetSO 2084±1360 4738±3367* 5633 ±3837* 3857 ±2641‡
Dityrosine 0.26(0.05-6.86) 16.7 (0.2-68.4)* 16.8(5.8-34.8)* 11.0 (0.2-47.1)*
Nitration
3-NT 2.3 (0.3-49.1) 0.9 (0.1-24.1)† 0.7 (0.1-15.4)∞ 2.0 (0.1-24.1)‡
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Considering all T2DM patients were studied, the mean fasting plasma glucose (FPG)
concentration was increased by70% and glycated haemoglobin was increased by 2.7% of total
haemoglobin with respect to control subjects (Table 7.3.2). FLresidue content of apoB100 of
LDL was not increased significantly. Marked increases for contents of dicarbonyl-derived
AGE residues was seen: CEL five-fold, G-H1 nine-fold, MG-H1 four-fold, 3DG-H three-
fold, MOLD five-fold, and pentosidine three-fold. Median total arginine-derived AGEresidue
content was increased more than three-fold, 316 vs. 103pmol/mg apoB100 (P<0.001);
whereas total lysine-derived AGE residue content was increased only 47%, 49 vs. 33
pmol/mg apoB100 (P<0.05). For oxidative markers, MetSO residue content of apoB100 of
T2DM patients was increased two-fold and dityrosine residue content was increased 64-fold.
3-NT residue content of apoB100 was decreased 61% in T2DM patients (Table 7.3.2). Only
one protein damage marker of apoB100 in T2DM patients was linked to donor sex: median
CMLcontent was 13.3 pmol/mg for males and 30.3 for females (P<0.05).
7.3.3 Correlation analysis for markers of glycaemic control and protein damage in plasma
apoB100 of T2DM patients
There was no correlation between protein damage markers of apoB100 and patient age,
suggesting that the significant age difference of T2DM patients with and without metformin
therapy did not compromise protein damage markers in these study groups. For markers of
glycaemic control, FPG concentration correlated positively with A1C and also with FL
residue content of apoB100. FL residue content correlated positively with CEL, MG-H1 and
3DG-H residue contents. There was a cluster of correlations of dicarbonyl-derived AGE
residue contents: G-H1 correlated positively with MG-H1 and CMA;MG-H1 also correlated
positively with CMA and 3DG-H, and also with CML and pentosidine;and 3DG-H
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correlated positively with CMA. In addition, there was a cluster of correlations of oxidative
marker residues with AGE residue contents: MetSO correlated positively with CEL, G-H1,
MG-H1, 3DG-H, CMA, and pentosidine;and CML and MOLD correlated positively with
dityrosine (Table 7.3.3). There were negative correlations of 3-NT with MG-H1 and 3DG-H.
Table 7.3.3 Correlation triangle of glycaemic control and protein damage-related variables
of T2DM patients
Data are correlation coefficients (Spearman) with significance: *P<0.05, **P <0.01, and
***P<0.001. Correlation was of glycaemic control indicators and protein damage markers of
apoB100 in T2DM patients with and without metformin therapy.
7.3.4 Protein damage markers in apolipoprotein B100 of LDL in patients with T2DM
receiving metformin.
Patients receiving metformin therapy were slightly younger and more obese than those
patients not receiving metformin therapy, although all other conventional clinical variables
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were not significantly different (Table 7.2.1). ApoB100 of LDL from patients receiving
metformin therapy had lower contents of AGEs (G-H1, MG-H1, 3DG-H, and CMA) and
MetSO but higher 3-NT content than apoB100 of LDLfrom patients not receiving metformin
therapy. MG-H1, CMA, MetSO and 3-NT residue contents of apoB100 of LDLfrom T2DM
patients receiving metformin therapy were not significantly different from those of healthy
subjects (Figure. 7.3.4).
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Figure 7.3.4 AGE and methionine sulfoxide residue contents of apolipoprotein B100 of
LDLof T2DM patients with and without metformin therapy
(A) CEL, (B) G-H1, (C) MG-H1, (D) 3DG-H, (E) CMA, and (F) MetSO. Data are median
(lower –upper quartile) except for MetSO, which is mean±SD. Significance: *P <0.05, **P
<0.01, and
***P <0.001, with respect to normal healthy control subjects;and oP <0.05 and ooP <0.01,
with respect to T2DM patients not receiving metformin therapy.
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7.4 Discussion
A new method for rapid isolation of LDL is described and used in this study. Principally, a
single ultracentrifugation step of only 2.5 hr at 16°C is used during sample processing,
whereas the conventional method of LDL isolation involves ultracentrifugation for 20–22 hr
at 15°C (Havel, Eder et al. 1955). This rapid method has the potential to decrease the risk of
apoB100 damage in pre-analytic processing and could facilitate clinical studies of LDL.
Glycation of LDLby glucose in vitro to form AGEmin-LDLshowed that the major glycation
adduct formed in apoB100 was FL residues with relatively minor increase of CML residue
content. CML is formed by the oxidative degradation of FL. Glycation of LDL by
methylglyoxal in vitro to form MGmin-LDLrevealed that the major glycation adduct formed
in apoB100 was MG-H1 residues (along with minor formation of CELand MOLD residues).
The rate constants for glycation of LDLby glucose and methylglyoxal are 11.2 (mol/l) /day
and 28,800 (mol/l)/day respectively, at pH 7.4and 37°C. This result is obtained based on
first order glycation for both LDL and glycating agent, assuming initial rate conditions (the
rate of glycation was approximately constant during the incubation time). This suggests that
methylglyoxal is 2,600-fold more reactive with LDL than is glucose. The predicted in situ
rates of glycation of LDL by glucose agent and methylglyoxal in plasma (McLellan,
Thornalley et al. 1994;Beisswenger, Howell et al. 1999), are 73nmol/l/day and 4nmol/l/day;
suggesting that the rate of LDL glycation by glucose is 18-fold faster than by methylglyoxal
in plasma. The apparent switch of relative reactivity of glucose and methylglyoxal with LDL
in situ is due to the markedly lower concentration of methylglyoxal than glucose in plasma:
100nmol/l vs. 5mmol/l. The ratio of FL to methylglyoxal-derived adducts in apoB100 of
healthy controls is 56. ApoB100 appears to have been glycated prior to assimilation into
LDL.
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The protein damage marker of highest quantitative content in apoB100 of LDL in healthy
human subjects is the early glycation adduct FL, equivalent to 0.42% lysine residues. These
levels are three-fold lower than reported in earlier studies using the tritiated borohydride
reduction technique of 1.3% (W itztum, Mahoney et al. 1982) but similar to the 2–3nmol FL
residues per milligram apoB100 estimates using the furosine technique (Schleicher, Deufel et
al. 1981).
FL, MG-H1, MetSO, and 3-NT are major adducts of early glycation, advanced glycation,
oxidation, and nitration of apoB100, LDL and total plasma protein. The rates of damage of
LDL and plasma protein can be predicted, assuming these rates are equal to the rate of
clearance of adducts in the steady state and taking into account half-lives of LDL and serum
albumin, are 3 and 19days, respectively (Langer, Strober et al. 1972). The outcome of these
predictions is shown in Table 7.4.
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Table 7.4 Comparison of the predicted reactivity of apolipoprotein B100 of LDL and
total plasma protein towards early glycation, advanced glycation, oxidation and nitration
*Data are from (Ahmed, Babaei-Jadidi et al. 2005).
kLDL/kAlbumin is the predicted ratio of the rate constants for modification of apoB100 of
LDL and albumin, and rLDL/rAlbumin is the predicted ratio of in situ rates of modification
of apoB100 of LDL and albumin (the latter taking into account the concentrations of LDL
and albumin in plasma).
Plasma concentrations of apoB100 of LDL and albumin are 1.28µmol/l (equivalent to
3.18mmol/l LDL cholesterol) and 682 µmol/l (equivalent to 44mg/ml), respectively. Total
plasma protein concentration is 64mg/ml, and plasma protein amino acid contents are Lys
820nmol/mg, Arg 262nmol/mg, Met 164nmol/mg and Tyr 183nmol/mg protein (Thornalley,
Battah et al. 2003). All protein damage in plasma protein, other than that of apoB100 of
LDL, is attributed to adduct of albumin.
189
Estimates of kLDL-Glucose-69 (mol/l)/day and kLDL-MG-55,452 (mol/l)/day from these
deductions are not markedly dissimilar from estimates from in vitro glycation studies
(Thornalley, Battah et al. 2003). Overestimation of rates from in vivo data may be attributed
to glycation of apoB100 prior to assimilation in LDL particles. Overall, apoB100 of LDL is
far more reactive to damage by these modifications than is albumin, even after the eight-fold
greater molecular mass of apoB100 relative to albumin is taken into account. ApoB100 is
highly susceptible to damage and may be a particularly good sensor of it. From the predicted
in situ rates of modification, the rate of early and advanced glycation of LDLis only 17 and
4% of that of albumin, whereas the in situ rates of oxidation and nitration are 10 and 76%
greater than those of albumin. As LDLhas a short plasma half-life, however, the steady levels
of protein glycation, oxidation, and nitration adducts in apoB100 represent only a minor part
of the total plasma adduct concentration (Table 6.4). The adduct content in apoB100 of
diabetic patients may be increased by effects of both increased rate of modification (due to
increased plasma concentrations of modifying agents), and decreased rate of elimination.
In T2DM patients, the FLand CMLresidue content of apoB100 is not significantly different
from that of apoB100 from healthy subjects. Increased plasma glucose concentration in
T2DM patients did not produce a significant increase in FLresidue content of apoB100. This
may indicate that formation of FL residues in apoB100 by glucose is less favoured when the
extent of glycation exceeds 2 molar equivalents, limiting further increase of FL residue
content in diabetes. However, dicarbonyl-derived AGE content of apoB100 from T2DM
patients is markedly increased. This suggests that dicarbonyl glycation is the main cause of
increased AGEcontent of apoB100 of LDLin T2DM patients. Arginine-derived AGEresidue
contents of apoB100 in these patients increased more than three-fold.
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Major quantitative oxidative damage, MetSO residue content, of apoB100 in T2DM patients
is two-fold higher than in apoB100 of control subjects. This is commensurate with increased
plasma peroxide concentration in T2DM patients (Banerjee, Madhusoodanan et al. 2003).
There is no repair of MetSO by MetSO reductase in plasma, hence plasma MetSO likely
reflects increased plasma reactive oxygen species in diabetes and decreased plasma reactive
oxygen species production for patients treated with metformin.
The 64-fold increase of dityrosine residue content of apoB100 in T2DM patients, however,
far exceeds this. Dityrosine residues are formed by both spontaneous and enzymatic
processes. Enzymatic formation is catalysed by dual oxidase-1 (Edens, Sharling et al.
2001)— a member of the NADPH oxidase family of enzymes implicated in signaling in
vascular disease in diabetes (Lambeth, Krause et al. 2008). Activation of NADPH
oxidase/dual oxidase isozymes in T2DM may markedly enhance the formation of dityrosine
residues in apoB100 (Bhattacharjee, Pennathur et al. 2001). Dityrosine content of apoB100 of
diabetic patients (0.06mmol/mol Tyr) was intermediate between that of control subjects
(0.001mmol/mol Tyr) and of apoB100 isolated form atherosclerotic plaques (0.25mmol/mol
Tyr) (Leeuwenburgh, Rasmussen et al. 1997).
For T2DM patients receiving metformin therapy, there are lower contents of dicarbonyl-
derived AGE and MetSO residues than in patients not receiving metformin therapy. CML
residue content of apoB100 of LDLwas linked to patient sex;imperfect matching of sexmay
have masked changes in CML residue content in patients receiving metformin therapy.
Metformin decreased the concentration of methylglyoxal in T2DM patients (Beisswenger,
Howell et al. 1999). It is also expected to react with glyoxal and 3-DG similarly;thereby
decreasing plasma levels of these dicarbonyls and preventing related formation of AGE
residues. Metformin reacts with methylglyoxal in vivo, forming a triazepinone adduct that has
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been detected in plasma and urine (Beisswenger and Ruggiero-Lopez2003). This decreases
methylglyoxal by a scavenging action. Improvement of glycaemic control by metformin
decreases dicarbonyl formation. This leads to decreased AGE formation of apoB100
indirectly, as suggested by the correlation of FLresidue content of apoB100 with contents of
CEL, MG-H1, and 3DG-H residues. Both mechanisms are likely to be involved.
A notable finding is the decrease in MetSO residue content of apoB100 in patients receiving
metformin therapy. In correlation analysis, there are strong correlations of MetSO with G-H1,
MG-H1 and CMA residue contents of apB100. These correlations are not found in similar
analysis of total plasma protein (Ahmed, Babaei-Jadidi et al. 2005), which suggests these
relationships are specific to LDL. Decreased fractional clearance of apoB100 has been linked
to oxidative damage of apoB100 and atherogenicity (Pietzsch, Lattke et al. 2000). Increased
binding to proteoglycan in the sub-endothelium is thought to be integral to this process
(Skalen, Gustafsson et al. 2002). Metformin may decrease dicarbonyl glycation of apoB100
and, in so doing, prevent decreased plasma clearance and increased oxidation and
atherogenicity of LDLin T2DM. In future studies, it will be of interest to test this hypothesis
in prospective placebo-controlled studies.
In this study, 3-NT residue content of apoB100 of LDL is lower in T2DM patients not
receiving metformin therapy than control subjects and it normalized in patients with
metformin therapy. The quantitative amount of 3-NT residues (0.03–0.1mol%) is unlikely to
be damaging, but it may be a marker of NO bioavailability. Metformin therapy has been
shown to be linked to activation of endothelial nitric oxide synthase (eNOS) (Calvert,
Gundewar et al. 2008) and demonstrates cardioprotective micro and macrovascular effects
(Bailey 2008). The changes in 3-NT residues of apoB100 of LDL here may reflect
bioavailability of NO in T2DM patients, thereby suggesting that these patients receiving
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metformin therapy may achieve normal vascular NO bio-availability. This suggests a further
mechanism by which metformin may be protective to the vasculature in T2DM.
In summary, the new rapid method used as part of this study, to isolate LDL, could facilitate
further robust clinical studies as the chances of damage to apoB100 is lesser. Finally, the
work in this chapter revealed that AGE content in apoB100 of T2DM patients is higher than
ND subjects. Metformin therapy appears to reduce the levels of these AGE and MetSO
residues and therefore, appears to limit the damage to endothelial function, due to T2DM.
Even though endothelial fuction was not tested in this chapter and cohort, it was demonstrated
earlier on in the previous chapters that AGE products reveal a causal relationship to the
development and progression of CVD (Peppa, Uribarri et al. 2002) mediated through
endothelial injury and dysfunction(W u, Liu et al. 2014) .
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Chapter 8
Finaldiscussion
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8.1 Discussion
Maintenance of a normal functioning endothelium is critical to prevent the onset of
atherosclerosis and development of related cardiovascular complications. Endothelial
function is a physiological response of the vascular endothelium to a stimulation or stress
which results in a chain of activities with the release of vaso-active proteins. Under normal
conditions, in healthy individuals, the endothelium performs various actions including
maintaining normal vascular tone and function, limiting smooth muscle cell proliferation,
maintaining homeostasis and limiting vascular inflammation (Vita and Keaney 2002;
Celermajer 2005). Healthy endothelium is, therefore, essential to maintain good
cardiovascular health (Poredos 2002). Impedance of this vascular control can lead to vascular
dysfunction and disease which appear to be exacerbated by conditions such as obesity
(Molica, Morel et al. 2015;Pareyn, Allegaert et al. 2015), hypertension, T2DM as well as
hypercholesterolaemia (Vita and Keaney 2002;Endemann and Schiffrin 2004). In these
conditions, the endothelial function is impaired giving rise to inflammation, thrombosis,
vasoconstriction and atherosclerotic lesion formation (Levine, Keaney et al. 1995;Vita and
Keaney 2002). This abnormal endothelial response, called endothelial dysfunction, is a
precursor of atherosclerosis and subsequent cardiovascular disease (CVD) and events
(Poredos 2002;Vita and Keaney 2002;Caballero 2003;Chan, Mancini et al. 2003) including
Myocardial infarction. W hilst measuring endothelial function and dysfunction is possible at
the coronary level, performing invasive measurements carries its own potential risk in leading
to serious harm in rare situations (Fujino, Mikuniya et al. 1993). The kit to perform such
procedures is costly and therefore could be beyond the scope for wide spread research
activities at this stage. It would also be unethical to perform or even offer such studies to
apparently healthy individuals at risk of future events. Therefore, developing and improving
non- invasive modalities including imaging which could detect early changes reliably could
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answer above difficulties. These imaging techniques could become surrogate for invasive
coronary measurements and therefore predicting cardiovascular outcomes and events.
This thesis sought to utilise such non-invasive methods to measure endothelial vascular
reactivity, as an indicator of endothelial dysfunction, in different risk groups and their
response to various physiologic insults (Benzuly, Padgett et al. 1994;Celermajer, Sorensen et
al. 1994;Heitzer, Yla-Herttuala et al. 1996;Drexler and Hornig 1999;Cai and Harrison 2000;
Quyyumi 2003;Landmesser, Hornig et al. 2004;Lerman and Zeiher 2005;Deanfield, Halcox
et al. 2007);(Peretz, Leotta et al. 2007). A couple of prospective studies did not reveal the
expected correlation between FMD and independent future CVD prediction (Chan, Mancini
et al. 2003;Fathi, Haluska et al. 2004;Frick, Suessenbacher et al. 2005). As these studies
were conducted with older methods and retrospective analysis which were partly responsible
for negative results, we opted for the newer method of instant online measurement for the
FMD analysis.
Risk estimation for CHD on asymptomatic or low risk population is usually based on
Framingham 10 year risk score (W ilson, D'Agostino et al. 1998), which estimates the risk
based on traditional risk factors into low, medium or high risk. This approach has been used
to initiate primary prevention measures where appropriate. However it is widely known now
that CVD risk prediction is not just based on traditional known risk factors alone. Newer risk
estimation algorithms include Q risk 2 and SCORE (Simmonds and W ald 2012). Even they
have same drawbacks as Framingham in terms of basing the risk estimation on traditional
known risk factors only. However FMD scanning and endothelial testing seem to correlate
well with risk factors in predicting CVD, even in low risk populations of Framingham score
(W itte, W esterink et al. 2005) and overweight children (Rodriguez, Coll et al. 2015). In fact
FMD scanning has produced a high level of specificity and sensitivity in predicting coronary
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disease in subjects with peripheral arterial disease. As this group of patients is at higher risk
of underlying systemic vascular dysfunction, accurate prediction was very valuable. In this
regard, FMD at least correlated with results obtained from myocardial perfusion scanning
results, validating the potential for FMD scanning (Perrone-Filardi, Cuocolo et al. 2005).
This current thesis sought to investigate subjects with obesity including early onset, IGT,
T2DM as well as non-obese, non-T2DM subjects (NOC) using physiological stress as a
stimulus to evaluate microvascular and macrovascular reactivity. The technology used to
assess both vascular beds was previously validated in the defined subjects groups (Polak,
Dorner et al. 2000;Newey and Nassiri 2002;Seifertl and Vilser 2002;Sidhu, Newey et al.
2002).
A standardized online technology for assessing vascular function of macro-vessels was used
as a surrogate to test a new technology for vascular function testing in micro-vessels, which
was, to that date, not been determined in cohorts with metabolic risk. Although micro-
vascular reactivity has been studied in a healthy population (Dorner, Garhöfer et al. 2003), a
comparative study in healthy controls versus groups with different metabolic states has not
been systematically examined before. Therefore, the work in this thesis sought to explain the
phenomenon described above.
These current studies identified that microvascular reactivity assessment provided a reliable
indicator of the functional status of microvasculature. The study revealed dynamic reactivity
changes acutely to physiologic stress in different metabolic groups. This is an important
finding as previous studies have shown that macrovascular reactivity, as assessed by FMD,
may predict prognostic disease (Cai and Harrison 2000;Schächinger, Britten et al. 2000)
(Heitzer, Schlinzig et al. 2001;Gokce, Keaney et al. 2002;Gokce, Keaney et al. 2003).
Similarly, endothelial dysfunction at the brachial level could represent and correlate similar
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dysfunction in coronary vessels (Anderson, Uehata et al. 1995;Takase, Uehata et al. 1998;
Pyke and Tschakovsky 2005). Therefore, the next step would be to investigate potential for a
possible link between dynamic change in microvascular reactivity and cardiovascular
outcome measures.
W ithin this thesis, microvascular reactivity was assessed through imaging retinal vessels, by
applying flickering light as stimulus before and after a meal. Previous studies have shown that
flicker light can induce vasodilatation (Nagel and Vilser 2004;Gugleta, Zawinka et al. 2006)
and blood flow (Michelson, Patzelt et al. 2002) of retinal vessels in a healthy population. This
response appears to be attenuated with hyperglycaemia (Dorner, Garhöfer et al. 2003). It has
also been shown that known subjects with T2DM have a reduced vaso-reactivity of their
microvessels compared with healthy subjects (Mandecka, Dawczynski et al. 2007;Nguyen,
Cheung et al. 2008;Pemp, Garhofer et al. 2009). In the first instance, this current thesis
revealed that, macrovascular reactivity appears to be immediately and profoundly depressed,
within 1 hr of glucose intake in healthy subjects. At the same time, microvascular reactivity
and function does not appear to be depressed immediately after glucose intake. Instead,
microvascular reactivity appears to initially increase in line with increasing glucose. This is
an interesting finding. Following the initial difference in reactivity, both vessels revealed
further depression of reactivity and function in response to the OGTT.
This study revealed that, in basal fasting conditions, both FMD and RVR measurements are
low in patients with T2DM compared with healthy control subjects in line with previous
studies (Nguyen, Kawasaki et al. 2009;Pemp, W eigert et al. 2009). Other risk groups
including Obese and IGT subjects also appear to reveal similar trend of low reactivity
measurements compared to healthy control subjects.
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Further more, this study evaluated the effects of fat ingestion on reactivity measurements and
correlated with markers of both endothelial and inflammatory markers for acute dynamic
changes. These studies revealed that circulating endotoxin levels rose in all subjects,
irrespective of their metabolic status, although circulating endotoxin revealed dramatic post-
prandial change in the high metabolic risk groups. Specific comparative analysis of ND
subjects versus subjects with T2DM at 4hr post-prandial, identified that the latter had a mean
endotoxin level 125.4% higher than ND subjects. During the same period, RVA and FMD
parameters were measured. This study revealed statistically significant correlations between
increasing triglyceride (TG) levels post fat meal with impaired functioning of endothelial
cells at both macrovascular and microvascular levels.
Cumulative data derived from the fasting state and the SFA post-prandial state indicated that
T2DM subjects are subjected to 336% more circulating endotoxin than ND subjects over the
4hr duration. Based on these studies, it might be deduced that more frequent saturated fat
exposure may exacerbate endotoxin, inflammation and depress vascular reactivity. Also,
smaller more frequent meals have the potential to allow endotoxin to spike several times a
day. However no direct associations were able to be noted between circulating endotoxin
levels and vascular function in these cohorts.
High childhood BMI was associated with an increased incidence of adult diabetes and
coronary artery disease (Llewellyn, Simmonds et al. 2015). Clinical studies have implicated
gut derived endotoxin as a direct ‘primary mediator’to activate the inflammatory state,
contributing to metabolic disease, with current cross sectional data showing elevated systemic
endotoxin levels in conditions of obesity, coronary artery disease and type 2 diabetes mellitus
(Creely, McTernan et al. 2007;Piya, Harte et al. 2013;Eguchi and Manabe 2014). Endotoxin
as a potential biomarker of sub-clinical inflammation was examined for early CVD risk in
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childhood obesity. Our study revealed that in childhood obesity, circulating endotoxin is
significantly correlated with pro-inflammatory markers, TNF-α, MCP-1, as well as 
biomarkers of atherogenesis. Endotoxin may also account for, in part, the continual pro-
inflammatory state experienced in obese children (Gilardini, McTernan et al. 2006;Al-Attas,
Al-Daghri et al. 2010;Kheirandish-Gozal, Peris et al. 2014;Chang, Jian et al. 2015). As we
already know that, CVD development in later life shows an increased risk when the condition
is preceded by prior chronic inflammatory conditions (John and Kitas 2012;Banerjee, Biggs
et al. 2013;Eguchi and Manabe 2014;Olza, Aguilera et al. 2014;Kranendonk, van
Herwaarden et al. 2015), this data supports that theory. This study did not look into other
potential causes of high endotoxin levels arising from gut such as irritable bowel syndrome.
As endotoxin levels appear to be related to type and frequency of diet, future studies could be
directed to address potential diet composition and types of diet that prove beneficial and
reduce endotoxin load from gut, particularly in high risk subjects like obese children.
Finally, whilst investigating the lipoprotein damage in the high risk T2DM group, it became
apparent that high fat meal led to immediate increase in AGEproducts which have long term
detrimental effects on the endothelium. The oxidative and glycative damage to LDL is less
pronounced in the groups who were taking metformin as medication to control
hyperglycaemia in T2DM compared with subjects not on Metformin. This study revealed
that 3-NT residue content of apoB100 of LDL is lower in T2DM patients not on metformin
therapy than control ND subjects and 3-NT residue is normalized in patients with metformin
therapy. As 3-NT is a marker of NO bioavailability (Ceriello, Bortolotti et al. 1998;Ceriello,
Taboga et al. 2002), the changes in 3-NT residues of apoB100 of LDL may reflect
bioavailability of NO in T2DM patients, thereby suggesting that these patients receiving
metformin therapy may achieve normal vascular NO bio-availability. Metformin therapy has
also previously been shown to be linked to activation of endothelial nitric oxide synthase
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(eNOS) (Calvert, Gundewar et al. 2008). This suggests a further mechanism by which
metformin may be protective to the vasculature in T2DM.
Finally, CVD risk groups demonstrate varying levels of underlying chronic pro-inflammatory
state which could be detected by non- invasive imaging modalities. The pro inflammatory
state is noticeable as early as childhood state with appropriate risk profile. Over time, it is
hoped that these non invasive methods could lead to pharmacological and therapeutic
interventions at an early stage thereby reducing the risk of CVD and prolonging healthy life.
8.2 Future directions
Endotoxin appears to be an exciting and promising marker which, in different metabolic
groups- appears to vary linking relative high risk to CVD. As this study was studying changes
related to acute effects of a meal, Endotoxin revealed significant acute change in differing
conditions in different metabolic groups. Therefore this marker reveals promising potential
for future studies linking CVD with gut related illnesses, dietary habits, type and nature of
diet and even lifestyle related issues.
The UK National screening programme for diabetic patients involves yearly digital
photography, mainly identifying parenchymal changes. Functional changes of arterial and
Retinal vessel reactivity precedes atherosclerotic changes (Celermajer, Sorensen et al. 1992;
Benzuly, Padgett et al. 1994;Landmesser, Hornig et al. 2004) by years. Therefore, it is
possible that, by using this retinal function study software and video added to the current
screening service, subjects with diabetes could be further risk stratified for early stage CVD.
Another area of future research around this technology could be based around examining
retinal vessel calibre which this study acquired the data but had no chance to analyse or
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investigate further. The calibre of both retinal artery and vein could be analysed as part of
routine study, information which could be used as a predictor of CVD. In a population-based
prospective study examining retinal vascular calibre, calibre size of the vessels predicted
cardiovascular death, independent of traditional cardiovascular risk factors in men and
women aged 49–75 years (W ang, Liew et al. 2006). Generalised narrowing of the retinal
arterioles has also been associated with stroke, coronary artery disease (CAD), as well as
hypertension (W ong, Knudtson et al. 2004). It has also shown that narrower retinal arterioles
are associated with lower hyperaemic myocardial blood flow and perfusion reserve in
asymptomatic adults, concluding that retinal arteriolar narrowing may serve as a marker of
coronary microvascular disease (W ang, W ong et al. 2008). Further analysis of retinal vascular
calibre has predicted CHD death independent of traditional cardiovascular risk factors in men
and women aged 49–75 years (Konno, Feke et al. 1996).
Newer method of measuring brachial artery reactivity using FMD as described in this thesis
could be used as a screening tool to further risk stratify healthy groups –to start with- people
involved in high risk sports like mountain biking, cross country running, and other high
endurance sports groups and clubs.
8.3 Conclusion
This thesis has sought to examine endothelial dysfunction in at-risk patients and groups using
updated and new technology. The aim was to investigate whether dynamic micro and
macrovascular changes can be identified acutely after induction of physiological stress. It is
recognized that, early intervention at vascular level could lead to potential reduction in future
cardiovascular events (Halcox, Schenke et al. 2002;Chan, Mancini et al. 2003;Fathi,
Haluska et al. 2004;Celermajer 2005;Frick, Suessenbacher et al. 2005). Therefore, studying
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the vascular reactivity, through the FMD and RVA, may contribute to provide the required
individualized prevention strategies to reduce the burden of cardiovascular disease. Finally
both these non invasive methods could be utilised not only in research arena, but also in
screening areas for sports clubs, high risk sports and finally in commercial domain
investigating the effects of drugs on endothelium, both immediate and long term in various
metabolic groups.
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1 f Figure - Physiology lab, UHCW
Physiology laboratory picture shows a subject in a resting position with FMD scan of his right
brachial artery being performed. The operator is looking at the ultrasound machine and the
personal computer shows the VIA software tracking the arterial wall. The 12 MHzprobe is
held in position by a specially made stereotactic clamp and the automatic blood pressure
machine can be seen below the table. It is connected to a cuff placed on the subjects’upper
forearm.
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1 g Picture VIVID 7 ECHO machine
Standard ECHO machine which uses ultrasound technology to scan the brachial artery in 2D
mode. The machine is connected to a 12 MHzprobe which scans the brachial artery. The
machine is connected to the personal computer using a frame grabber which transmits the
image of the brachial artery to the VIA software which tracks the walls and measures the
FMD values.
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Micro-vascular Function
1 h Figure RVA system with Fundus camera and CCD (Charge coupled device) device
The above picture shows the RVA system with the camera, CCD camera and the personal
computer and printer installed on a single table. The computer has the software installed,
which can track the retinal vessel walls for reactivity measurements. The subjects will sit in
front of the camera with the right eye positioned looking directly into the camera and light.
Once the subject is comfortable with the position, height and light, the measurements are
started as per protocol.
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1 i Figure
RVA picture to identify the best area for artery and vein scanning for the ROI
The above picture shows a still picture of the right eye/fundus with optic disc and the
radiating retinal artery and vein. The metal pointer is at the centre of the macula. Both the
artery and vein are marked in the inferior temporal region, at which point the reactivity
measurements are undertaken. Repeat scans will pick the same spot to get the best results to
check for dynamic shifts in reactivity measurements.
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AppendixII
Protocols and examples
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MICRO VASCULAR STUDY
Flow mediated dilatation (FMD) and Retinal vessel Analysis (RVA)
Scanning Schedule Date:
8.00-8.30 AM
Check list
Blood pressure
W eight, BMI, BMR and Fat %
Left arm Venflon and Bloods
Consent check
1 % tropicamide drops right eye
Urine sample
Subject 1 Subject 2
8.35-9.00 AM Baseline FMD RVA
9.05–9.30 AM Baseline RVA FMD
75 Grams Glucose drink ------OGTT
10.25-10.45AM 1 Hour Post FMD RVA
10.45-11.05 AM 1 Hour Post RVA FMD
Blood test 1 Hour post
11.25-11.45 AM 1 Hour Post FMD RVA
11.45-12.05 PM 1 Hour Post RVA FMD
Blood test 2 Hour post
12.25-12.45 PM 1 Hour Post FMD RVA
12.45-13.05 PM 1 Hour Post RVA FMD
Blood test 3 Hour post
13.25-13.45 PM 1 Hour Post FMD RVA
13.45-14.05 PM 1 Hour Post RVA FMD
Blood test 4 Hour post
Test Finish- Venflon removed- Lunch
2 a. Figure Protocol used for the study
The detailed protocol followed for the physiological tests performed each day of the study.
The figure clearly shows that the subjects usually attended the sessions before 8AM in the
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morning. There were usually 2 subjects who were studied each day. After confirming the
identity and consent from each subject, the baselines of both macro- and micro-vascular
function was performed on both subjects by 2 operators, respectively. Then baseline blood
samples were obtained. Oral glucose (70 grams) was ingested by both subjects and 1 hr after
that (5 minutes before the hr ), RVA was performed on 1 subject by 1 operator whilst the
other had FMD performed by the other operator. Then they swapped over within 15 minutes.
After 1 hr post blood samples, the subjects rested until the 2 hr scan. This procedure
continued till they finished all 4post scans and blood tests.
 The final scan after the FMD was repeated after 250 μgrams of sublingual nitroglycerine 
(GTN) was administered. The protocol required that an FMD scan was performed at the end
of 5 minutes after the GTN was administered. FMD was continuously monitored and
recorded during this time. At the end of this scan the subject had the final 4hr scan on the
RVA with the GTN on board. The same protocol was followed for the other subject at the 4
hr point.
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2 b Figure
Real time standard record sheet. VIA and ECHO parameters recorded live as the scan is
done. Record of FMD scanning for each subject, which included recording all cardiovascular
parameters obtained from both standard ECHO machines with 2D scan parameters, as well as
VIA software parameters. These were recorded at all 3 stages of scanning, including at
baseline, cuff inflation and after deflation.
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2 c Figure
Final analysis of both arterial and venous reactivity in the retina: Real time report of RVA
scans on a subject with both arterial and venous reactivity measurements, along with location
and validity measurements clearly shown. Two graphs, one arterial and the other venous
reactivity measurements to flicker light, are shown with dilatation % recorded. Validity
measurements for each scan were generated by the software.
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2 d Figure
The above example from the study clearly shows a difference in the arterial reactivity
measurements between the top scan results versus the bottom. They happen to show the scan
results between a diabetic subject, on the top graph, compared with a non-diabetic (ND)
subject in the bottom graph. The reactivity in the diabetic subject appears to be low in the
fasting state compared with the control subject.
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2 e Figure Final analysis of Arterio-venous ratio.
The above figure shows the still picture of the right eye/fundus, with arterial and venous
markings in a circular panel created by the DVA software. The system generates the report
once the arteries and veins within the area are highlighted. The final ratio of the arterial
versus venous size on this picture is 0.85. The bottom part of the picture is a graph with the
obtained value marked as a cross. The graph is based on ARIC study findings for AV ratio.
ARIC- Atherosclerosis risk in communities study.
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2 f Figure
Sample storage database for the study at the freezers.
The above figure is an example of anonymised coding used in the study for all samples stored
at -80ºc.
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2 g Figure
Summary of individual scan results along with laboratory markers
The above chart shows a summary sheet with results from both micro- and macro-vascular
reactivity noted. It also summarises time points for these results, along with plasma and
serum markers. It also monitors the AV ratio for the time points.
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